MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

1. Introduction

1.1. Glucocorticoids in the Treatment of Lymphoid Malignancies

Glucocorticoids (GCs) are among the most effective drugs used in the treatment of hematopoietic malignancies of the lymphoid lineage in virtue of their ability to induce apoptosis of these cancerous cells [ 1 – 3 ]. The main hematopoietic cancer types that respond well to GC therapy include T acute lymphoblastic leukemia (T-ALL), chronic B lymphocytic leukemia (CLL), multiple myeloma (MM), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). GCs appear, however, to have little value in the treatment of acute or chronic myeloid leukemia (AML/CML). A major drawback of GC therapy is the gradual development of resistance to GC during treatment that limits the clinical utility of this drug. Poor response to a 7-day monotherapy with the GC prednisone is one of the strongest predictors of adverse outcomes in the treatment of pediatric ALL [ 2 , 4 ]. A great challenge today is to develop strategies that can overcome the drug resistant phenotype. For this purpose it is important to understand the underlying mechanisms of GC resistance and the signaling pathways regulating apoptosis induced by GCs.

Besides inducing apoptosis of lymphoid cells, GCs are used in palliative care. GC treatment produces rapid symptomatic improvements, including relief of fever, sweats, lethargy, weakness, and other nonspecific effects of cancer.GCs decrease the severity of chemotherapy-induced emesis. GCs are also used in the clinics for other medical conditions such as autoimmune diseases, asthma, ulcerative colitis, chronic obstructive pulmonary disease, kidney diseases, and rheumatologic disorders due to their strong anti-inflammatory and immunosuppressive properties. GC therapy is hampered by a variety of metabolic and medical complications, including insulin resistance, diabetes, hypertension, glaucoma, osteoporosis, and osteonecrosis with increased risk of bone fractures [ 5 – 10 ]. Diabetes may develop by direct GC-mediated induction of apoptosis in insulin-producing beta cells of the Langerhans islets [ 11 – 13 ], and osteoporosis may develop due to apoptosis of osteoblasts [ 14 – 16 ]. GCs also suppress cell growth and proliferation processes in the brain [ 17 , 18 ].

Besides being used as monotherapy at high dosages, GCs are frequently combined with other chemotherapeutic drugs to achieve rapid and more efficient therapeutic effects. For the treatment of T-ALL, GCs such as prednisone, methylprednisolone, and dexamethasone are usually used in combination with other chemotherapeutic drugs such as vincristine, daunorubicine, L-asparaginase, cytosine arabinoside, doxorubicin, and cyclophosphamide. This multidrug regimen prolongs remission, minimizes the long-term use of prednisone, and thus reduces the steroid-mediated adverse effects.

Typical B-cell chronic lymphocytic leukemia (CLL) in the early stage of progression responds well to combination chemotherapy including an alkylating agent (such as chlorambucil) plus or minus prednisolone.Advanced stages of the disease often require the addition of an anthracycline and a vinca alkaloid for successful therapy. One commonly used combination is cyclophosphamide, doxorubicin, vincristine, and prednisolone, a drug combination termed CHOP. Rituximab, a chimeric monoclonal antibody directed against the B-cell specific antigen CD20, is often added to the therapy, which is here termed R-CHOP. Rituximab is also combined with fludarabine and cyclophosphamide in the treatment of CLL [ 19 , 20 ]. Another antibody proved to be efficient against CLL in combination with methylprednisolone is alemtuzumab, which targets CD52. This combination is also effective in p53-defective CLLs [ 21 ]. However, alemtuzumab was not found to be superior to rituximab [ 22 ]. The immunomodulatory drug lenalidomide shows also good activity in relapse/refractory or treatment-naïve CLL [ 23 , 24 ].

CHOP is also used for non-Hodgkin's lymphomas and anaplastic large cell lymphoma (ALCL). Sometimes interferon- α 2b is added in the treatment of the former. GCs are also effective for the treatment of Hodgkin's lymphoma. Here, prednisone has been used in combination with carmustine, vincristine (Oncovin), procarbazine (MOPP), and rituximab. Recently, brentuximab vedotin (Adcetris), an antibody directed towards CD30 conjugated with the anti-tubulin chemotherapeutic agent monomethyl auristatin E [ 25 ], has been approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. CD30 expression is restricted to only a relative small population of activated T and B cells, and therefore this treatment is expected to be more selective for CD30-positive tumor cells. Another monoclonal antibody entered the clinics is epratuzumab, which targets CD22 and is proved to be efficient in the treatment of adult non-Hodgkin's lymphoma as a single agent or in combination with chemotherapy. A phase II clinical trial showed that combining epratuzumab with rituximab and CHOP (ER-CHOP) may have a favorable response on diffusing large B-cell non-Hodgkin lymphoma (DLBCL) [ 26 ].

Multiple myeloma (MM) has frequently been treated with vincristine, doxorubicine (Adriamycin), and dexamethasone (VAD) or prednisone/melphalan. Bortezomib (Velcade), lenalidomide, and to a lesser extend thalidomide have proven efficient in the treatment of MM in combination with dexamethasone. This is in addition to autologous or allogeneic hematopoietic stem cell transplantation. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurological side effects of thalidomide and has emerged as a drug with activity against various hematological malignancies [ 27 , 28 ]. Bortezomib is a selective inhibitor of the 26S proteasome that stabilizes many cell cycle-regulatory proteins. The antitumor effects of bortezomib in lymphoid tumors have been attributed to NF κ B inhibition through stabilization of its inhibitor I κ B. Other tumors that have been treated with combination chemotherapy involving a GC include medulloblastoma, primitive neuroectodermal tumors, and ependymomas.

1.2. Alternative Treatment Approaches for Overcoming GC Resistance

One major obstacle in the therapy of lymphoid malignancies is the appearance of GC resistant cells. Drug resistance may occur at the level of the glucocorticoid receptor (GR) or through alterations in downstream regulatory pathways. In most GC-resistant ALL primary biopsy specimens, GR was found to be functional [ 29 ], suggesting that pharmacological intervention may restore drug sensitivity. Several strategies have been developed that aim to overcome drug resistance through specifically targeting anti-apoptotic pathways. Below, three major strategies applicative for GC therapy are discussed.

1.2.1. Targeting Anti-Apoptotic Bcl-2 Members as a Therapeutic Approach for Overcoming GC Resistance

GC resistance may occur due to overexpression of anti-apoptotic proteins of the Bcl-2 superfamily [ 30 , 31 ]. Among these, Bcl-2, Bcl-X L , and Mcl-1 are frequently overexpressed in lymphomas [ 32 ].

1.2.1.1. Targeting Bcl-2 with Small Molecular Inhibitors . Small molecules that target the anti-apoptotic proteins of the Bcl-2 family are attractive drugs that should be able to overcome GC resistance. One example is ABT-737, a BH3 mimetic that inhibits the pro-survival function of Bcl-2, Bcl-X L , and Bcl-w and induces apoptosis in a variety of cancer cell types including leukemias [ 33 – 35 ]. Treatment of the lymphoma-prone E μ -Myc transgenic mice with ABT-737 prevented the development of Myc-driven lymphomagenesis [ 36 ], understating the need for these anti-apoptotic proteins. Combined use of ABT-737 and the dual specificity PI3K/mTOR inhibitor PI-103 led to loss of c-Myc expression and apoptosis of Burkitt's lymphoma cells, whose tumorigenicity is driven by overexpression of the c-Myc gene [ 37 ].

The pro-apoptotic effect of ABT-737 in CLL depends on sufficient amount of Bcl-2 that tonically sequesters the pro-apoptotic Bim protein [ 38 ]. Also, the sensitivity of lymphoma cell lines to Bcl-2 antagonism is directly related to the amount of Bcl-2 primed with Bim [ 35 ]. The sequestration of Bim may explain the marked chemosensitivity of CLL and follicular lymphoma (FL) that express abundant Bcl-2 [ 38 ]. This drug-responsive condition is termed “primed for death”.

ABT-737 potentiated the effect of vincristine, dexamethasone, and L-asparaginase (VXL) treatment on ALL cells [ 39 ] and could potentiate the effect of the VXL combination in chemoresistant human primary ALL xenografts [ 40 ]. This study also shows a synergistic effect between the three components of the VXL regimen. An additive effect was observed in primary MM cells when ABT-737 was combined with dexamethasone [ 41 , 42 ].

ABT-263 (Navitoclax) is a second generation, orally bioavailable small molecule Bcl-2 family protein inhibitor that has entered clinical trials with promising efficacy on CLL [ 43 – 46 ]. ABT-263 has been shown to have synergistic effects with R-CHOP treatment on mantle cell lymphoma [ 45 ]. It also synergizes with rapamycin in killing lymphomas [ 47 ].

1.2.1.2. Overcoming ABT-737 Resistance by Targeting Mcl-1 . Resistance to ABT-737 occurs in lymphoma cells with high expression of Mcl-1 and/or Bfl-1/A1 [ 48 ]. The pro-apoptotic Bim that is displaced from Bcl-2 by ABT-737, becomes captured by either Bfl-1 or Mcl-1. The resistance could be overcome by decreasing the Mcl-1 level with the cyclin-dependent kinase (Cdk) inhibitors flavopiridol and PHA767491 [ 48 ], or by inhibiting mTOR complex 1 (mTORC1) [ 49 ] or glycolysis [ 49 , 50 ].

Another approach to overcome Mcl-1-dependent resistance is to use the small molecule obatoclax (GX15-070) that has entered clinical trials in the combined treatment of various hematopoietic neoplasms [ 51 – 53 ]. Obatoclax disrupts the interaction between Mcl-1 and its pro-apoptotic counterparts including Bak, Bax, and Noxa [ 54 , 55 ]. Obatoclax and flavopiridol synergized in overcoming drug resistance in human myeloma cells through a mechanism involving Bim and Noxa [ 56 ]. The multikinase inhibitor sorafenib could synergize with Obatoclax in inducing apoptosis in acute myeloid leukemia (AML) through downregulating Mcl-1 [ 57 ]. Obatoclax could overcome GC resistance in ALL through induction of apoptosis and autophagy, an effect that depends on the pro-apoptotic Bak and to a certain extent also on Beclin-1 [ 58 , 59 ], a mammalian orthologue of yeast Atg6 that plays a central role in autophagy [ 60 ]. Under certain conditions, cell death induced by Obatoclax and GC may be executed in the absence of both Bax and Bak [ 59 ]. Under these conditions, necroptosis ensues necroptosis ensues, a process mediated by RIP-1 (receptor-interacting protein-1) kinase and the cylindromatosis deubiquitinase CYLD [ 59 ]. RIP-1 kinase plays a dual role in determining the cell fate. It may promote either cell death or cell survival dependent on its ubiquitinated state, which is regulated by CYLD and A20, two NF κ B target genes [ 61 ]. Altogether, there is a general consensus that Obatoclax might be a favorable drug that ought to be combined with dexamethasone/prednisone and/or rapamycin to overcome GC resistance in ALL cells and other hematological lymphoid malignancies.

1.2.1.3. Overcoming Bcl-2-Mediated Resistance with Small Molecular Inhibitors of XIAP (X-Linked Inhibitor of Apoptosis) . Bcl-2-mediated resistance in CLL may also be overcome by small molecular inhibitors of the anti-apoptotic XIAP (X-linked inhibitor of apoptosis) when exposed to TRAIL [ 62 , 63 ]. XIAP and the cellular cIAPs 1 and 2 are expressed at high levels in CLL cells [ 62 , 63 ]. XIAP inhibitors enhanced Bcl-2 cleavage and induced a conformational change in Bax [ 62 ]. Similarly, XIAP inhibitors sensitized ALL for CD95-induced apoptosis [ 64 ]. In patients with T-ALL, poor prednisone response was associated with increased XIAP expression [ 65 ]. XIAP inhibition using the low-molecular-weight SMAC mimetic LBW242 resulted in increased prednisone-induced apoptosis in vitro [ 65 ].

1.2.2. Targeting Notch1 as a Therapeutic Approach for Overcoming GC Resistance

Another anti-apoptotic protein that negatively regulates GC-induced apoptosis is Notch1 [ 66 – 68 ]. Notch1 is indispensable for normal T-cell development [ 69 – 71 ] and is an attractive target in the treatment of hematopoietic malignancies of the T lineage [ 72 ]. Mice transplanted with bone marrow cells transduced with a constitutively active form of Notch1 develop T-cell neoplasms [ 73 ], while mice transgenic for constitutively active form of Notch3 develop thymic lymphomas [ 74 ]. Acute lymphoblastic T-cell leukemia is frequently associated with increased Notch signaling [ 75 – 79 ], which may be caused by the chromosomal translocation t(7; 9)(q34; q34.3) [ 80 ], gain-of-function mutations of Notch1 [ 81 ], and/or mutations in Fbw7 (F-box and WD repeat domain-containing 7), a negative regulator of Notch1 [ 82 ].

One approach to avoid Notch activation is to prevent its cleavage by the γ -secretase complex using γ -secretase inhibitors (GSI) [ 83 ]. GSIs can induce apoptosis of various lymphoma cell lines [ 84 – 87 ]. However, GSI as a monotherapeutic agent is often insufficient for inducing apoptosis. Rather, GSI can enhance the pro-apoptotic effect of GCs and other chemotherapeutic agents including the mTOR inhibitor rapamycin [ 84 , 88 ]. GSI restored GR auto-upregulation and induced apoptosis through induction of Bim [ 88 ]. GSI does not overcome GC resistance in T-ALL deficient for PTEN [ 89 , 90 ], supposedly due to elevated Akt activity. The constitutive Akt activation in the absence of PTEN leads to increased glucose metabolism and bypasses the requirement of Notch signaling to sustain cell growth [ 89 ]. In this context it should be noted that Notch1 by itself may upregulate the P13K/Akt pathway via its target gene Hes1 [ 89 ]. As PTEN is a target of several microRNAs that are often expressed abnormally in cancer (see Section 2.4.2.3), resistance to GSI may be far more prevalent. GSI is also not efficient in T-ALL carrying activating mutations in Notch1. Nevertheless, GSI compounds, such as PF-03084014, have entered clinical trials for refractory T-ALL [ 91 ]. Preclinical data do show a synergistic effect between GSI inhibition and GC in reducing xenografted T-ALL tumor burden [ 92 ]. Another concern associated with the clinical use of GSIs is severe toxicity to various organs at therapeutic doses, which may be explained by the broad action of Notch1 as well as γ -secretase on various biological systems. The simultaneous use of GCs may prevent the GSI-induced gastrointestinal toxicity via inhibition of goblet cell metaplasia [ 92 ]. A more specific inhibition of Notch1 can be achieved by the SAHM1 peptide that prevents Notch-mediated transcription by interfering with the Mastermind-Notch interaction essential for Notch-mediated transcription of target genes [ 93 ]. The effect of this peptide on GC sensitivity awaits examination as well as its toxicity. Since Notch signaling is intertwined with the PI3K/Akt/mTOR signaling axis [ 94 – 96 ], the inhibition of the latter has proven to be more efficient in overcoming GC resistance (see Section 1.2.3) and would be a better therapeutic choice.

1.2.3. Targeting Pro-Survival Protein Kinases

Accumulating data show that GC therapy can affect the activity of several protein kinases, and, vice versa, many protein kinases can affect GC-induced apoptosis [ 30 , 31 , 97 – 99 ]. The mTOR signaling pathway is frequently activated and found to be essential for cell growth and survival in lymphoid malignancies [ 100 – 106 ]. GC resistance frequently appears in malignant cells due to aberrant activation of various protein kinases that exert anti-apoptotic effects [ 30 , 31 , 67 , 97 , 107 – 109 ]. One strategy to overcome GC resistance would be to prevent the activities of the PI3K/Akt/mTOR, MEK1/ERK1/2, and other activated protein kinase pathways. The mTOR inhibitor rapamycin especially has proven efficient in sensitizing human GC-resistant T-ALL, B-ALL, MM, and NPM-ALK + (nucleophosmin-anaplastic lymphoma kinase)-DLBCL to GC-induced apoptosis [ 110 – 117 ]. The combinatory therapy of rapamycin with dexamethasone was proven to be effective also in PTEN-negative cells [ 111 ]. A lower dose of dexamethasone was sufficient for reducing T-ALL burden in a xenograft model when used together with rapamycin [ 111 ]. One major drawback with rapamycin therapy is its immunosuppressive function, which adds to the immunosuppressive function of GCs.

The dual PI3K/mTOR inhibitor NVP-BEZ235 synergistically enhanced cytotoxicity of dexamethasone, doxorubicine, and cytosine arabinoside (AraC), even in GC-resistant ALL cells [ 118 ]. NVP-BEZ235 also overcomes bortezomib resistance in mantle cell lymphoma cells [ 119 ]. The broad-acting protein kinase staurosporine was especially effective in overcoming GC resistance in mouse lymphomas that overexpressed Notch-1, Bcl-2, and/or Bcl-X L [ 120 ]. This sensitization was achieved through prevention of Akt-mediated inhibition of GSK3 [ 67 ] and induction of the pro-apoptotic Nur77 [ 120 ]. However, staurosporine was less effective on human T-ALL cell lines (unpublished data), which could rather be sensitized to GC by rapamycin. In order to choose the right kinase inhibitor for combinatory therapy, it is important to determine the kinase responsible for GC resistance prior to therapy.

The cyclin-dependent kinase (Cdk) inhibitors flavopiridol (Alvocidib), BMS-387032 (SNS-032), sunitinib, and sorafenib are currently under clinical trials for relapsed/refractory CLL [ 121 ]. Multityrosine kinase inhibitors have also been developed for the treatment of lymphoid malignancies. These include Vandetanib (ZD6474), Bosutinib (SKI-606), TKI258 (CHIR-258), Pazopanib ( GW786034 ), and Axitinib ( AG013736 ). CHIR-258, a potent inhibitor of Flt3 (fms-like tyrosine kinase receptor-3), c-Kit tyrosine kinase, and fibroblast growth factor receptor 3 (FGFR3), prevented cell growth of FGFR3-positive human multiple myeloma cell lines and augmented their sensitivity to GC-induced apoptosis [ 122 ]. Importantly, neither interleukin-6 (IL-6) nor stromal cells conferred resistance to CHIR-258 [ 122 ].

Other protein kinase inhibitors with more cell-type specific effects have been developed, which are expected to have less adverse effects. The classical example for efficient use of a specific protein kinase inhibitor in the clinics is the Bcr-Abl kinase inhibitor STI-572 (Imatinib) used for the treatment of chronic myelogenic leukemia (CML) [ 123 ]. A similar strong response of a single agent was observed in ALK + -anaplastic large cell lymphoma (ALCL) patients treated with Crizotinib, an inhibitor of the ALK tyrosine kinase [ 124 ]. Two patients that relapsed after CHOP treatment received Crizotinib as a single agent. Both showed complete response [ 124 ].

Another promising target is the B-cell receptor (BCR) signaling, which is important during B-cell oncogenesis and is a key to the survival of malignant B cells, including CLL and DLBCL [ 125 , 126 ]. The survival of DLBCL may depend on the nonligand-dependent (tonic) signals from the BCR. The BCR signaling can be targeted with small molecular inhibitors directed against Bruton's tyrosine kinase (Btk), spleen tyrosine kinase (Syk), or phosphoinositide 3′-kinase (PI3K) isoform p110 δ (PI3K δ ), all being efficient in the treatment of CLL [ 125 ]. Targeting Btk with the inhibitor PCI-32765 leads to disruption of BCR signaling and was effective in a preclinical model of B cell non-Hodgin's lymphoma [ 127 , 128 ]. PCI-32765 seems also to be promising for the treatment of CLL [ 128 – 131 ] and MM [ 132 ]. Importantly, PCI-32765 induced apoptosis in CLL cells even in the presence of various exogenous stimuli, including CD40L, BAFF, IL-6, and IL-4 and when cultivated together with stromal cells [ 131 ]. Two other Btk inhibitors, Ibrutinib and AVL-263, are also under investigation for CLL [ 121 ]. The Syk (spleen tyrosine kinase) inhibitor Fostamatinib had clinical activity in non-Hodgkin lymphoma and CLL [ 133 ]. Syk is a cytoplasmic tyrosine kinase that is important for immunoreceptor signaling in B cells. Syk has also been shown to be critical for the survival and maintenance of mature normal and malignant B cells [ 125 , 134 ] and is frequently expressed at high levels in follicular lymphoma [ 135 ]. The PI3K δ inhibitor GS-1101 (CAL-101) had preclinical and clinical activity against CLL, mantle cell lymphoma, and MM [ 121 , 129 , 136 – 138 ]. While the PI3K α and β isoforms are ubiquitously expressed, PI3K δ expression is largely restricted to hematopoietic cells, where it plays a role in B-cell homeostasis and function [ 139 ]. PI3Ks are constitutively activated in CLL cells [ 140 – 142 ]. The effect of the Btk, Syk, and PI3K δ kinase inhibitors on the sensitivity to GCs warrants investigations.

Accordi et al. [ 143 ] found aberrant activation of protein kinases in poor prognosis pediatric B-cell precursor-ALL patients. The p56 Lck (lymphocyte cell-specific tyrosine kinase) activity was enhanced in patients with poor clinical response to prednisone with respect to those with good response [ 143 ]. p56 Lck is a nonreceptor tyrosine kinase of the Src oncogene family mostly expressed in T cells where it plays an essential role in activation and development, and in some B cells. Its activity is negatively regulated by the membrane-bound tyrosine kinase Csk (c-Src tyrosine kinase). The p56 Lck inhibitor Dasatinib (BMS-354825) was shown to enhance apoptosis induction by dexamethasone in otherwise GC-resistant CLL cells [ 144 ]. This finding concurs with the observation by Sade et al. [ 68 ] showing that Notch-mediated resistance of a mouse lymphoma cell line could be overcome by inhibiting p56 Lck . In MM, a synergistic effect was observed between the Aurora A kinase inhibitor MNL8237 (Alisertib) and dexamethasone [ 145 ].

AMPK (AMP activated protein kinase) activation has a dual effect on cell death and survival, which contextually depends on signaling alterations with related oncogenic pathways [ 146 ]. MLL-rearranged tumors showed Bcl-2 hyperphosphorylation through AMPK activation [ 143 ]. However, in ALL and CLL, activation of AMPK by AICAR (5-Aminoimidazole-4-carboxamide riboside or Acadesine), a cell-permeable nucleotide, induces growth inhibition and apoptosis [ 146 – 148 ]. However, AICAR prevented glucocorticoid-induced apoptosis [ 149 ] and thus cannot be combined with steroids in the treatment of lymphoid malignancies.

Of note, inhibition of either Bcl-2 family members, Notch1, or the Akt/mTOR survival pathways was independently sufficient for sensitizing resistant cells to GC, suggesting a tight crosstalk between these pathways, interruption of one of them being sufficient for abrogating the resistant phenotype. However, it is likely that using a combination of these three strategies together with GC should lead to a more efficient therapy, which may require lower dosages with reduced adverse effects.

2. Parameters Affecting the Susceptibility of Lymphoid Malignancies to GC-Induced Apoptosis

In order to develop strategies to overcome GC resistance, it is essential to understand the signaling network regulating GC-induced apoptosis. Main factors affecting the response to GC include the basal and inducible GR expression levels, the induction of and basal expression of genes involved in the intrinsic apoptotic pathway, the ability of GR to translocate to the mitochondria, the activity of GSK3 (glycogen synthase kinase 3), the general protein kinase activation profile of the cell prior to and following GC therapy, the expression profile of anti-apoptotic proteins, and the activities of pro-survival signaling pathways. The main traits will only be briefly described here as these have been extensively reviewed elsewhere [ 30 , 31 , 99 , 150 – 153 ], and the scope of this paper is to provide updated data with a specific focus on the microRNA world that has emerged to comprise important regulators of most biological processes.

2.1. Sufficient Expression Levels of the Glucocorticoid Receptor (GR/NR3C1)

Numerous factors have been shown to affect GC responsiveness by regulating glucocorticoid receptor (GR) activity and expression level. These include GR co-activators and corepressors [ 154 , 155 ], GR splice variants [ 156 – 159 ], GR isoforms [ 160 , 161 ], and regulators of GC nucleocytoplasmic shuttle [ 162 – 164 ].

The transcription of human GR is regulated by at least 11 different promoters (1A1, 1A2, 1A3, 1B, 1C, 1D, 1E, 1F, 1H, 1I, and 1J) [ 155 , 165 ], seven of them being embedded in a highly enriched CpG island region subjected to methylation and harbor single nucleotide polymorphisms (SNPs) that affect their activity [ 166 ]. Promoter 1A is involved in the upregulation of GR by GC in some kinds of T cells, while downregulated in other cell types [ 167 – 169 ]. GC resistance in primary pediatric T- and B-ALL could not be correlated with either basal or stimulated expression of the 1A-, 1B, or 1C transcripts [ 170 ].

The GR expression level prior and following GC therapy affects drug responsiveness. The cellular response to GCs depends on sufficient GR expression [ 30 , 171 – 179 ], and resistance to GC therapy has been associated with downregulation and loss of GR expression in malignant plasma cells [ 180 , 181 ]. However, most primary ALL cells showed upregulation of GR expression upon prednisolone treatment regardless of their phenotype or sensitivity to GC-induced apoptosis, suggesting that other factors are more dominant for conferring a GC-resistant phenotype in these cells [ 29 , 170 , 182 – 184 ]. Many glucocorticoid-regulated genes (e.g., FKBP5 and SOCS1) were upregulated by dexamethasone in all primary ALL xenografts tested, suggesting for a functional GR in these leukemic cells [ 29 ]. Also, Beesley et al. [ 185 ] observed that receptor mutation is not a common mechanism of GC resistant in primary ALL [ 185 ]. However, the minor C allele of rs10482605 (1C) has been associated with a higher complication rate in childhood ALL [ 186 ]. A BclI polymorphism in the NR3C1 gene was associated with increased lymphocyte response to methylprednisolone [ 187 ]. Also, initial good responder cells may develop resistance upon repeated GC dosages, a phenomenon that sometimes occurs due to downregulation of GR [ 156 , 179 , 188 , 189 ]. Regulation of GR expression by microRNAs is discussed in Section 4.1.

Posttranslational modifications of GR are another way of regulating its target gene specificity and involve several cell-signaling cascades [ 30 , 190 , 191 ]. GR can be phosphorylated at Ser211 by CDKs and p38 MAP kinase, and at Ser226 by JNK. Phosphorylation of GR modulates its transcriptional activity, alters its protein stability and subcellular location [ 192 – 195 ]. GR phosphorylation appears to be cell-cycle dependent [ 196 , 197 ] and may affect GC-sensitivity of T-ALL cells [ 98 , 195 ].

2.2. The Ability to Upregulate the Pro-Apoptotic Gene Bim in Response to GC

2.2.1. GR as a Transcription Factor

GR is a well-known regulator of transcription. In the absence of ligand, GR is mostly located to the cytosol sequestered to heat-shock protein complexes [ 30 , 162 ]. Following GC binding to GR, the receptor undergoes phosphorylation, dissociates from the heat-shock complexes, dimerizes, and translocates to the nucleus where it either promotes or represses a whole series of genes. Transcriptional activation is either directly mediated by binding of GR to glucocorticoid response elements (GREs), or through interaction with other transcription factors such as forkhead transcription factors, thereby increasing their transcriptional activity on target genes. GR may repress gene expression either through binding to negative GREs (nGREs) or through interaction with and inhibition of the transcription factors activating protein-1 (AP-1) and NF κ B. The O-GlcNAc transferase (OGT) was found to be involved in GC-mediated transrepression [ 198 ]. Hundreds of genes are regulated by GCs [ 199 – 203 ], and some genes are differentially regulated in GC-sensitive versus GC-resistant cells [ 29 , 199 , 204 ].

2.2.2. Importance of Bim in GC-Induced Apoptosis

Of special importance is the induction of the pro-apoptotic Bim (BH3-only B-cell lymphoma 2 (Bcl-2) interacting mediator of cell death; or BCL2L11—Bcl-2-like apoptosis initiator-11) for achieving the propensity to undergo apoptosis in response to GC [ 29 , 30 , 67 , 205 – 208 ]. The central role of Bim in GC-induced apoptosis is understated by the partial GC response of Bim −/− thymocytes [ 205 ], and GC resistance of lymphoma cells after knocking down Bim [ 67 , 207 ]. Bim is often expressed at high basal levels in lymphoid cells [ 30 , 120 , 209 , 210 ], and in these cells there is no further need for upregulating Bim in order to achieve an apoptotic response to GCs [ 30 , 59 ]. However, in several T-ALL and B-ALL cells, an upregulation of Bim in response to GCs is an absolute must, especially when the basal level is low.

Bim was shown to be upregulated in GC-sensitive primary T-ALL samples, but not in resistant ones [ 29 , 182 ]. Also, a comparison of established T-ALL cell lines, Bim was upregulated in the sensitive ones only [ 211 ]. When sufficient Bim expression cannot be achieved, GC resistance pursued. A significantly lower Bim expression was detected in high risk childhood ALL patients who exhibited slow early response to a standard 4-drug induction regimen compared with patients who responded rapidly [ 212 ].

Homozygous deletion of Bim has been seen in many mantle cell lymphomas [ 213 ] and silencing of Bim by promoter methylation and mutation is common in B-cell lymphomas [ 214 ]. However, in pediatric ALL, no correlation between Bim CpG methylation and GC resistance was found [ 29 ]. Rather, GC resistance in primary pediatric ALL samples correlated with decreased histone H3 acetylation [ 29 ]. The histone deacetylase inhibitor vorinostat relieved Bim repression and exerted synergistic antileukemic efficacy with dexamethasone both in vitro and in vivo using a xenograft model [ 29 ]. Bim has been shown to be a prognostic biomarker for early prednisolone response in pediatric ALL [ 4 ].

2.2.3. The Pro-Apoptotic Function of Bim and Other Proteins in GC-Induced Apoptosis

Bim is a potent pro-apoptotic protein belonging to the Bcl-2 protein family [ 215 , 216 ]. Bim binds to the pro-survival proteins Bcl-2, Bcl-X L , and Mcl-1, thereby allowing Bax and Bak to promote apoptosis [ 217 ]. Bim may also directly bind to Bax and Bak, triggering a conformational change required for their subsequent oligomerization on the mitochondrial outer membrane [ 215 ]. Bim appears in various alternative splice variants, which exhibit different intrinsic toxicities and modes of regulation [ 218 ]. In GC-resistant primary CLL, Bim was upregulated by dexamethasone, but failed to activate Bax and Bak due to exclusive sequestration to Bcl-2 [ 219 ].

Bim may cooperate with the pro-apoptotic PUMA (p53 upregulated modulator of apoptosis) in mediating apoptosis induced by dexamethasone [ 220 ]. In B-lymphoid cells, Bmf (Bcl-2 modifying factor) is also important for GC-induced apoptosis [ 221 ]. Other pro-apoptotic members of the Bcl-2 family that is not directly upregulated by GCs, but may contribute to the cell death response, include Bid, Bad, and Noxa. Essential downstream mediators are Bak and Bax [ 222 ] that are activated by Bim. Also the thioredoxin-interacting protein Txnip (VDUP1/TBP-2) has been shown to be upregulated by GC and could contribute to GC-induced apoptosis in one mouse lymphoma cell line [ 223 ]. During GC monotherapy of childhood ALL, GC was found to repress the expression of the pro-apoptotic PMAIP/Noxa, which could be one mechanism leading to impaired GC sensitivity [ 224 ]. Conditional overexpression of Noxa restored GC sensitivity [ 224 ]. Another transcript of the Bim locus, termed “Bam,” is also induced by GCs in ALL cells, but its importance in GC-induced apoptosis is still not defined [ 225 ].

2.2.4. Regulation of Bim Expression by Transcription Factors

Bim expression is tightly regulated both at the transcription and posttranscriptional levels [ 215 , 218 ] ( Figure 1 ). No GRE element has been found in the Bim promoter. Rather, GC-induced Bim expression in lymphoid cells requires p38 activation and is mediated by the forkhead transcription factor FoxO3a/FKHR-L1 [ 226 ]. FoxO3a has also been shown to promote Bim transcription in various other cellular systems [ 227 – 229 ] and may cooperate with Runx1 (Runt-related transcription factor 1) [ 230 ]. Differential recruitment of FoxO3a to the Bim promoter was observed after dexamethasone treatment of GC-sensitive versus GC-resistant childhood ALL xenografts [ 29 ]. FoxO3 was found to be an immediate early GR target, whose transcription is further enhanced by stimuli that activate the AMP-activated protein kinase AMPK [ 231 ]. The activity of FoxO transcription factors is tightly regulated, inhibited by Akt and ERK signaling, while promoted by p38 signaling [ 232 – 236 ].

Both ERK1/2 and Akt antagonize apoptosis by reducing the Bim expression level. ERK1/2 also directly phosphorylates Bim leading to its proteosomal-dependent degradation [ 237 ]. The ribosomal protein S6 kinase (RSK) activated downstream of ERK1/2, phosphorylates BimEL, providing a binding site for the F-box proteins beta-transducin repeat containing protein ( β TrCP)1 and β TrCP2, which promote the polyubiquitination of BimEL [ 238 ]. ERK1/2 phosphorylates BimEL at Ser55, Ser69, and Ser73. The ERK1/2-mediated phosphorylation of BimEL at Ser69 facilitates optimal phosphorylation by RSK at Ser93, Ser94, and Ser98 and this motif serves as the binding sites for β TrCP1/2 [ 238 ]. While ERK1/2 lowers the affinity of Bim for Mcl-1 and Bcl-X L and targets Bim for degradation [ 239 ], phosphorylation of Bim by JNK increases the pro-apoptotic activity of Bim [ 240 , 241 ]. GCs may repress ERK1/2 activity through upregulation of mitogen-activated protein kinase phosphatase 1 (MKP-1) [ 242 ]. Several drugs that inhibit the ERK1/2 and PKB/Akt pathways may facilitate upregulation of Bim expression. MEK inhibitor-induced Bim expression per se is usually insufficient to promote apoptosis. Additional signals are required, such as simultaneous inhibition of the PKB/Akt pathway or the downstream mammalian target of rapamycin (mTOR) kinase [ 218 ]. Apoptosis may be induced in a variety of ALL cells when cotreated with dexamethasone and a MEK/ERK inhibitor or an Akt inhibitor [ 67 , 108 , 243 ].

Early studies by the Thompson research group noticed that c-Jun played a role in GC-induced apoptosis [ 244 ]. An increase in c-Jun was observed in GC-sensitive, but not GC-resistant T-ALL cell lines, while c-Fos and JunD were unaffected by the steroid. Antisense to c-Jun conferred GC resistance [ 244 ]. Recently, the c-Jun issue was revisited. Chen et al. [ 204 ] reconfirmed that c-Jun was upregulated by GCs in GC-sensitive, but not GC-resistant ALL cells. They further showed that c-Jun is recruited to the AP-1 site of the Bim promoter upon GC treatment [ 204 ]. Another study showed that dexamethasone-induced Bim expression was decreased in cells harboring a dominant-negative c-Jun [ 245 ], suggesting a role for c-Jun in the upregulation of Bim. This research group also found a Runx2-dependent upregulation of Bim. A p38 inhibitor prevented dexamethasone-induced expression of Runx2, c-Jun, and Bim, suggesting that p38-MAPK activation acts upstream to the induction of these three molecules [ 245 ].

2.2.5. Regulation of Bim Expression by MicroRNAs

Another level of Bim regulation is through microRNAs. Bim transcription is repressed by the miR-17~92 microRNA cluster [ 246 ], which, in turn, is repressed by GCs [ 206 ]. Thus, one mechanism by which GCs upregulate Bim is through repression of miR-17~92. Of note, the miR-17~92 cluster is often overexpressed or amplified in human cancers [ 247 – 252 ], thereby preventing the upregulation of Bim required for an apoptotic response. Another microRNA that suppresses Bim expression is miR-26a, which is frequently upregulated in T-ALL patients [ 253 ]. In gastric cancer, miR-106a~363 targets Bim [ 254 ]. The miR-106a~363 cluster located at chromosome Xq26.2 is the paralogue of miR-17~92 and encodes for miR-363, miR-106a, and miR-20b [ 255 ]. In hepatocellular carcinoma, miR-25 of the miR-106b~25 cluster targets Bim [ 256 ]. Also, the miR-106b~25 cluster, which includes miR-106b, miR-93 and miR-25, is a paralogue of the miR-17~92 cluster and located on chromosome 7 within the thirteenth intron of the protein-coding gene Mcm7.

2.2.6. Regulation of FoxO Transcription Factors by MicroRNAs

Also, the FoxO transcription factors, important for Bim upregulation, are regulated by microRNAs [ 257 ] ( Figure 2 ). FoxO1 and FoxO3 transcripts might be targeted by miR-182 [ 258 – 261 ], miR-1 [ 262 ], miR-27a [ 258 ], miR-96 [ 258 ], and miR-155 [ 263 , 264 ]. miR-155 plays a role in the activation and function of B and T lymphocytes [ 265 , 266 ] (see Section 3.1.6). miR-182 is upregulated in several human lymphoid cell lines [ 261 ]. miR-182 expression was higher in GC-resistant cells in comparison to GC sensitive ones [ 261 ]. Increased expression of miR-182 reduced total FoxO3a expression in T-ALL cells with consequent lower Bim expression. FoxO3a and Bim increased upon downregulation of miR-182, suggesting that miR-182 is involved in conferring GC resistance [ 261 ].

The expression of the miR-182~96~183 cluster was induced in splenocytes from mouse with experimental systemic lupus erythematosus (SLE) [ 267 ], suggesting a role of these microRNAs in the breakdown of immunological tolerance and the manifestation of chronic autoimmune inflammation. This microRNA cluster was also upregulated upon T-cell activation by an IL-2-dependent manner. Prevention of the expression of the miR-182~96~183 cluster led to increased FoxO1 expression and limited population expansion of activated T-helper cells, due to increased cell death [ 260 ].

Vice versa, FoxO3a was found to negatively regulate the oncomiR miR-21, which may be one mechanism by which FoxO3a regulates apoptosis [ 268 ]. As miR-21 targets PTEN [ 269 , 270 ], activation of FoxO3 by GCs [ 271 ] may be one mechanism responsible for the GC-induced reduction in Akt activity.

2.3. Mitochondrial Translocation of GR

Besides function as a transcription factor in the nucleus, GR was found to translocate to the mitochondria in GC-sensitive, but not GC-resistant, lymphoma cell lines [ 272 ]. GR was also found to translocate to the mitochondria in GC-sensitive thymocytes [ 272 , 273 ]. Although there is one paper describing an interaction between GR and Bcl-2 in the mitochondria [ 274 ], GC-induced mitochondrial GR translocation in GC-sensitive thymocytes and lymphoma cells proceeded in the absence of Bcl-2 [ 272 ]. Exclusive overexpression of GR in the mitochondria was sufficient for inducing apoptosis [ 272 ], suggesting that mitochondrial GR may contribute to GC-induced apoptosis.

Glucocorticoids are known to exert multiple effects on the mitochondria. Glucocorticoid treatment inhibited Complex I and Complex III of the electron transport chain, and the mitochondria was found to be the primary source of H 2 O 2 production required for GC-induced apoptosis of lymphoma cells [ 275 , 276 ]. GCs may interact with the mitochondrial thioredoxin Trx2, a redox regulator [ 277 ], and directly modulate mitochondrial gene transcription [ 278 ]. Several mitochondrial metabolite and protein transporters and two subunits of the ATP synthase were downregulated in T-ALL and precursor B-ALL cells at the gene expression level by dexamethasone. These changes were observed in GC-sensitive, but not GC-resistant, cells [ 279 ]. Corticosterone and other steroids were found to directly act on mitochondria to inhibit mitochondrial ATP production by suppressing electron transfer from NADH to the electron transfer chain through complex I [ 280 ].

2.4. The Kinome

The cellular protein kinase network (kinome) has critical influence on the GC sensitivity of lymphoid cells [ 30 , 31 , 97 , 281 ]. Above, I discussed the importance of p38 in Bim induction and activity. Below, I will provide data supporting an involvement of GSK3 (glycogen synthase kinase 3) in GC-induced apoptosis, and the antagonism of its activity by protein kinases such as Akt and mTOR, which leads to GC resistance.

2.4.1. GSK3 (Glycogen Synthase Kinase 3) Activity

The activity of GSK3 was found to be essential for GC-induced apoptosis [ 67 , 282 ]. GSK3 inhibitors prevented GC-induced apoptosis, and GC resistance frequently occurs through inhibition of GSK activity. Reactivating GSK3 by using inhibitors of the PI3K-Akt or mTOR pathways sensitized GC-resistant cells to GC-induced apoptosis [ 67 , 108 , 115 , 116 , 243 , 283 ]. GSK3 α was found to interact with GR in the absence of ligand and released from GR following exposure to GC [ 67 ]. GC treatment led to interaction of both GSK3 α and GSK3 β with Bim [ 67 ]. GSK3 β also regulates GR transcriptional activity of Bim, IAP1 (Inhibitor of Apoptosis 1), and GILZ (glucocorticoid-induced leucine zipper) [ 282 , 284 ]. This effect of GSK3 on GR transactivation was independent of known GSK3 β phosphorylation sites [ 284 ]. GSK3 β was also shown to be involved in GC-induced bone lost [ 285 ].

2.4.2. Activity of the PI3K-PKB/Akt, mTOR, and ERK Pro-Survival Pathways

The PI3K/Akt and mTOR signaling pathways are frequently hyperactivated in GC-resistant T-ALL [ 104 , 286 , 287 ] and is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor ALL [ 288 ]. mTOR is a crucial regulator of cell metabolism, growth, and proliferation and mTOR is positively regulated by PI3K/Akt and Notch1 [ 96 , 289 ], while negatively regulated by the tuberous sclerosis tumor suppressor complex (TSC1/TSC2). mTORC2 activity was essential for Notch-driven T lymphomagenesis [ 290 ]. Activation of mTOR contributes to tumor cell survival in ALK (anaplastic lymphoma kinase)-positive ALCL (anaplastic large cell lymphoma) [ 102 ], mantle cell lymphoma [ 103 ], childhood B-precursor ALL [ 112 ], T-ALL [ 110 ], and AML [ 291 ]. Akt and mTOR confer drug resistance by phosphorylating a series of targets [ 292 , 293 ]. Phosphorylation and inactivation of GSK3 is a major cause for GC resistance [ 67 ] that can be overcome by reactivating GSK3, for example, by Akt inhibitors or mTOR inhibitors. As mentioned in Section 1.2.3, the mTOR inhibitor Rapamycin is efficient in overcoming GC resistance in various lymphoid malignancies. GC resistance can also be overcome in Akt-active lymphoma cells by inhibiting Src members (e.g., by PP1), PI3K (e.g., Wortmannin), or an Akt inhibitor [ 67 , 68 ].

Combination of GC with rapamycin or GC with Obatoclax led to reduced Akt phosphorylation at Ser473 [ 59 ], suggesting that mTOR may also act upstream to Akt [ 294 ]. mTORC1 directly phosphorylates Akt/PKB on Ser473 and facilitates Thr308 phosphorylation by PDK1 [ 295 ]. GCs could also independent of other cytotoxic agents reduce mTOR activity in lymphoid cells [ 296 ]. Low-dose arsenic trioxide could sensitize GC-resistant ALL to Dex through an Akt-dependent pathway [ 286 ]. Inhibition of mTOR with rapamycin, which binds to FKBP12, leads to increased Bim expression and overcomes Ras-dependent survival signals [ 297 ]. Synergy between mTOR inhibitors (e.g., rapamycin (Sirolimus) and CCI-779 (Temsirolimus)) and other chemotherapeutic agents has been observed in B- and T-lineage ALL cell lines and preclinical models [ 96 , 298 ].

2.4.2.1. Negative Regulation of Akt by PTEN . The Akt activity is negatively regulated by PTEN (phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor gene that is suppressed, mutated, or deleted at high frequency in a large number of cancers [ 299 ]. PTEN mutations or deletions are frequent in T-ALL and PTEN deletions are associated with less favorable outcome in T-ALL [ 104 , 300 ]. The PTEN status of the cell affects drug sensitivity. For instance, treatment of T-ALL with gamma secretase inhibitor (GSI) was only efficient if the cells expressed functional PTEN [ 90 ]. One mechanism by which Notch confers GC resistance is through PTEN inhibition leading to Akt activation. PTEN specifically catalyzes the dephosphorylation of 3′-phosphate of the inositol ring in phosphatidylinositol (3,4,5)-triphosphate (PIP 3 ) resulting in the biphosphate product phosphatidyl (4,5)-biphosphate (PIP 2 ). PIP 3 is a second messenger generated by PI3K that binds to the pleckstrin homology (PH) domain of Akt, which allows its phosphorylation and activation by the 3-phosphoinositide-dependent protein kinase 1 (PDK1) [ 292 ].

2.4.2.2. Regulation of PTEN Stability by Phosphorylation and Ubiquitination . Taken into account the important role of PTEN in determining drug sensitivity, mechanisms regulating PTEN activity and stability have strong impact on the drug response. PTEN is regulated by several mechanisms [ 301 ]. Besides gene mutation and deletion, reduced PTEN expression has been attributed to epigenetic events such as promoter methylation [ 302 , 303 ]. At the posttranslational level, phosphorylation and ubiquitination decrease PTEN protein levels, while oxidation and acetylation reduce PTEN activity [ 301 ]. Rak phosphorylation of PTEN at Tyr336 stabilizes the PTEN protein [ 304 ], while phosphorylation at Thr366, Ser370, Ser380, Thr382, and Ser385 by casein kinase 2 (CK2) and GSK3 β reduces its stability [ 305 , 306 ].

PTEN is regulated by the protooncogene ubiquitin ligase NEDD4-1 (neural precursor cell expressed, developmentally downregulated 4) that promotes PTEN for proteasomal degradation [ 307 ]. In multiple human cancer samples where the genetic background of PTEN was normal, but its protein level was low, NEDD4-1 was highly expressed [ 307 ]. Upon TCR/CD28 stimulation of T cells, PTEN undergoes inactivation by NEDD4-1 [ 308 ]. The association between PTEN and NEDD4 could be impeded by the E3 ubiquitin ligase Cbl-b (Casitas-B-lineage lymphoma protein-b) [ 308 ]. Cbl-b −/− T cells show elevated Akt activity, which was abrogated by simultaneous deficiency in NEDD4 [ 308 ]. PTEN is also negatively regulated by the anti-apoptotic XIAP (X-linked inhibitor of apoptosis) that promotes PTEN for polyubiquitination and proteosomal degradation [ 309 ]. Induction of apoptosis in B-CLL by arsenic trioxide was shown to lead to activation of c-Jun-NH 2 terminal kinase (JNK), inactivation of AKT and NF κ B, XIAP downregulation, and PTEN upregulation [ 310 ]. Two other E3 ligases downregulating PTEN include WWP2 (WW-domain containing protein-2 or AIP-2, atrophin-1-interacting protein 2) [ 311 ], and CHIP (chaperone-associated E3 ligase C terminus of Hsc70-interacting protein) [ 312 ]. Recently, PTEN was shown to be upregulated by dexamethasone [ 313 ].

2.4.2.3. Regulation of PTEN Stability by MicroRNAs . PTEN expression can also be repressed by a range of microRNAs including the miR-17~92 cluster [ 247 , 248 ], miR-106b~25 [ 314 ], miR-21 [ 269 ], miR-26a [ 253 , 315 ], miR-29b [ 316 ], miR-214 [ 317 , 318 ], miR-216a and miR-217 [ 319 ], miR-212 [ 320 ], miR-221, and miR-222 [ 321 ] ( Figure 3 ).

2.5. Expression Levels of Anti-Apoptotic Proteins of the Bcl-2 Superfamily

2.5.1. Bcl-2 and Bcl- X L

Bcl-2 and Bcl-X L are anti-apoptotic proteins residing in the mitochondrial outer membrane and in the endoplasmic reticulum. They prevent apoptosis of various chemotherapeutic drugs including GCs by capturing pro-apoptotic members of the Bcl-2 superfamily, including Bim, Bax, and Bak [ 215 , 322 , 323 ]. Bcl-2 may also regulate gene expression [ 324 , 325 ], cell cycle [ 326 – 328 ], activate ERK1/2 [ 324 , 329 ], and modulate the activities of transcription factors such as p53 [ 330 ], E2F [ 325 ], NF κ B [ 331 ], and Notch [ 332 , 333 ]. Bcl-2 promotes T-cell lymphoma in a p27 Kip1 -deficient background [ 334 ]. This may be explained by the ability of Bcl-2 to modulate p27 Kip1 expression and promote G 0 arrest [ 325 , 327 , 331 , 335 , 336 ].

Long-term exposure to GCs could overcome resistance caused by either Bcl-2 or Bcl-X L [ 30 , 120 , 337 ]. Overexpression of Bcl-2 is common in leukemias and lymphomas [ 338 – 341 ]. In follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), Bcl-2 upregulation is commonly due to the t(14,18)(q32; q21) translocation, which places the Bcl-2 gene under the control of Ig heavy chain enhancers [ 342 – 344 ].

2.5.1.1. Targeting of Bcl-2 by MicroRNAs . Overexpression of Bcl-2 is common in CLL due to the loss or downregulation of the human chromosome 13q14 locus, which harbors the miR-15a and miR-16-1 cluster [ 345 ]. These microRNAs directly target the anti-apoptotic Bcl-2 protein [ 346 ]. Overexpression of either microRNA was sufficient to completely abrogate Bcl-2 expression in CLL cells. Overexpression of miR-15a and miR-16-1 in CLL cells led to cleavage of procaspase-9 and PARP (poly-ADP-ribose polymerase) and activation of the intrinsic apoptosis pathway. These two microRNAs could serve as natural antisense Bcl-2 actors that have potential use in the therapy of Bcl-2 overexpressing tumors [ 346 ].

The tumor-suppressor miR-34a, a pivotal member of the p53 network, also downregulates Bcl-2 [ 347 , 348 ], which may be one mechanism by which p53 activation leads to downregulation of Bcl-2. Recent studies suggest that miR-125b also may contribute to Bcl-2 repression [ 349 – 351 ]. It also targets Mcl-1 and Bcl-w, and indirectly Bcl-X L by attenuating IL-6/STAT-3 (signal transducer and activator of transcription 3) signaling pathway [ 350 , 352 ]. miR-125b may function both as tumor suppressor and as an oncogene [ 350 ] and has been widely considered as conferring drug resistance, among others by downregulating Bak1 (Bcl-2 antagonist killer 1) [ 353 – 355 ] and Bmf [ 356 ]. Over-expression of miR-125b could induce leukemia in a mouse model [ 357 ].

miR-181a/b that shows altered expression in CLL could also target Bcl-2, besides acting on Mcl-1 and XIAP [ 358 – 360 ]. Bcl-X L can be targeted by the tumor suppressor microRNA let-7 [ 361 ] and miR-491 [ 362 ]. A putative GR binding site was found within the promoter region of let7a2 [ 363 ].

2.5.2. Mcl-1

A predominant feature of the gene expression signature leading to GC resistance in ALL was found to be elevated expression of the anti-apoptotic Mcl-1 (myeloid cell leukemia sequence 1) [ 364 , 365 ]. Mcl-1 expression is especially high in MLL-rearranged ALL, which represents an unfavorable type of leukemia that is often highly resistant to GCs [ 365 ]. Mcl-1 is also frequently overexpressed in B-cell and mantle-cell lymphomas, CML, CLL, and MM. Mcl-1 expression renders cancer cells resistant to the Bcl-2 antagonist ABT-737.

Mcl-1 is an anti-apoptotic protein that sequesters the pro-apoptotic proteins tBid, Bim, Puma, Noxa, and Bak [ 366 ]. Besides preventing GC-induced apoptosis [ 287 ], Mcl-1 confers resistance to TRAIL (tumor necrosis factor-related apoptosis inducing ligand)-induced cell death [ 367 ].

2.5.2.1. Regulation of Mcl-1 Stability . Mcl-1 differs from Bcl-2 and Bcl-X L in having a short protein turnover regulated by the 26S proteasome and its expression is tightly regulated [ 368 ]. Unlike Bcl-2, chromosomal translocations have not been implicated in dysregulated Mcl-1 levels. Rather, cellular signaling regulates Mcl-1 function and expression at the posttranslational level.

Rapamycin, a mTOR inhibitor that sensitizes resistant ALL cells to GC, reduces the expression level of Mcl-1 [ 113 , 287 ]. Mcl-1 level could also be reduced by the protein kinase inhibitor Sorafenib. The degradation of Mcl-1 depends on GSK3-mediated phosphorylation of Mcl-1 at Ser159 [ 369 , 370 ]. E3 ubiquitin ligases implicated in the regulation of Mcl-1 include Mule (Mcl-1-ubiquitinase ligase E3) [ 371 ], SCF β -TrCP (Skp1/Cul1/F-box protein β -transducin repeat-containing protein) [ 369 ], and Fbw7 (F-box and WD repeat domain-containing 7) which is part of the Skp1-Cullin1-F-box (SCF) E3 ligase complex [ 372 ]. The deubiquitinase USP9X (ubiquitin specific peptidase 9 X-linked) is an important regulator of Mcl-1 stability [ 373 ]. Silencing of USP9X resulted in loss of Mcl-1. USP9X removes degradative Lys48-linked polyubiquitin chains on Mcl-1. High levels of Mcl-1 correlated with elevated USP9X expression in follicular lymphoma, diffuse large B-cell lymphoma, and some other cancer samples. Increased expression of USP9X mRNA was associated with poor prognosis of multiple myeloma [ 373 ]. USP9X also interacts with mTOR, negatively regulating its activity [ 374 ].

Interaction with BH3-only family members may also affect Mcl-1 stability. Whereas Noxa may destabilize Mcl-1, Bim increases its stabilization [ 375 ]. Noxa-induced degradation of Mcl-1 requires the E3 ligase Mule. Overexpression of Noxa triggered an increase in the Mule/Mcl-1 interaction in parallel to a decrease in Mule/USP9X complex formation [ 376 ].

In an Akt-driven, E μ -Myc lymphoma mouse model, translational regulation of Mcl-1 by mTOR has been implicated in promoting lymphomagenesis [ 377 ]. As GC may activate GSK3 [ 67 ] and GSK3 inhibits mTOR through phosphorylation of TSC2 [ 378 ] and promotes Mcl-1 degradation [ 369 , 370 ], Mcl-1 expressing lymphoid cells may ultimately undergo apoptosis if the exposure time to GC is sufficiently long. This may explain why many Mcl-1-positive ALL cells exhibit delayed response to GCs, and not complete resistance [ 67 , 108 ]. Also, the anti-apoptotic function of Mcl-1 appears to require simultaneous expression of other anti-apoptotic Bcl-2 family members [ 379 ]. Similarly, overexpression of Mcl-1 in Bcl-2- and Bcl-X L -negative mouse double positive thymic lymphoma cells did not confer GC resistance upon these cells [ 120 ]. Usually, Mcl-1 is expressed together with other anti-apoptotic proteins in GC-resistant lymphoid malignancies.

2.5.2.2. Regulation of Mcl-1 by MicroRNAs . Mcl-1 is also regulated by microRNAs ( Figure 2 ), including miR-29a [ 380 ], miR-29b [ 381 – 383 ], miR-101 [ 384 ], miR-125b [ 350 ], miR-181a/b [ 358 , 385 ], miR-133b [ 386 ], miR-193b [ 387 ], and miR-512 [ 388 ]. ALK-positive anaplastic large cell lymphomas (ALCL) express low levels of miR-29a, whose downregulation requires an active NPM-ALK kinase, and may probably also be due to methylation repression [ 380 ]. Enforced miR-29a expression reduced Mcl-1 expression in ALCL cells and reduced tumor growth in a xenografted model [ 380 ]. miR-29b is downregulated in primary MM and AML samples and forced overexpression of miR-29b-induced apoptosis in MM and AML cells [ 381 , 383 ]. miR-29b overexpression also downregulated the expression of the DNA methyltransferase isoforms DNMT1, DNMT3A, and 3B [ 383 ]. The global DNA hypomethylation induced by miR-29b led to reexpression of tumor suppressor genes such as the CDK inhibitor p15 INK4b [ 383 ]. Altogether, these data propose that targeting Mcl-1 with microRNAs such as miR-29 represents a potential tool to constrict tumor growth of Mcl-1 positive lymphomas.

2.5.3. Effect of Bcl-2 Family Proteins on Intracellular Ca 2+ Mobilization

GCs release Ca 2+ from the endoplasmic reticulum into the cytosol, which in turn increases the amount of mitochondrial Ca 2+ . The increase in mitochondrial Ca 2+ induces cytochrome C release and trigger apoptosis. Elevated expression of calcium-binding proteins S100A8 and S100A9 and of the anti-apoptotic Mcl-1 (myeloid cell leukemia-1) inhibits the free cytosolic Ca 2+ and mitochondrial Ca 2+ signals, respectively, thereby imposing GC resistance [ 287 , 365 , 389 , 390 ]. Downregulation of S100A8 and S100A9 by the Src kinase inhibitor PP2 sensitized MLL-arranged ALL cells otherwise resistant to prednisolone-induced cell death [ 389 ]. Bcl-2 inhibits apoptosis in part by decreasing the size of Ca 2+ stores in the endoplasmic reticulum resulting in reduced Ca 2+ transfer to the mitochondria [ 391 – 393 ]. One mechanism is through interaction of Bcl-2 with IP 3 R (inositol 1,4,5-triphosphate (InsP3) receptor), which is the principle ER Ca 2+ release channel in most cell types [ 394 ]. Also, Bcl-X L and Mcl-1 act in part by inhibiting IP 3 R [ 393 , 395 , 396 ]. Bcl-X L overexpression also leads to reduced expression of IP 3 R [ 397 ].

2.6. Presence of Reactive Oxygen Species (ROS) Scavengers

An increase in hydrogen peroxide (H 2 O 2 ) is a necessary signal for GC-induced apoptosis [ 276 ]. The mitochondria is the source of this signal [ 275 ], GCs inhibit complex I and complex III of the electron transport chain [ 275 ]. Expression of anti-oxidant defense proteins such as manganese superoxide dismutase, thioredoxin, and catalase prevents GC-induced apoptosis [ 276 , 398 – 400 ]. The anti-apoptotic Bcl-2 may regulate the mitochondrial redox state in cancer cells [ 323 , 401 ].

2.7. Increased Notch Activity

Notch is frequently activated in T-ALL cells, which may be due to mutations in Notch1 (gain-of-function) and/or in the E3 ligase Fbw7 that targets Notch1 for degradation [ 76 – 78 , 80 , 81 , 402 – 405 ]. Some other E3 ligases also regulate Notch signaling [ 406 , 407 ]. For example LNX1 (ligand of Numb-protein X1) is a positive regulator of Notch signaling through degradation of Numb, a membrane-associated protein that inhibits the function of the Notch receptor [ 408 ]. Neuralized ( neur ) and Mind bomb ( mib ) promote the monoubiquitination and endocytosis of Delta [ 409 , 410 ]. Itch binds to the N-terminal portion of the Notch intracellular domain via its WW domains and promotes ubiquitination of ICN-Notch1 through its HECT ubiquitin ligase domain [ 411 ]. Recent studies showed that Notch1 can be activated in leukemic cells through interaction with bone marrow stromal cells that express Notch receptors and ligands [ 412 , 413 ]. Interaction with bone marrow stroma is also a mechanism for Notch activation in multiple myeloma [ 414 ]. The simultaneous expression of Bcl-2 may enforce Notch activity [ 332 , 333 ]. Cyclin E, which is targeted for degradation by Fbw7 [ 415 , 416 ], is expressed at higher levels in early relapsed pediatric B-cell precursor ALL patients, who usually show an unfavorable prognosis [ 143 ].

Notch1 prevents GC-induced apoptosis, among others, through activation of p56 Lck , which activates the PI3K-Akt axis [ 68 ], and through the transactivation of its target genes Deltex and Hes1 [ 88 ]. Hes1 leads to downregulation of PTEN, thereby activating the PI3K/Akt pathway [ 88 ]. Deltex is a RING-domain ubiquitin ligase that may affect Notch activity [ 417 ], and its overexpression prevents GC-induced apoptosis [ 418 ]. Activation of the pro-survival PI3K/Akt/mTOR pathway by Notch has also been observed in other studies [ 95 , 106 , 419 , 420 ] and may be responsible for Notch-mediated inhibition of the p53 tumor suppressor gene [ 95 ]. Another mechanism by which Notch1 protects T-ALL cells from GC-induced apoptosis, is through the anti-apoptotic GIMAP5/IAN5 (GTPase of the immunity-associated protein/immune-associated nucleotide-binding protein 5) [ 421 , 422 ]. GIAMP5/IAN5 interacts with Bcl-2 and Bcl-X L and inhibits apoptosis during T-cell development [ 423 ] and is highly expressed in human B-cell lymphoid malignancies [ 424 ]. It is localized within the mitochondria and endoplasmic reticulum (ER) and regulates mitochondrial integrity [ 425 ]. GIMAP has been linked to immunological diseases such as T-cell lymphopenia and autoimmune diseases [ 426 ]. Notch also activates NF κ B signaling [ 74 , 427 ] and induces c-Myc expression [ 428 – 430 ], both contributing to apoptotic resistance. Long-term treatment with GCs can overcome Notch1 resistance [ 67 ]. This resistance can be overcome by the simultaneous exposure of the cells to Src inhibitors, PI3K/Akt inhibitors, or mTOR inhibitors [ 67 , 68 ], understating the importance of the protein kinase network in regulating the effects of Notch1 on GC-induced apoptosis.

A recent report showed that GC sensitivity of T-ALL is associated with GR-mediated inhibition of Notch1 expression [ 431 ]. The serum- and glucocorticoid-inducible kinase 1 (SGK1) was also shown to control Notch1 signaling by downregulating its protein stability through Fbw7 ubiquitin ligase [ 432 ]. SGK1 phosphorylates Fbw7 at Ser227, an effect inducing ICN-Notch1 ubiquitination and degradation [ 432 ]. Despite GC resistance induced by Notch, Notch- and Fbw7-mutated T-ALL shows in general a favorable response to GC therapy and in some studies, but not all, also exhibits a better prognosis [ 405 , 433 – 436 ]. This may be related to the fact that GCs may overcome Notch-dependent drug resistance, and in these T-ALL cases the cell survival depends on Notch signaling.

2.7.1. Regulation of Notch Activity by MicroRNAs

Notch activity may be affected by microRNAs [ 437 ]. Various microRNAs negatively regulate Fbw7 expression including miR-27a, miR-182, miR-363~92, and miR-223 [ 253 , 438 , 439 ] and may increase the expression of Fbw7-regulated target genes including Notch1, Mcl-1, c-Jun, c-Myc, and Cyclin E [ 438 ]. miR-451 and miR-709 suppressed oncogenesis in Notch1-induced mouse T-ALL [ 440 ]. miR-150, which is upregulated upon thymocyte maturation, targets Notch3 and thus regulates T-cell proliferation and survival [ 441 ]. miR-326 acts in a feedback loop with Notch signaling [ 442 ]. The p53-induced miR-34a also targets the Notch1 receptor as well as its ligand DLL1 (Delta like-1) [ 443 , 444 ].

Prevention of Notch activation in cutaneous T-cell lymphoma (CTLC) by GSI ( γ -secretase inhibitor) treatment led to alterations in the microRNA profile of the cell [ 445 ]. Among others, miR-27a, miR92b, miR-181a, miR-18a, miR-19b, miR-222, and miR-221 were downregulated, while miR-122 and miR-214 upregulated [ 445 ]. miR-27a targets Fbw7/hCDC4 [ 253 , 438 , 439 ], the substrate recognition component of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex that targets Notch1 for degradation [ 82 ]. The repressive effect of miR-27a on Fbw7 mRNA is especially pronounced at the G 2 /M and early G 1 phases [ 438 ]. Thus, GSI may indirectly deregulate Notch1 through the miR-27a-Fbw7 pathway. Other targets of miR-27a includes ZBTB10 (zinc finger and BTB domain containing 10), which acts as a repressor of Sp (specificity proteins) transcription factors and induces G1 arrest, and the Myt-1 kinase, which inhibits the transition through G2-M by enhanced phosphorylation and inactivation of Cdc2 (Cdk1, cyclin-dependent kinase 1) [ 446 ]. miR-27a is frequently upregulated in pediatric B-ALL [ 438 ]. Upregulation of miR-122 by GSI seems to be mediated by p53 and has an antagonistic effect on apoptosis through activation of Akt [ 85 ].

2.8. c-Myc Overexpression

c-Myc is, among others, a target of Notch [ 428 – 430 ] and has broad effects on tumorigenesis [ 447 ] and modulates GC-induced apoptosis [ 99 , 448 ]. Conditional overexpression of c-Myc in hematopoietic cells in mice culminated in the formation of malignant T-cell lymphomas and acute myeloid leukemias [ 449 ]. c-Myc may also be activated in T-ALL independently of Notch1 [ 450 ]. These authors demonstrated a role for the PI3K/Akt axis in c-Myc activation. Dysregulation of the c-Myc gene is a common trait of Burkitt's lymphoma due to chromosomal translocations, the most frequent one being t(8; 14)(q24:q32) involving c-Myc and IgH (Immunoglobulin heavy locus) [ 451 – 453 ]. Other hematopoietic malignancies characterized with c-Myc overexpression include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, CLL, B-cell lymphoma, and AML [ 454 – 459 ]. Earlier studies have shown that dexamethasone-induced apoptosis of a T-ALL cell line was associated with c-Myc suppression [ 460 , 461 ]. The GC-mediated down-regulation of c-Myc expression was initially thought to be one mechanism that contributes to apoptosis. Not all studies have confirmed this finding [ 462 ], which may be explained by the many signaling pathways induced by GCs.

2.8.1. The c-Myc-E2F1-MicroRNA Network

c-Myc uses distinct mechanisms for activating and repressing gene expression. For transcriptional activation, c-Myc dimerizes with Max and binds to the promoters of its target genes [ 463 – 465 ]. Transcriptional repression is achieved through protein-protein interactions, where it antagonizes the activity of positive regulators of transcriptions [ 466 ]. c-Myc also regulates gene expression by regulating microRNA transcription [ 255 ]. The c-Myc-mediated upregulation of miR-17 and miR-20a (belonging to the miR-17~92 cluster) negatively regulates E2F1 translation by targeting the 3-UTR of E2F1 mRNA and may therefore fine tune the direct Myc-mediated transcriptional activation of E2F1, allowing a tightly regulated proliferative signal [ 255 ] ( Figure 4 ). E2F1-3 also binds to the promoter of the miR-17~92 cluster and activates its transcription, thus generating an autoregulatory feedback loop [ 467 ]. Another target of the miR-17~92 cluster is cyclin D1, which also induces the expression of miR-17 and miR-20a by binding to the promoter regulatory region of the miR-17~92 cluster [ 468 ]. The miR-17~92 cluster prevents c-Myc-induced apoptosis [ 469 ]. The GC-induced down-regulation of miR-17~92 [ 206 ] should actually stimulate E2F1 expression, which under certain circumstances may exert pro-apoptotic effects [ 470 ]. E2F1 may promote apoptosis through transcriptional activation of the pro-apoptotic miR-15a~16 cluster [ 471 ] and by activating JNK [ 472 ]. In a B-cell lymphoma model, c-Myc down-regulated a series of microRNAs, an action that may contribute to tumorigenesis [ 473 ]. The c-Myc mediated repression of the miR-30 cluster [ 473 ] may affect autophagy, as Beclin-1 expression is regulated by miR-30a [ 474 ]. Some of the pro-autophagy activity of cancer therapy is mediated through down-regulation of miR-30a [ 475 ]. Also the down-regulation of miR-15a and miR-16 by c-Myc [ 473 ] is of interest as these microRNAs are deleted or downregulated in over two-thirds of individuals with CLL, and they target the anti-apoptotic Bcl-2 gene [ 345 , 346 ]. A third miRNA downregulated by c-Myc is the tumor suppressor let-7 miRNA cluster [ 473 ], which targets, among others, the Ras oncogene [ 476 ], HMGA2 (high mobility group A2) [ 477 , 478 ], Bcl-X L [ 361 ], Cdc25A, CDK6 (cyclin-dependent kinase 6), and cyclin D2 [ 479 ]. Other miRNAs repressed by Myc include miR-22, miR-23a/b, miR-26a/b, miR-29a/b/c, miR-34a, miR-146a, miR-150, and miR-195 [ 465 , 473 , 480 ].

miR-26a levels were found to be reduced in various B-cell lymphomas, especially Burkitt lymphoma [ 465 ] as well as various solid tumors [ 481 , 482 ]. B-CLL, which does not have a prominent pathological role of c-Myc, showed higher expression of miR-26a than Myc-dependent Burkitt lymphoma [ 465 ]. miR-26 restoration in Burkitt lymphoma or nasopharyngeal carcinomas reduced proliferation and colony formation through G1 arrest and repression of the histone-lysine N-methyltransferase EZH2, a global regulator of gene expression [ 465 , 481 , 483 ]. The tumor-suppression function was only seen in Myc-transformed cells, but not in v-Abl transformed cells [ 465 , 483 ]. However, in T-ALL, miR-26a was one of five microRNAs that independently promoted tumorigenesis through inhibition of PTEN [ 253 ]. In the background of activating mutations in Notch1, miR-26a overexpression decreased the latency of T-ALL [ 253 ].

Forced overexpression of miR-34a, miR-150, and miR-15a/16-1 attenuated in vivo tumor growth of Myc-induced B-cell lymphoma [ 473 ]. miR-34a is a crucial component of the p53 tumor suppressor network with potential anti-proliferative and pro-apoptotic activity [ 484 – 486 ]. c-Myc transcriptionally induces Lin28B, which is an RNA-binding protein that suppresses the maturation of let-7 family microRNA precursors [ 487 , 488 ]. This seems to be one mechanism used by c-Myc to repress let-7 [ 487 ]. Lin28 is involved in stem cell maintenance [ 489 – 491 ] and is a marker of cancer stem cells [ 492 ].

2.9. GC-Induced Autophagy

The effect of autophagy on the cellular response to chemotherapy is dual [ 493 ]. Under certain conditions, autophagy acts as a pro-survival mechanism to protect cancer cells from chemotherapy, whereas under other circumstances, autophagy mediates the therapeutic effects of the anticancer agents. Autophagy is regulated by Beclin-1 and autophagy-related genes (ATG) [ 60 ]. Another important regulator of autophagy is the activity of mTOR (mammalian target of rapamycin), which is a central element signaling cell growth and enhancing protein translation. When this kinase is inhibited, autophagy is promoted [ 60 ].

It should be noted that Beclin-1 may play a dual role in both regulating autophagy and apoptosis, thus being at the cross-road between these two physiological processes. Beclin-1 has recently been recognized as a BH3-only protein interacting with Bcl-2, Bcl-X L and Mcl-1 [ 59 , 60 , 494 – 496 ]. One report provides evidence that after initiating apoptosis, Beclin-1 is cleaved by caspases and the N-terminal fragment of Beclin can inhibit autophagy, while the C-terminal fragment can amplify mitochondrial-mediated apoptosis [ 497 ]. Perturbation of Beclin-1 cleavage by knockin mutation phenocopied the autophagy induction observed in apoptosis-defective cancer cells and rendered chemotherapy resistance both in vitro and in vivo [ 498 ]. A role for Beclin in regulating tumorigenesis has been demonstrated in mice with heterozygous disruption of Beclin-1 [ 499 ]. These mice have increased frequency of spontaneous malignancies. DLBCL expressing high Beclin-1 levels had a favorable clinical outcome with R-CHOP treatment than those with low Beclin-1 expression [ 500 ].

GCs have been shown to promote autophagy in lymphocyte cell lines and primary T-ALL cells [ 501 , 502 ]. One mechanism for induction of autophagy is through upregulation of the mTOR-inhibitory stress protein Dig2 (dexamethasone-induced gene 2), also known as RTP801 and REDD1 (regulated in development and DNA damage responses 1) [ 503 ]. mTOR inhibition by dexamethasone was demonstrated by reduced phosphorylation of S6K (70kD ribosomal protein S6 kinase 1), a member of the RSK family of serine/threonine kinases [ 503 ]. Dig2 releases TSC2 from 14-3-3, thereby promoting the assembly of the TSC1/TSC2 complex, which inhibits mTOR [ 504 ]. Dig2 knockout thymocytes underwent more extensive dexamethasone-induced cell death, suggesting that autophagy promotes cell survival [ 503 ]. However, rapamycin, an inhibitor of mTOR and inducer of autophagy, strongly sensitizes resistant MM and T-ALL cells to GC-induced apoptosis [ 59 , 111 , 116 , 117 ], suggesting that induction of autophagy does not always combat apoptosis. It could be that the higher degree of autophagy induced by rapamycin itself may be pro-apoptotic. Bonapace et al. [ 59 ] showed that rapamycin induces an autophagy-dependent necroptosis, which is required for childhood T-ALL to overcome GC resistance. Necroptosis is a form of programmed necrosis that occurs when apoptosis is abortive due to caspase inhibition [ 505 ]. The GC-mediated necroptosis was mediated by RIP-1 (receptor-interacting protein-1) and CYLD (cylindromatosis) [ 59 ]. miR-19, which is frequently overexpressed in T-ALL patients and cell lines, represses CYLD expression [ 506 ]. A miR-19 inhibitor induces CYLD expression with consequent decrease in NF κ B expression [ 506 ]. Obatoclax, a putative antagonist of Bcl-2 family members, could also sensitize T-ALL cells to GC-induced apoptosis through induction of autophagy [ 59 ]. This effect was associated with dissociation of the autophagy inducer Beclin-1 from Mcl-1 and decreased mTOR activity [ 59 ]. The cell death process could proceed in the absence of Bax and Bak [ 59 ]. The apoptosis induced by GC in combination with Obatoclax or rapamycin could be prevented by the autophagy inhibitors 3-methyladenine and bafilomycin [ 59 ]. GCs may also induce autophagy by inhibiting Akt activity [ 501 ].

2.10. Additional Mechanisms Leading to GC Resistance

CDKN2/p16 INK4a , which acts as a G 0 /G 1 cycle inhibitor, is frequently lost in T-ALL [ 507 , 508 ] and predicts relapse in children with ALL [ 508 – 510 ]. p16 INK4a sensitizes T-ALL cell lines to GC-induced apoptosis through induction of BBC3/Puma and repression of Mcl-1 and Bcl-2 [ 511 ]. Noxa was repressed in p16 INK4a transgenic cells, which could be a result of the simultaneous repression of E2F1 due to retinoblastoma protein and p130 activation [ 511 ]. The Bim level was unaffected by p16 INK4a overexpression [ 511 ]. Diffuse large B-cell lymphoma with CDKN2A deletion had a poor prognosis under R-CHOP treatment [ 512 ]. Also, Myc gene arrangement in diffuse large B-cell lymphoma patients had a poor prognosis with R-CHOP chemotherapy [ 513 ].

3. MicroRNA in Normal and Malignant Lymphoid Cells

During the last decade, microRNAs have become the focus of having a central role in the pathogenesis of cancer including lymphoid malignancies, besides their role in regulating gene expression during cell division, development, and differentiation [ 514 – 523 ]. MicroRNAs are short noncoding RNAs that induce posttranscriptional gene silencing through base pairing with the 3′ untranslated region (UTR) of their target mRNAs, thereby inhibiting their translation, with subsequent reduced protein levels [ 524 , 525 ]. Bases 2–7 or 2–8 of the microRNA are primary contributors to target specificity and are referred to as the microRNA seed region. The microRNAs are usually transcribed by RNA polymerase II, and sometimes by RNA polymerase III, into long primary precursor transcripts referred to as pri-miRNAs. miRNA are encoded by one arm of a stem loop structure embedded in introns or, less frequently, exons of protein-coding or noncoding transcripts. In the nucleus, the pri-miRNAs stem loop is cleaved by the nuclear RNase III enzyme Drosha together with its cofactor DGCR8 (DiGeorge syndrome critical region 8)/Pasha (the microprocessor complex) to generate ~70 nucleotides long precursors called pre-miRNAs. In some cases, an entire intron consists of such a stem loop structure, which is released by the splicing machinery in a Drosha-independent manner. Such miRNAs are referred to as mirtrons [ 526 , 527 ]. Pre-miRNAs are exported by RanGTP/exportin-5 to the cytoplasm, where they are further processed by Dicer, another RNase III enzyme, to generate ~22 base pair microRNA duplexes that enter effector complexes called miRISC (miRNA-containing RNA-induced silencing complex). Here, they are converted into single-stranded mature miRNAs that target mRNAs and thereby affect their translation and stability [ 516 , 528 , 529 ].

Cancer cells frequently display reduced levels of microRNAs that act as tumor suppressors, while expressing elevated levels of oncogenic microRNAs, called “oncomiRs” that promote tumor development by negatively regulating tumor suppressor genes and/or genes that control cell differentiation and apoptosis. A network of oncomiRs expressed in lymphoid malignancies is depicted in Figure 5 . Below I will describe briefly prominent microRNAs detected in normal and malignant lymphoid cells. There are variations in the microRNA expression pattern described between the various scientific reports, which can be explained by the use of different internal standards, different controls for comparison, and the use of sample materials of malignant cells at different developmental stage and at different ontogeny tumor grade.

3.1. MicroRNAs in T- and B-Cell Development

Virtually every step in hematopoiesis seems to be finely tuned by specific microRNAs [ 514 , 530 – 533 ]. Dicer has an essential role in the development of the adaptive immune system. Conditional deletion of Dicer expression in the T-cell compartment resulted in impaired T-cell development and diminished regulatory T-cell function [ 534 – 536 ], and ablation of Dicer in the B-cell compartment attenuates B-cell development and alters the antibody repertoire [ 537 ]. It should be noted that there exists an alternative microRNA processing pathway that is independent of Dicer, but dependent on Argonaute-2 [ 538 ].

3.1.1. MicroRNA during Thymocyte Development

MicroRNA expression is dynamically regulated during thymocyte development, with different enriched microRNAs expressed at each developmental stage [ 539 ] ( Table 1 ). It should be emphasized that the CD4 + CD8 + (double positive, DP) thymocytes are the most GC-sensitive thymocyte population [ 540 – 542 ]. Dicer-deficient DP thymocytes expressed higher levels of CD69 and TCR (T-cell receptor), but lower levels of Bcl-2 [ 539 ]. The Dicer-deficient thymocytes were more prone to apoptosis than control cells [ 539 , 543 ], understating the role of microRNAs in regulating cell survival. Some microRNAs, such as miR-146a and miR-182, play a dominant role in the regulation of the innate and adaptive immune responses, respectively [ 544 , 545 ].

According to Neilson et al. [ 539 ], the pro-apoptotic miR-15b is almost not expressed at the immature DN1 (double negative 1) thymocyte stage but becomes gradually upregulated in DN3 and DN4, and further in DP cells. The pro-apoptotic miR-16 is also low in DP1 and reaches a maximum in DN4 cells, with a reduction upon transition to DP cells. The oncogenic miR-21 is expressed at the highest level in DN1 and becomes reduced upon transition to DN3 and is almost not expressed in DP cells. miR-181a/b is expressed at the highest level in DP thymocytes, together with miR-92 and miR-350. It should be noted that in this study the expression of each microRNA was determined relative to the general microRNA pool of each subpopulation. Since the amount of total microRNA becomes strongly reduced upon transition from DN4 to DP (a drop from 32000 to 5200 copies/cell), the absolute microRNA number in each cell population differs, which can be demonstrated by the miR-181a transcript. While miR-181a presents 15.6% of the microRNA in DP cells and 6.7% and 5% in DN3 and DN4, respectively, the numbers of miR-181a copies in these three populations were estimated to be 810 in DP, 1400 in DN3, and 1600 in DN4 [ 539 ]. Li et al. [ 546 ] showed that miR-181a is expressed at DN1 and becomes upregulated during DN2 and DN3 and then downregulated at DN4. miR-181 is still significantly expressed in DP cells, albeit at a slight lesser extent than in DN4 and becomes downregulated upon differentiation to the SP (single positive) stage [ 546 ]. miR-146 is upregulated in CD4 + T cells [ 547 ].

3.1.2. Differentiation Stage-Specific Expression of MicroRNAs in B Lymphocytes

Malumbres et al. [ 533 ] performed an extensive microRNA profiling to identify microRNAs specifically expressed in B-cell subsets during peripheral B-cell differentiation. Notably, miR-18a, miR-28, miR-15a~16-1, and miR-181 are expressed at higher levels in centroblasts (germinal center B lymphocytes) compared with memory B cells, whereas miR-101c, miR-150, miR-29a,b,c, and miR-23a~24 are enriched in memory B cells. miR-17~92, miR-363~106a, and miR25~106b are highly expressed in all B-cell subtypes. The high level of miR-15a~16-1 in germinal center B-cells corresponds with low Bcl-2 expression in these cells. miR-223 is highly expressed in naïve and memory B cells, but not in centroblasts. miR-125b is especially expressed in germinal center B lymphocytes [ 533 ].

3.1.3. miR-181a/b in T- and B-Cell Development

miR-181a represses the expression of Bcl-2, CD69, and the T-cell receptor (TCR) α -chain [ 539 ]. miR-181a augments the strength of TCR signaling and down-regulates several phosphatases including DUSP5, DUSP6, SHP-2, and PTPN22 that regulate the sensitivity of T cells to antigens [ 546 ]. The down-regulation of PTPN22 by miR-181a led to elevated phosphorylation of p56 Lck at Y394 and the down-regulation of DUSP5/6 to increased ERK activation [ 546 ]. The normally high levels of miR-181a maintain T-cell tolerance to self-peptide/MHC molecules, with a reduction in this microRNA increasing the number of self-reactive T cells [ 548 ]. Also, dampening miR-181a expression using antagomiR-181a impaired positive selection with about a 70% reduction of mature CD4 + SP thymocytes [ 546 ]. Thus, miR-181a plays a role in regulating TCR response during T-cell development. Recently, miR-181a-1/b-1, but notmiR-181a-2b-2andmiR-181-c/d, was found to control the development of normal thymic T cells and leukemia cells [ 549 ]. EctopicmiR-181a-1expression in thymic progenitor cells potentiated DP cell development[ 549 ]. Conditional deletion of miR-181ab1 allele resulted in 50%–75% decrease in cellularity in the thymus and a significant reduction in the percentage of DP cells [ 549 ]. miR-181a expression decreased during the DN3a to DN3b transition during β -selection, and loss ofmir-181ab1resulted in a reduction in the percentage of DN3 and DN4 cells that expressed intracellular TCR- β , while preT α expression in DN3 thymocytes was normal [ 549 ].

miR-181a becomes downregulated when mouse T cells are costimulated with TCR and CD28 [ 317 ]. Other alterations occurring upon TCR/CD28 co-stimulation includes the upregulation of the miR-466 family, miR-574, miR-346, miR-214, miR-155, and miR-709, and the down-regulation of the miR-29 family, miR-15a, miR-15b, miR-16, miR-146b, miR-142, miR-27a, miR-150, and let-7 family [ 317 ].

Chen et al. [ 550 ] showed that miR-181 is expressed in the B-lymphoid cells of the mouse bone marrow, and its ectopic overexpression in hematopoietic stem/progenitor cells significantly increased B-cell production [ 550 ]. miR-181 also affects the development of NK cells through targeting the Nemo-like kinase (NLK), an inhibitor of Notch signaling [ 551 ]. miR-181 targets the RNA-binding protein Lin28, thereby disrupting the Lin28-let-7 reciprocal regulatory loop, with concomitant upregulation of let-7 and differentiation of megakaryocytes [ 552 ].

3.1.4. miR-150 in T- and B-Cell Development

miR-150 is highly expressed in mature and resting lymphocytes, but not in their progenitors [ 547 , 553 ]. Overexpression of miR-150 led to a block in B-cell formation at the pro-B to pre-B-cell transition by downregulating c-Myb, among other targets [ 547 ], suggesting for a role for this microRNA in B-cell differentiation. Within the lymphoid lineage the choice between T and B cells is regulated by miR-150 [ 547 , 553 ]. The T-cell population level was unaffected by overexpression of miR-150 in hematopoietic progenitor cells, while the mature B-cell levels were strongly reduced [ 553 ]. miR-150 drives megakaryocyte-erythrocyte progenitor (MEP) cells towards megakaryocytes at the expense of erythroid cells [ 554 ]. miR-150 also regulates the development of NK (natural killer) and iNKT (invariant NK) cells [ 555 ]. Mice with target deletion in miR-150 had a defect in their ability to generate mature NK cells, while overexpression of miR-150 resulted in a substantial reduction in iNKT in the thymus and in the peripheral lymphoid organs [ 555 ], supposedly through targeting of c-Myb by miR-150 [ 556 ].

3.1.5. miR-125b in T- and B-Cell Development

miR-125b affects T-cell differentiation through regulation of IFN γ (Interferon γ ), IL-2R β , IL-10R α , and PRDM1/Blimp1 (B lymphocyte-induced maturation protein-1) [ 592 ]. Ectopic expression of miR-125b in naïve lymphocytes inhibited differentiation to effector cells [ 592 ]. During normal B-cell development, miR-125b is enriched in germinal center B cells and keeps the transcription factor IRF4 and PRDM1/Blimp1 down, while miR-223 is enriched in memory B cells, where it targets the transcription factor LMO2, which is specifically expressed in germinal center B cells [ 533 ]. IRF4 and PRDM1/Blimp1 expression are repressed in centroblasts, but is necessary for differentiation into memory and plasma cells [ 593 , 594 ]. Overexpression of miR-125b alone in mice causes an aggressive, transplantable myeloid leukemia [ 357 ]. Before leukemia, these mice did not display elevation of white blood cells in the spleen or bone marrow, rather the hematopoietic compartment showed lineage-skewing, with myeloid cell numbers dramatically increase and B-cell numbers severely diminished [ 357 ]. miR-125b targets Lin28A , an induced pluripotent stem cell gene [ 595 ]. Knockdown of Lin28A led to hematopoietic lineage-skewing similar to ectopic miR-125b overexpression, with increased myeloid and decreased B-cell number [ 595 ]. miR-125b is also a potent oncomiR in the development of megakaryoblastic leukemia [ 596 ].

3.1.6. miR-155 in T- and B-Cell Development

miR-155 is also important for lymphopoiesis and for preserving normal immune system responses [ 266 , 597 – 599 ]. miR-155 is processed within the second exon of the nonprotein-encoding gene BIC (B-cell integration cluster). miR-155 is upregulated upon TCR/CD28 costimulation in mouse T cells [ 317 ], and in macrophages by several TLR (Toll-like receptor) pathways [ 600 ]. B cells require miR-155 for normal production of isotype-switched, high-affinity antibodies and for a memory response [ 599 ]. miR-155 knockout mice are immunocomprised owing to defects in B and T lymphocytes [ 597 ]. The transcription factor PU.1, which down-regulates IgG1 levels, is a target gene of miR-155 in B cells [ 599 ]. This may explain the reduced amount of circulating IgG1 in miR-155 knockout mice [ 599 ]. As with B cells, it seems that miR-155 is involved in T-cell differentiation [ 266 , 597 ]. Naïve T cells derived from miR-155 knockout mice showed increased propensity to differentiate into Th2 rather than Th1 cells, with the concomitant production of Th2 cytokines such as IL-4, IL-5, and IL-10 [ 266 , 597 ]. One explanation for this biased development of Th2 cells might be the miR-155 mediated targeting of c-Maf (musculoaponeurotic fibrosarcoma), a transcription factor that transactivates the IL-4 gene [ 597 ]. With regard to the acute immune response, the T cells had an impaired response and showed attenuated IL-2 and IFN γ release in response to antigens [ 266 , 597 ]. miR-155 is upregulated by the transcription factor FoxP3 and critical for T regulatory cell function [ 601 ]. Mice overexpressing miR-155 in the B-cell lineage results in preleukemic pre-B-cell proliferation in the spleen and bone marrow, followed later in life by B-cell malignancy [ 602 ]. miR-155 represses genes encoding DNA damage response proteins [ 603 ].

3.1.7. miR-17~92 in T- and B-Cell Development

The miR-17~92 cluster located on chromosome 13 at locus q31.3 is essential for B-cell development [ 246 ]. The expression of miR-17~92 peaked in pre-B cells, where it inhibited cell death [ 246 ]. It is expressed at higher levels in normal germinal center B cells compared to naïve and memory B cells [ 533 ]. Knockout of miR-17~92 leads to increased Bim expression and inhibits B-cell development at the pro-B to pre-B transition [ 246 ], a step also blocked by miR-150 [ 553 ]. Mice overexpressing the miR-17~92 cluster in lymphocytes developed lymphoproliferative disease and autoimmunity and they died prematurely [ 247 ]. These animals were found to have increased numbers of activated B cells, and a higher ratio of activated CD4 + T cells versus CD8 + T cells. The enhanced proliferation and survival of B and T cells may result from the down-regulation of Bim and PTEN [ 247 ]. miR-17~92 expression is strongly induced after activation of CD8 + T cells, which is critical for the rapid clonal expansion of these cells [ 604 ]. However, following the clonal expansion, miR-17~92 is downregulated and further silenced during memory development [ 604 ].

3.2. MicroRNAs in Lymphoid Malignancies

Malignant lymphomas arise from normal B- or T-cell counterparts at different ontogeny stages and commonly continue to express gene signatures inherited from their nontransformed cellular progenitors. Extensive miRNA profiling studies have been performed on various lymphoid malignancies, including T-ALL [ 605 ], cutaneous T-cell lymphoma [ 606 ], CLL [ 557 , 563 ], pre-B-ALL [ 557 , 605 , 607 ], diffuse large B-cell lymphoma (DLBCL) [ 564 , 580 – 582 , 608 – 610 ], anaplastic large cell lymphoma (ALCL) [ 587 ], multiple myeloma (MM) [ 574 , 611 , 612 ], mantle cell lymphoma (MCL) [ 583 , 591 , 613 ], Burkitt Lymphoma (BL) [ 564 , 614 ], and follicular lymphoma (FL) [ 135 , 582 , 615 ]. A comprehensive study aimed to integrate the many miRNAs upregulated in T-ALL into a microRNA-transcription factor coregulatory network was performed by Ye et al. [ 506 ]. Various microRNAs have also been associated with poor prognosis [ 515 ]. A short description of some important microRNAs in malignant lymphoid diseases is described below and summarized in Tables 2 and 3 .

3.2.1. MicroRNAs in T-Acute Lymphoblastic Leukemia (T-ALL)

In general, T-ALL is characterized by upregulation of the miR-17~92 cluster, miR-26a, miR-128a/b, miR-146a, miR-181a/b, miR-150, and miR-155, while let-7b and miR-223 are downregulated [ 253 , 557 – 561 ].

3.2.1.1. miR-17 ~ 92 in T-ALL . The miR-19, miR-20a, miR-92a, and miR-17 especially of the miR-17~92 cluster are upregulated in T-ALL [ 506 ]. All six miRNAs miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a, of the miR-17~92 cluster promoted leukemogenesis in Notch1-induced T-ALL in vivo [ 253 , 616 ]. Among them, the miR-19 family has been considered the key oncogenic component [ 248 , 506 , 617 ]. The miR-17~92 cluster is located within a fragile site that is frequently amplified in a range of hematopoietic malignancies [ 618 ]. Paralogues to the miR-17~92 cluster include miR-106b~25 and miR-106a~363 [ 246 , 619 ].

miR-19 represses Notch1, PTEN, Hoxa9, Cyld, Runx1, E2F1, and Bcl2L11 (Bim) [ 506 , 616 , 620 ]. Reduced expression of Bim attenuates GC-induced apoptosis. Posttranslational inactivation of PTEN by miR-19 promotes activation of the PI3K/Akt pathway, and incontrollable proliferation of T cells [ 104 , 105 ]. Increased Akt signaling antagonizes GC-induced apoptosis by several mechanisms, including phosphorylation of FoxO3a, thus preventing its nuclear translocation and transcriptional activation of Bim, and through inactivation of GSK3, which is essential for GC-induced apoptosis [ 30 , 67 , 97 ].

Hoxa9 is a leukemogenic homeoprotein in T-ALL [ 621 ], and a target gene of the oncogenic MLL-AF4 fusion protein [ 622 ]. High expression of miR-196b was found in pediatric ALL with aberrant activation of Hoxa genes [ 623 ].

Notch1 plays a vital role in T-cell development and transformation, and about 50% of primary T-ALL samples show abnormal Notch1 expression [ 79 ]. Downstream transcriptional targets of Notch1 include Hes1 and c-Myc, the former affecting the PI3K/Akt and NF κ B signaling pathways [ 624 , 625 ]. c-Myc is a potent and direct transcriptional activator of miR-17~92, leading to modulation of E2F1 expression [ 255 ]. Deletion of miR-17~92 cluster repressed Myc-induced oncogenesis [ 246 , 248 ]. GCs repress the expression of miR-17~92 [ 206 ], which may be one means to overcome the tumorigenicity of T-ALL cells and to elevate Bim expression [ 206 ].

In contrast to miR-19, miR-451, and miR-709 are potent suppressors of oncogenesis in Notch1-induced mouse T-ALL [ 440 ]. miR-451 represses c-Myc, while miR-709 represses Ras-GRF-1 that acts upstream to Ras and prevents Akt activation [ 625 ]. Both miR-451 and miR-709 are transcriptional targets of the bHLH E2A tumor suppressor, which is degraded upon Notch1 induction in mouse T-ALL cells [ 626 , 627 ]. Repression of tumor suppressor miR-451 is essential for Notch1-induced oncogenesis in a murine model of T-ALL [ 440 ]. Human T-ALLs with activating Notch1 mutations have decreased miR-451 and increased c-Myc levels compared with T-ALLs with wild-type Notch1 [ 440 ]. One mechanism of the tumor suppressive action of miR-451 could be through down-regulation of the PI3K/Akt survival pathway [ 628 ].

3.2.1.2. miR-26a in T-ALL . Primary T-ALL cells also express elevated levels of miR-26a that suppresses PTEN and Bim [ 253 ]. miR-26a enhanced leukemogenesis in a mouse model of T-ALL [ 253 ]. miR-26a was found to be repressed by c-Myc in a mouse lymphoma model, leading to enhanced expression of the EZH2 oncogene, a component of the Polycomb repressive complex 2 [ 483 ]. c-Myc may also directly upregulate EZH2 [ 629 ]. In mantle cell lymphoma, miR-26a was found to affect NF κ B nuclear translocation [ 591 ].

3.2.1.3. miR-146a in T-ALL . miR-146a, miR-181a/c, and miR-221 were associated with overall survival in ALL patients [ 559 ]. miR-146 seems to have opposing roles in tumorigenesis depending on the cellular context [ 517 ]. miR-146a and miR-146b are elevated in several types of solid tumor [ 630 – 633 ]. However, overexpression studies of miR-146a in transplanted bone marrow cells suggest a tumor-suppressive role for this microRNA [ 634 ]. miR-146 overexpression reduced the survival and engulfment of hematopoietic stem cells in recipient cells [ 634 ]. miR-146a knockout mice developed massive myeloproliferation followed by hematopoietic tumors, including myeloid sarcomas and lymphomas [ 635 , 636 ]. The myeloproliferative phenotype correlated with enhanced NF κ B signaling [ 636 ]. miR-146a suppresses the NF κ B activators IRAK1 (interleukin 1 receptor-associated kinase 1) and TRAF6 (TNF receptor-associated factor 6) [ 635 , 637 , 638 ]. Thereby, overexpression of miR-146a leads to inhibition of NF κ B activity. A negative feedback loop exists between NF κ B and miR-146. Whereas miR-146 represses NF κ B signaling, NF κ B signaling upregulates miR-146 [ 637 ].

3.2.1.4. miR-181a in T-ALL . miR-181a family members are highly expressed in T-ALL leukemia cells and downregulated during remission[ 639 ]. Deletion ofmiR-181a-1/b-1expression inhibits the development ofNotch1 oncogene-induced T-ALL in a mouse model [ 549 ]. miR-181a/bcontrols the strength and threshold of Notch activity in tumorigenesis in part by dampening multiple negative feedback regulators downstream of Notch and pre-T-cell receptor (TCR) signaling pathways [ 549 ].

3.2.1.5. miR-124a in T-ALL . miR-124a has been shown to be downregulated in more than 50% of ALL cases and associated with higher relapse rate and mortality rate [ 560 ]. It targets CDK6 and reduces Rb (retinoblastoma) phosphorylation. Its down-regulation contributes to the abnormal proliferation of ALL. Inhibition of CDK6 by sodium butyrate or PD0332991 decreased ALL cell growth. Overexpression of miR-124a reduced tumorigenicity in a xenogeneic mouse model [ 560 ].

3.2.2. MicroRNAs in Chronic Lymphocytic Leukemia (CLL)

A comparison study of primary CLL samples with normal unstimulated or CpG-stimulated B cells showed high similarities between CLL and activated B cells, including upregulation of miR-34a, miR-155, and miR-342 and down-regulation of miR-103 and miR-181a/b [ 565 ]. Activation of normal B cells led to reduced miR-23a, miR-23b, miR-24, miR-27b, miR-181a/b, and miR-223 and increased miR-155 with all activation agents used. Differential effect on miR-29 family was observed with the different activation agents. One particular difference between activated B cells and CLL was seen with miR-150. miR-150 was reduced during B-cell activation, whereas it was upregulated in most CLL cases [ 565 ]. The latter confirms the study of Fulci et al. [ 566 ], but is opposed to Wang et al. [ 682 ] showing that miR-150 is downregulated in CLL. Ectopic miR-150 expression increased cell death in pro-B cells, while miR-150 deficiency led to B-cell expansion and an enhanced humoral immune response [ 547 ]. Some differences in miR-150 are observed between the mutated versus unmutated IgV H (immunoglobulin heavy chain variable-region genes) subgroups, where expression is higher at the average in the mutated IgV H subgroup [ 566 ].

CLL cases with unmutated IgV H or with high expression levels of ZAP-70 (70kD zeta-associated protein) show an unfavorable course with rapid progression in comparison to patients with a mutated IgV H [ 567 ]. Two research groups [ 565 , 566 ] observed decreased levels of miR-29c and miR-223 in CLL with ZAP70 + and IgV H unmutated status. Calin et al. [ 643 ] observed that the unmutated IgV H CLL subgroup exhibited high levels of Tcl-1 due to low expression of miR-29 and miR-181 that negatively regulate this oncogene. miR-181 and miR-29 might therefore be considered to have tumor-suppressor functions. Tcl-1 functions as a coactivator of Akt [ 707 ], and B-cell forced expression of Tcl-1 in transgenic mice resulted in tumors that resembled CLL [ 567 ]. CLL with unmutated IgV H and high expression of ZAP-70 showed also relative high expression of miR-15a, miR-16-1, miR-16-2, miR-195, miR-23b, miR-155, miR24-1, and miR-146, while low expression of miR-223, miR-29a-2, miR-29b-2, and miR-29c [ 563 ]. In an aggressive subtype of CLL with abnormalities in the TP53 gene, the microRNAs miR-34a, miR-29c, and miR-17 were downregulated [ 567 ].

3.2.2.1. miR-15a~16 in CLL . CLL cases with good prognostic features are typically characterized by down-regulation of miR-15a and miR-16-1 [ 643 , 708 ], located at the 13q14.3 locus. These miRNAs map to a region between exon 2 and 5 of the Leu2 gene. Deletion of 13q14.3 (del(13q)) is the most common cytogenetic abnormality in CLL occurring in more than 50% of the cases and implies for a favorable prognosis [ 709 ]. This deletion occurs also frequently in MM patients [ 575 ].Deletion in mice of the 13q14-minimal deleted region, which encompasses the miR-15a~16 cluster, caused the development of indolent B-cell-autonomous, clonal lymphoproliferative disorders, recapitulating the spectrum of CLL-associated phenotypes observed in humans [ 644 ]. Repression of miR-15a and miR-16-1, as well as miR-29b, in CLL may also be mediated by histone deacetylases (HDACs) [ 710 ]. HDAC inhibition triggered the accumulation of the transcriptionally activating chromatin modification H3K4me2 and restored the expression of miR-15a, miR-16-1, and miR-29b [ 710 ]. Deacetylase inhibition may therefore be an attractive therapeutic strategy.

Both miR-15a and miR-16-1 negatively regulate Bcl-2 [ 643 ], and miR-29 targets Mcl-1 [ 381 , 382 ]. The expression of Bcl-2 in CLL cases is inversely correlated with the expression of miR-15a and miR-16-1 [ 563 , 711 ]. Other targets of miR-15/16 include CHEK1 [ 615 ], CyclinD1, CyclinD2, and Cdc25A [ 525 , 645 ]. Overexpression of miR-15a and miR-16-1 induced cell cycle arrest at G1/G0 in an Rb-dependent manner [ 712 ]. A germ-line mutation in the primary precursor of miR-15a/16-1 that impairs their processing was observed in familial CLL patients [ 563 ]. Targeting deletion of miR-15a~16 in mice led to the development of a spectrum of diseases resembling CLL-associated lymphoproliferation in humans, including CLL, CD5 + monoclonal B-cell lymphocytosis, and CD5 − non-Hodgkin's lymphomas [ 644 ]. The New Zealand black (NZB) mouse that harbor a point mutation in the 3′-flanking region of miR-16 that leads to reduced miR-16 expression and develops symptoms similar to B-CLL in humans, further confirming the tumor suppressor function of this locus [ 713 ].

3.2.2.2. miR-181a/b in CLL . Underexpression of miR-181a/b was associated with shorter overall survival in CLL [ 358 ], while higher levels of miR-181a were associated with a shorter time from diagnosis to initial therapy [ 563 ]. During the course of CLL progression, the miR-181a/b levels were decreased, which inversely correlated with increased levels of its target genes Mcl-1 and Bcl-2 [ 385 ]. miR-181b was especially downregulated in treatment-refractory cases [ 714 ]. The study of Marton et al. [ 568 ] showed consistent underexpression of miR-181a, as well as let-7a and miR-30d in all CLL cases studied. However, increased expression of miR-181a/b was associated with favorable outcome in patients with cytogenetically normal acute myeloid leukemia (AML) [ 692 ].

Ectopic overexpression of miR-181a/b into primary CLL increased fludarabine-sensitivity in p53 wild-type cells, but not in CLL with attenuated p53 response [ 358 ]. The importance of the miR-181 target Mcl-1 in CLL survival was demonstrated by rapid apoptosis of CLL cells following siRNA-mediated down-regulation of Mcl-1 [ 715 ], and by the Mcl-1 transgenic mice, which developed B-cell lymphoma [ 715 ]. Thus, low miR-181 and miR-29 expression in CLL could confer drug resistance through upregulation of Mcl-1 expression.

3.2.2.3. miR-29 in CLL and Other B-Cell Malignancies . The miR-29 family consisting of miR-29a and miR-29b seems to play a dual role in tumorigenesis [ 517 ]. On the one hand, miR-29a and miR-29b are downregulated in mantle cell lymphoma [ 583 ], aggressive CLL samples (high ZAP-70 with unmutated IgV H ) [ 659 , 710 , 716 ], ALK-positive anaplastic large cell lymphomas (ALCL) [ 380 ], MM [ 381 ], and AML [ 383 ]. On the other hand, miR-29a and b are expressed at higher degree in indolent CLL (low ZAP-70/mutated IgV H ) than in normal CD19 + cells [ 563 , 569 , 716 ]. miR-29c together with miR-223 down-regulation is associated with higher tumor burden, disease aggressiveness, and poor prognosis in CLL [ 700 ].

Forced overexpression of miR-29b induced apoptosis in MM and AML cells [ 381 , 383 ]. The tumor suppressor activity of miR-29 may be achieved through targeting cell cycle regulators and oncogenes such as Cdk6, DNA methyltransferase 3A (DNM3A) and 3B (DNMT3B), Mcl-1, and Tcl1A [ 382 , 569 , 583 , 717 ]. Another tumor suppressor function of miR-29 is mediated through activation of p53, which is achieved by targeting p85 α (the regulatory subunit of PI3K kinase) and CDC42 (a Rho family GTPase) [ 660 ].

However, in another setting miR-29 acts as an oncogene. miR29a overexpression in immature and mature B cells promoted CLL development [ 716 ], and transplantation of miR-29-transduced hematopoietic stem and progenitor cells into irradiated mice resulted in myeloproliferative disease and AML [ 661 ]. One mechanism for the oncogenic feature of miR-29 could be through repression of the tumor suppressor cell-adhesion molecule peroxidasin homologue (PXDN) [ 716 ]. Thus, depending on the cellular contexts,miR-29 can function as an oncogene or a tumor suppressor.

3.2.2.4. miR-221/222 in CLL . miR-221 and miR-222 are expressed at higher levels in CLL with unmutated IgV H and high expression of ZAP-70, the most aggressive CLL subtype with poor prognosis [ 563 ]. These microRNAs may contribute to oncogenesis by targeting the CDK inhibitor p27 Kip1 [ 695 , 696 , 718 , 719 ], FoxO3a [ 720 , 721 ], Apaf-1 [ 721 , 722 ], p57 Kip2 [ 719 ], Bmf [ 723 ], PTEN [ 321 ], and TIMP3 (tissue inhibitor of metalloproteinase 3) [ 321 ]. In other CLL cases, the miR-222 was found to be lower than that of normal CD19 + cells [ 566 ]. miR-221 was expressed at reduced levels in CLL harboring the 13q14 deletion [ 711 ].

3.2.2.5. miR-34 in CLL . The p53 target miR-34a is decreased in CLL patients with 11q deletions, leading to increased ZAP-70 expression [ 663 ]. miR-34a also targets Bcl-2 [ 348 , 484 ], and the E2F1 and B-Myb oncogenes in CLL [ 664 ]. Reduced miR-34a expression has been associated with resistance to DNA damage in CLL [ 570 ].

3.2.2.6. miR-17~92 in CLL . Members of the miR-17~92 polycistron are upregulated in B-cell lymphoma, as well as miR-155 [ 469 , 568 , 685 ]. Adoptive transfer of hematopoietic stem cells bearing a truncated portion of the miR-17~92 polycistron in c-Myc transgenic mice resulted in a more rapid onset of malignant B-cell lymphomas. These lymphomas exhibited resistance to apoptosis and increased proliferation [ 469 ]. Transgenic overexpression of the entire miR-17~92 in the murine hematopoietic compartment led to the development of lymphoproliferative disease and increased lethality [ 247 ]. The negative regulation of Bim by the miR-17~92 cluster seems to be a major mechanism by which B-cell lymphomas evade apoptosis [ 247 ]. Silencing of miR-17 and miR-20a in mantle cell lymphoma led to upregulation of the cyclin-dependent kinase (CDK) inhibitor p21, suggesting that p21 is an essential target of the miR-17~92 cluster during B-cell lymphomagenesis [ 647 ]. Overexpression of c-Myc mRNA together with miR-17-5p/miR-20a was associated with a more aggressive behavior in mantle cell lymphoma [ 724 ]. miR-17~92 confers chemoresistance in mantle cell lymphoma through activation of the PI3K/Akt pathway [ 725 ]. Knockdown of miR-17~92 inhibited tumor growth in a xenograft mantle cell lymphoma model [ 725 ].

3.2.2.7. miR-21 in CLL . miR-21 is commonly upregulated in CLL [ 650 ] as well as CML [ 726 ] and many other cancer cell types [ 525 ]. Forced overexpression of miR-21 under the control of the nestin promoter resulted in severe pre-B-cell lymphoma [ 727 ]. miR-21 overexpression potentiated lung tumorigenesis of a constitutively activated K-Ras proto-oncogene [ 728 ]. miR-21 deletion in mice reduced 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate(TPA) skin carcinogenesis [ 729 ]. miR-21-null mice exhibited an increase in cellular apoptosis and decrease in cell proliferation [ 729 ]. miR-21 is an oncomiR that promotes tumorigenesis by targeting a range of genes involved in regulating cell proliferation and/or survival, including PTEN [ 269 ], Sprouty (Spry2) [ 730 ], PDCD4 (programmed cell death 4) [ 731 ], TPM1 (tropomyosin 1) [ 651 ], and human DNA MutS homolog 2 (hMSH2) [ 732 ]. In glioblastoma cells, miR-21 also targets a network of p53 pathways, TGF β , and mitochondrial tumor suppressor genes [ 733 ]. PDCD4 inhibits AP-1-mediated transactivation [ 734 ] and negatively regulates the pro-survival RAL guanine-nucleotide dissociation stimulator (RALGDS) signaling pathways [ 517 , 729 ]. PDCD4 also induces the expression of the CDK inhibitor p21 [ 735 ]. Down-regulation of PDCD4 by miR-21 confers growth advantages to the cells. PDCD4 is a tumor suppressor that is upregulated during apoptosis [ 736 ] and downregulated in several cancer forms [ 737 – 739 ]. Spouty, which is downregulated by miR-21, negatively regulates the c-Raf pro-survival signaling pathway [ 729 ].

3.2.2.8. miR-125b in CLL . Both aggressive and indolent CLL patients showed reduced expression of miR-125b [ 571 ]. Overexpression of miR-125b in CLL-derived cell lines resulted in the repression of many transcripts encoding enzymes implicated in cell metabolism [ 571 ]. These authors proposed that miR-125b acts as a regulator for the adaptation of cell metabolism to a transformed state.

3.2.2.9. miR-150 in CLL . One microRNA consistently downregulated in most B-lymphomas is miR-150 [ 682 ], which is proposed to act as a tumor suppressor [ 523 , 547 , 589 ]. Mice lacking miR-150 have increased expression of its target transcription factor c-Myb, which plays an important role in lymphocyte development and maturation [ 547 ]. miR-150 is especially expressed in mature lymphocytes, but not in their progenitors [ 547 ]. Premature expression of miR-150 blocked the transition from pro-B to the pre-B stage [ 553 ]. Overexpression of miR-150 in NK/T lymphomas increased apoptosis and reduced cell proliferation, with concomitant reduction in DKC1 (Dyskeratosis congenita 1) and Akt2, reduced Akt phosphorylation, and elevated levels of Bim and p53 [ 683 ].

3.2.2.10. miR-155 in CLL . miR-155 is overexpressed in many B-cell lymphomas including CLL, primary mediastinal B-cell lymphoma (PMBL), aggressive activated B-cell like (ABC) subtype of DLBCL, Hodgkin's lymphoma, and pediatric Burkitt's lymphoma, but is almost absent in adult Burkitt's lymphoma [ 515 , 566 , 568 , 576 , 583 , 584 , 587 , 602 , 685 , 686 ]. c-Myb (v-Myb myeloblastosis viral oncogene homolog), which is overexpressed in a subset of CLL patients, associates with the promoter of miR-155 host genes (miR155HG, also known as BIC, B-cell integration cluster) and stimulates its transcription [ 687 ]. Forced overexpression of miR-155 in B cells (E μ -miR-155 transgenic mice) led to initial preleukemic pre-B-cell proliferation followed by frank B-cell malignancy [ 602 ]. The miR-155 orthologue miR-K12-11 in Kaposi sarcoma-associated herpes virus (KSHV) has been associated with B-cell tumors [ 740 ]. miR-155 is essential for immune function and is strongly induced in activated T and B cells [ 597 ]. miR-155 represses SH2-domain containing inositol-5-phosphatase-1 (SHIP-1), which is a critical phosphatase that negatively downmodulates Akt pathway and is involved in normal B cell development [ 688 ]. Thus, sustained overexpression of miR-155 in B cells unblocks Akt activity, inducing B-cell development. miR-155 targets c-Maf in lymphocytes [ 597 ], and HGAL and SMAD5 in diffuse large B-cell lymphoma (DLBCL) [ 741 , 742 ]. HGAL , a germinal center (GC)-specific gene, inhibits lymphocyte and lymphoma cell motility by activating RhoA signaling cascade [ 743 ] and by interacting with actin and myosin proteins [ 744 ]. SMAD5 is a bone morphogenetic protein (BMP)-responsive transcription factor and is activated by various cytokines [ 745 ]. DLBCL expressing high levels of miR-155 concomitant with low HGAL expression showed high aggressiveness and cell dissemination [ 741 ]. siRNA-based SMAD5 knockdown recapitulated the effects of miR-155 overexpression in DLBCL [ 742 ]. Thus, down-regulation of SMAD5 in diffuse large B-cell lymphoma defines a unique mechanism used by the cancerous cells to escape TGF β growth inhibitory effects [ 742 ]. In breast cancer, miR-155 targeted FoxO3a, thus modulating their response to chemotherapy [ 264 ]. As FoxO3a is a positive regulator of the pro-apoptotic Bim essential for GC-induced apoptosis [ 227 – 229 ], miR-155 overexpression may prevent Bim upregulation.

3.2.3. miRNAs in Multiple Myeloma (MM)

In one study, miR-93, miR-25, miR-92, miR-19a/b, miR-181a/b, and miR-32 were shown to be significantly overexpressed, while let7-b, let7-I, let7-c, miR-29a, and -29b significantly downregulated in MM [ 574 ]. Roccaro et al. [ 575 ] found decreased expression of miR-15a~16 and increased expression of miR-222, miR-221, miR-382, and miR-181a/b in their MM samples. Heterogeneous expression of miR-181a and -181b was observed in MM cells from many patients [ 574 ]. Also, the 13q14.3 locus containing the miR-15a and miR-16-1 is sometimes deleted in MM [ 345 , 746 – 748 ]. The absence of miR-15a expression and overexpression of miR-181a/b correlated with worse prognosis of MM [ 575 ]. Antagonists especially to miR-19a/b and miR-181a/b (AntagomiRs) suppressed tumor growth of human myeloma cells implanted into nude mice [ 574 ]. This finding demonstrates the potential use of microRNAs in therapy.

Some differential miRNA expression was observed between malignant MM and MGUS (monoclonal gammopathy of undetermined significance) [ 574 ], which is the precancerous state preceding MM [ 749 ]. MGUS show already upregulation of miR-21, miR-106~25, miR-181a/b, miR-1, and miR-133a, while during the progression to malignant multiple myeloma miR-17~92, miR-32, miR-193b~365 are upregulated and miR-192~194~215 and miR-15a~16 are downregulated [ 574 , 576 , 577 ]. The upregulation of miR-17~92 could be related to the upregulation of c-Myc observed during MM progression [ 750 , 751 ]. Upregulation of miR-1 and miR-133a correlated with t(14; 16) translocation in MM cases, suggesting that deregulation of microRNA expression could be associated with chromosomal abberations [ 578 ]. MGUS premalignant cases displayed higher levels of Dicer than MM cells [ 752 ]. Higher expression of Dicer was associated with improved progression-free survival in symptomatic MM cases [ 752 ].

The global increase in microRNA expression in high-risk MM patients with poor prognosis was associated with increased expression of Argonaute (AGO2/ElF2C2) [ 611 ], a master regulator of miRNA maturation and function [ 753 , 754 ]. Silencing of AGO2 decreased viability in MM cell lines [ 611 ].

3.2.3.1. IL-6 and MM . Adhesion of multiple myeloma to bone marrow stroma triggers cytokine production and enhances cell proliferation and resistance to chemotherapy through IL-6-induced activation of NF κ B, PI3K/Akt, and STAT3 pathways [ 755 ]. It should be noted that these pro-survival pathways antagonize GC-induced apoptosis in MM [ 756 – 760 ]. miR-19a and miR-19b that are part of the miR-17~92 cluster downregulate SOCS-1 (suppressor of cytokine signaling-1), a gene frequently silenced in MM that plays a critical role as inhibitor of IL-6 growth signaling [ 574 ], thus enforcing the IL-6-induced survival signals.

3.2.3.2. miR-21 in MM . The oncogenic miR-21 is upregulated in MM patient samples and cell lines [ 574 , 579 , 652 ]. In IL-6-dependent MM cell lines, miR-21 transcription is controlled by IL-6 through a STAT-3 mechanism. Ectopic miR-21 expression was sufficient to sustain growth of IL-6-dependent cell lines in the absence of IL-6 [ 761 ]. miR-21 is upregulated in a NF κ B-dependent manner in MM cells upon cell adhesion to bone marrow stromal cells [ 762 ]. Combining miR-21 inhibition with dexamethasone inhibited MM cell survival more effectively than either treatment alone [ 762 ]. The p300-CBP-associated factor (PCAF) was found to be a target of the combined action of the miR106b~25 cluster and miR-32 [ 574 ]. PCAF is a positive regulator of p53 through ubiquitination activity on Hdm2 [ 763 ]. miR106b~25, miR-17, and miR-20a target the CDKN1A1/p21 cell cycle regulator, which prevents cell cycle progression in general and prevents the growth of MM cells [ 764 , 765 ].

3.2.3.3. miR-15a~16 in MM . miR-15a~16 is a pro-apoptotic microRNA that targets Bcl-2, cyclin D1, cyclin D2, and Cdc25A [ 346 , 748 , 766 – 768 ]. Overexpression of miR-15a~16 in MM led to inhibition of Akt3, ribosomal protein S6, MAP kinases, and the NF κ B-activator MAP3KIP3, ultimately resulting in an antiproliferative effect and apoptosis [ 575 ]. The anti-MM effect of miR-15a~16 was observed even in the context of the bone marrow microenvironment [ 575 ]. miR-15a~16 reduced VEGF secretion from MM cells, thereby reducing MM cell-induced pro-angiogenic activity on endothelial cells [ 575 ]. VEGF represents one of the major pro-angiogenic cytokines responsible for the induction of neoangiogenesis in MM patients [ 769 , 770 ].

3.2.4. miRNAs in Anaplastic Large Cell Lymphoma (ALCL)

A distinct microRNA profile could distinguish between ALK + and ALK − subtypes of ALCL, an aggressive form of non-Hodgkin's lymphoma (NHL) belonging to the T-cell lineage [ 587 ]. More than 80% of ALK + ALCL harbor the t(2; 5)(p23; q35) translocation, resulting in the expression of the chimeric nucleophosmin (NPM)-ALK [ 771 ]. The constitutive ALK activity leads to the activation of many different growth-promoting and anti-apoptotic pathways including PI3K/Akt/mTOR, Jak/Stat, c-Jun, JunB, and c-Myc. The prognosis of ALK − ALCL is worse [ 772 , 773 ]. ALK + ALCL has a high cure rate with CHOP treatment, in contrast to ALK − cells that are relative resistant [ 774 ]. Five members of the miR-17~92 cluster were expressed higher in ALK + ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK − ALCL [ 587 ]. The upregulation of miR-17~92 cluster in ALK + ALCL cells is in agreement with the observation that c-Myc is expressed in ALK + ALCL and absent from ALK − samples [ 775 ]. miR-101 was downregulated in all ALCL tested [ 587 ]. miR-101 targets mTOR [ 776 ], Mcl-1 [ 777 ], and the histone methyltransferase EZH2 [ 778 , 779 ]. Inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models [ 587 ]. Overexpression of miR-101 reduced cell proliferation in ALK + , but not in ALK − [ 587 ]. The former was also more sensitive to mTOR inhibition by the rapamycin analogue CCI-779 [ 587 ]. miR-29a and miR29b down-regulation in ALK + ALCL confer apoptotic resistance due to Mcl-1 upregulation [ 380 , 587 ].

Another microRNA that has been implicated in NPM-ALK-driven oncogenicity is miR-135b [ 588 ]. miR-135b targets FoxO1 and promotes a IL-17-producing immunophenotype. miR-135b inhibition reduced tumor angiogenesis and growth in vivo, suggesting that targeting this microRNA has therapeutic potential [ 588 ].

3.2.5. miRNAs in Diffuse Large B-Cell Lymphoma (DLBCL)

A 9-miRNA signature (miR-146b-5p, miR-146a, miR-21, miR-155, miR-500, miR-222, miR-363, miR-574-3p, and miR-574-5p) could differentiate the diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, into ABC (activated B-cell) or GCB (germinal center B-cell) subtypes, with a general higher expression in the ABC subtype [ 533 ]. Another study [ 780 ] found that miR-331, miR-151, miR-28, and miR-454 were upregulated in the GCB type, whereas miR-222, miR-144, miR-451, and miR-221 upregulated in the ABC type. The microRNA expression of both GCB-like and ABC-like cells was more similar to germinal center lymphocytes than memory B-cells [ 533 ]. The region encoding the miR-17~92 cluster was more commonly amplified in GCB-like than ABC-like DLBCL [ 781 ]. Lawrie et al. [ 580 ] identified 3 miRNAs, miR-155, miR-21, and miR-221, more highly expressed in ABC type than GCB type cells. Expression of miR-21 was an independent prognostic indicator in DLBCL [ 580 ]. Expression of miR-155 and miR-21 was also higher in nonmalignant ABC than in GCB cells [ 580 ]. miR-150 was strongly downregulated in both ABC and GCB-like DLBCL cells [ 533 ]. Patients with GCB DLBCL have longer overall survival and event-free survival compared with patients with an ABC phenotype when treated with R-CHOP [ 782 , 783 ]. Increased expression of miR-18a in DLBCL was associated with a shorter OS (overall survival) of patients receiving R-CHOP regimen [ 693 ]. Increased expression of miR-181a was associated with longer PFS (progression-free survival), while increased expression of miR-222 was associated with shorter PFS [ 693 ]. In DLBCL, miR-181a regulates FoxP1 (Forkhead Box protein P1) and MGMT (O 6 -methylguanine-DNA methyltransferase) expression in DLBCL cells [ 693 ]. FoxP1 is expressed in normal activated B cells, mantle zone B cells, and some germinal center B cells [ 784 , 785 ]. FoxP1 is recurrently targeted by chromosomal translocations involving the immunoglobulin heavy chain locus in marginal zone lymphomas and DLBCL, suggesting a potential role for FoxP1 in lymphomagenesis [ 786 , 787 ]. FoxP1 has in some studies been shown to be associated with poor prognosis and survival [ 788 , 789 ]. MGMT encodes an enzyme that protects cells from the toxicity of alkylating agents. The ability of miR-181a to reduce MGMT protein expression may contribute to better cyclophosphamide chemosensitivity [ 693 ].

miR-222 is part of the miR-221/miR-222 cluster, which is highly expressed in ABC-like DLBCL cell lines [ 533 ] and ABC-like DLBCL tumors [ 580 ]. miR-222 regulates the expression of the stem cell factor c-Kit [ 697 ], and the cyclin-dependent kinase inhibitors p27 Kip1 and p57 Kip2 [ 695 , 698 ]. High expression of miR-222 was associated with inferior overall survival and progression-free survival [ 533 ].

3.2.6. MicroRNA in Follicular Lymphoma (FL)

FL is characterized by high miR-9, miR-138, miR-20a/b, and miR-155 expression [ 135 , 564 , 582 ].

3.2.6.1. miR-9 in FL . miR-9, which is activated by c-Myc, regulates NF κ B [ 641 ]. miR-9 targets also the transcription factor PRDM1/Blimp1 in lymphoma and may contribute to the phenotype maintenance and pathogenesis of lymphoma cells by interfering with normal B-cell terminal differentiation [ 582 , 608 ]. BRDM1/Blimp1 has been considered to be a tumor suppressor [ 790 , 791 ]. Besides miR-9, let7a and miR-125b regulate BRDM1/Blimp1 expression [ 533 , 640 ]. BRDM1/Blimp1 and Bcl6 are critical regulators of germinal center B-cell differentiation [ 594 , 792 , 793 ]. BRDM1/Blimp1 and Bcl6 are expressed in a mutual exclusive pattern and evidence suggests that they repress each other in germinal center B cells [ 792 , 794 ]. A marked decrease of BRDM1/Blimp1 and an increase of Bcl6 were observed in follicular lymphoma cells [ 135 ], which might be related to the increased miR-9 levels in these cells [ 564 ]. Mutations in BRDM1/Blimp1 are frequently found in activated B cell (ABC)-like DLBCL [ 790 , 795 ].

3.2.7. miRNAs in Hodgkin's Lymphoma (HL)

The malignant Hodgkin's lymphoma cells are usually derived from B cells, but have lost the expression of typical B-cell genes. Multiple signaling pathways are deregulated, including NF κ B, JAK (Janus kinase)/STAT (signal transducer and activator of transcription), PI3K/Akt, ERK, Notch1, and receptor tyrosine kinases [ 796 ]. Patients with low miR-135a expression had a higher probability of relapse and a shorter disease-free survival [ 677 ]. miR-135a targets JAK2, a cytoplasmic tyrosine kinase involved in a subset of cytokine receptor signaling pathways. Transfection of pre-miR-135a into classical HL (cHL) caused apoptosis and decreased cell growth [ 677 ]. The miR-135a-mediated JAK2 down-regulation led to decreased Bcl-X L expression [ 677 ], a downstream effector of JAK2 [ 797 ].

About 40%–60% of Hodgkin's lymphomas have EBV (Epstein-Barr virus) associated with the malignant cells. EBV could transactive miR-155 through NF κ B activation [ 689 ]. Since miR-155 is overexpressed in Hodgkin's lymphoma [ 590 ] and promotes B-cell lymphoma formation [ 602 , 798 , 799 ], EBV may be important in the pathogenesis of cHL.

4. MicroRNA in Regulating GC-Induced Apoptosis of Lymphoid Malignancies

4.1. MicroRNAs in the Regulation of GR Expression

4.1.1. Downregulation of GR by miR-18 and miR-124a

MicroRNAs have been shown to modulate GR expression in neuronal tissue [ 649 , 800 , 801 ]. miR-18 and miR-124a especially reduced GR-mediated events in addition to decreasing GR protein levels [ 649 ]. miR-18 is part of the miR-17~92 cluster, which is repressed by GCs [ 206 ]. Upregulation of the miR-17~92 has causally been related to small cell lung cancer [ 802 , 803 ], where reduced GR levels have been associated with GC resistance [ 804 ].

miR-124a was found to bind to the 3′ untranslated region of GR mRNA [ 649 ]. Activation of the GR-responsive glucocorticoid-induced leucine zipper (GILZ) was impaired by miR-124a and -18 overexpression, while miRs-22, -328, and -524 did not have any effect [ 649 ]. Of note, miR-124 regulates Hes1 expression in P19 teratocarcinoma cells [ 670 ], a transcription factor that negatively regulate GR expression [ 88 ]. GC resistance in sepsis patients was associated with miR-124-induced downregulation of GR [ 805 ].

4.1.2. Downregulation of GR by miR-130b

While miR-130b, -181a, and -636 have putative complimentary binding sites in the 3′-UTR of GR α , only miR-130b was found to down-regulate endogeneous GR protein expression in the multiple myeloma cell line MM.1 [ 674 ]. The miR-130b, -181a, and -636 were differentially expressed between GC-sensitive and GC-resistant MM.1 cell lines [ 674 ]. miR-130b was expressed at higher levels in the resistant MM cell line [ 674 ]. Overexpression of miR-130b in MM.1S cells resulted in decreased expression of endogeneous GR, decreased induction of the GR-target gene GILZ, and induction of GC resistance [ 674 ]. Expression of miR-130b was therefore suggested to be a potential biomarker for patients who could be refractory to GC therapy.

In gastric cancers, miR-130b regulated the tumor suppressor gene RUNX3 [ 675 ]. miR-130b may also down-regulate p21 Waf1/Cip1 , resulting in inhibition of cellular senescence [ 676 , 806 ].

4.1.3. Downregulation of GR by miR-142 and miR-181a

Another study [ 678 ] showed that elevated miR-142 expression in human T-ALL cells confers GC resistance by reducing the GR expression level. Other mechanism for the oncogenic role of miR-142 might be explained by its targeting of adenylyl cyclase 9 mRNA [ 679 ] leading to reduced production of cyclic adenosine monophosphate (cAMP) production with concomitant inhibition of the protein kinase A (PKA) signaling pathway [ 678 ]. The reduction in cAMP levels and reduced PKA activity caused by miR-142 relieve the inhibitory effect of PKA on T-leukemic cell proliferation. T-ALL with poor prognosis expressed higher levels of miR-142 than those with good prognosis [ 678 ]. Also, miR-142 was expressed at higher levels in relapsed T-ALL than newly diagnosed samples [ 678 ]. Transfection of miR-142 inhibitor increased GR α expression levels and sensitized T-ALL cells to GC-induced apoptosis [ 678 ].

These findings are in accord with previous findings showing a synergistic effect of cAMP mimetics on GC-induced apoptosis [ 99 , 460 , 807 ]. cAMP signaling can also be negatively regulated by phosphodiesterase 4B (PDE4B) that is frequently overexpressed in diffuse large B-cell lymphoma (DLBCL) [ 808 ]. Pharmacological inhibition of PDE4 in a xenograft model of human lymphoma unleashed cAMP effects, inhibited Akt, and restored GC sensitivity [ 808 ]. PDE4 inhibitors may thus improve the clinical outcome of patients with B-cell malignancies.

Triptolide, a drug that overcomes dexamethasone-resistance in human multiple myeloma cells [ 809 ], was found to regulate GR expression in the MM1.S cell line by downregulating the expression of miR-142 and miR-181a [ 680 ]. miR-142 and miR-181a mimetics slightly attenuated, whereas miR-142 and miR-181a inhibitors enforced GC-induced apoptosis of MM1.S cells [ 680 ]. miR-181a/b can also increase GC-induced apoptosis in virtue of their ability to repress the expression of the anti-apoptotic Bcl-2, Mcl-1, and XIAP proteins [ 385 , 539 , 810 ].

4.2. MicroRNAs Affected by GCs in Lymphoid Cells

4.2.1. Repression of miR-17~92 by GCs

Smith et al. [ 648 ] showed that broad microRNA repression occurs during GC-induced apoptosis of rat thymocytes. This repression was associated with reduced expression of both nuclear (Drosha and DGCR8/Pasha) and cytoplasmic (Dicer) microRNA processing enzymes. Silencing of Dicer in two human leukemic cell lines (CEM-C7 and ectopic GR α -overexpressed Jurkat cells) led to enhanced sensitivity to GC-induced apoptosis [ 648 ]. Global downregulation of microRNA levels, especially the miR-17 family, by GCs was also observed in GC-sensitive ALL cell lines, with concomitant upregulation of Bim [ 657 ]. Later studies showed that GCs selectively upregulate and downmodulate specific miRNAs [ 646 ] that cannot be explained by altered Dicer expression.

One polycistron cluster repressed by GCs is miR-17~92 [ 648 , 657 ], which regulates Bim expression [ 246 , 247 ]. Downregulation of miR-17~92 contributes to the GC-mediated upregulation of Bim [ 206 ]. This microRNA cluster also represses PTEN [ 247 ], a negative regulator of the PI3K/Akt signaling pathway. The GC-mediated downregulation of miR-17~92 might be one mechanism responsible for the GC-induced dephosphorylation of Akt. Primary thymocytes derived from mice transgenic for the miR-17~92 polycistron members in the lymphocyte compartment exhibited diminished sensitivity to GC-induced apoptosis in lymphocytes, further supporting a role for GC-induced repression of miR-17~92 in promoting apoptosis [ 648 ]. Harada et al. [ 657 ] observed that GCs reduced miR-17 family expression in 50% of primary GC-sensitive ALL, but not in any of the GC-resistant ones. Overexpression of miR-17~92 attenuated GC-induced cell death, while inhibition of miR-17~92 increased the sensitivity to GC [ 657 ]. They also reported that in a pre-B ALL cell line, a 10-hour dexamethasone treatment led to a reduction in miR-142 and miR-27a, while miR-9 was induced. There is also some evidence that GCs can reduce miR-27a expression in mouse muscle cells [ 811 ].

4.2.2. Upregulation of miR-15~16 by GCs

Rainer et al. [ 646 ] reported an induction of the myeloid-specific miR-223 and the apoptosis and cell-cycle arrest inducing miR-15~16 clusters by GC in a subset of B- and T-ALL cells, together with downregulation of the miR-17~92 complex. A transient upregulation of miR-19b and miR-181a was also observed. Overexpression of miR-15b~16 mimics increased, whereas silencing by miR-15b~16 inhibitors decreased GC sensitivity [ 646 ]. The miRNAs of the miR-15~16 family are encoded in two clusters (15a~16-1 and 15b~16-2) embedded in the DLEU2 (deleted in leukemia 2) and SMC4 loci, respectively [ 766 , 812 ]. They have been implicated in cell-cycle arrest [ 813 ] and in cell death/survival decisions, the latter supposedly by targeting Bcl-2 [ 346 ]. Other microRNAs affected by GCs in pediatric ALL include upregulation of miR-548d-1 and repression of miR-128b along with miR-106b~25~93, the paralogue of miR-17~92 [ 646 ].

4.2.3. Upregulation of miR-223 by GCs

It is still not known whether the GC-induced upregulation of miR-223 affects GC-induced apoptosis [ 646 ]. Increased expression of miR-223 is involved in the differentiation of myeloid precursors into granulocytes such as neutrophils [ 701 , 814 ]. During granulopoiesis, miR-223 targets E2F1, which in turn represses miR-223 expression, creating an autoregulatory negative feedback loop [ 702 ]. A negative feedback loop also exists between miR-223 and the transcription factor NFI-A [ 814 ]. miR-223 is positively regulated by C/EBP α during differentiation to granulocytes [ 814 ] and negatively regulated by AML1/ETO in leukemia cells [ 703 ]. Moreover, miR-223 targets the myeloid ELF-1-like factor (Mef)-2c and IGFR (insulin-like growth factor receptor), which may account for some of its negative regulation of granulocyte proliferation [ 701 ]. Through suppression of IGF-1R, the downstream PI3K/Akt/mTOR/p70S6K pathway is suppressed, with consequent inhibition of cell proliferation [ 704 ]. miR-223 attenuates hematopoietic cell proliferation and positively regulates miR-142 through LMO2 isoforms and C/EBP β [ 815 ]. Ectopic expression of miR-223 restores differentiation of AML leukemic cells [ 703 ]. miR-223 knockout mice showed increased numbers of granulocyte progenitors in the bone marrow and hypermature neutrophils in the circulation, suggesting that miR-223 is involved in the negative regulation of maturation rather than differentiation of granulocytes [ 701 ]. miR-223 may also target Fbw7 [ 705 , 816 ], a negative regulator of the anti-apoptotic Mcl-1 [ 372 ]. Thus, it may indirectly increase apoptotic resistance by up-regulating Mcl-1.

4.2.4. Upregulation of miR-150 and miR-342 by GCs

Dexamethasone treatment of thymocytes led to upregulation of miR-150 and miR-342, while miR-181a and miR-181d were downregulated [ 684 ]. miR-181d represses CD69 and Prox-1 to a similar extent as miR-181a [ 684 ]. miR-181d, but not miR-181a, repressed Lif (leukemia inhibitory factor) [ 684 ]. Lif is a member of the IL-6 cytokine family expressed in thymic epithelial cells and T lymphocytes, which elevates GC levels following LPS exposure and is responsible for thymic atropy induced by stress [ 817 – 819 ]. Other effects of miR-181 are described in Sections 3.1.3 and 3.2.2.2. The effects of miR-150 are described in Sections 3.1.4 and 3.2.2.9.

4.2.5. Effect of GCs on MicroRNA Expression in Macrophages

A recent report showed that GCs could prevent lipopolysaccharide (LPS)-mediated inflammatory responses in macrophages by downregulating miR-155 [ 690 ]. LPS induces miR-155 expression in macrophages through TLR4-mediated activation of NF κ B [ 690 ]. Overexpression of miR-155 reversed the suppressive action of GCs, while inhibition of miR-155 exhibited an effect similar to that of GCs on LPS-treated macrophages, suggesting that GC-induced repression of miR-155 is one mechanism for the immunosuppressive function of GC. This effect of GC on miR-155 was dependent on GR and NF κ B [ 690 ]. miR-155 transgenic mice produced more proinflammatory cytokines in response to LPS [ 820 ]. miR-155 is transcribed from B-cell integration cluster (BIC) [ 584 , 691 ] and targets among others SOCS1 (suppressor of cytokine signaling 1), which negatively regulates JAK/STAT signaling. GCs also prevented the LPS-mediated upregulation of miR-146, miR-147, miR-148, miR-32b, and miR-301 in macrophages [ 690 ].

4.2.6. Other MicroRNAs Affected by GCs

In the brain, GCs prevents BDNF (brain-derived neurotrophic factor)-regulated synaptic function through suppression of miR-132 expression [ 821 ]. miR-132 is increased by BDNF and is involved in promotion of neuronal outgrowth [ 822 ]. In some carcinoma cell lines, dexamethasone was shown to down-regulate miR-27b, miR-148a, and miR-451 [ 823 ].

4.3. MicroRNAs in the Regulation of Apoptotic GC-Sensitivity

From all we have learned above, any microRNA that modulates any of the many factors regulating GC-induced apoptosis may affect the apoptotic response to GCs (Figures 1 – 6 ). These include microRNAs that affect GR expression (e.g., miR-18, miR-124a, miR-130b, miR-142, and miR-181a), those affecting Bim expression (miR-26a, miR-93, miR-17~92, miR-106a~363, and miR-106b~25) or its transcription factor FoxO3 (e.g., miR-1, miR-21, miR-27a, miR-96, miR-135b, miR-155, and miR-182), those affecting PTEN expression (miR-17~92, miR-106b~25, miR-21, miR-26a, miR-29b, miR-214, miR-216a, miR-217, miR-221, and miR-222) or mTOR (e.g., miR-101), and those downregulating directly or indirectly the anti-apoptotic proteins Bcl-2, Bcl-X L , Mcl-1, XIAP, and CYLD (e.g., miR-15a~16, miR-181a/b, miR-34a, miR-125b, miR-29a/b/c, miR-101, miR-133b, miR-193b, miR-512, let-7, and miR-491). The effect of some of these microRNAs on GC-sensitivity has already been described above and will not be repeated here. Rather, I will present here some data from primary samples showing the influence of microRNAs on clinical outcome.

A study searching for differential miRNAs expression in ALL relapse cells versus childhood ALL with complete remission showed significant associations for miR-708, miR-223, and miR-27a with individual relapse-free survival [ 655 ]. For samples at relapse versus diagnosis, the most differentially expressed microRNAs included miR-223, miR-23a, let-7g, miR-181, miR-708, and miR-130b, while comparison of complete response with diagnostic samples showed differential expression pattern of miR-27a, miR-223, miR-23a, miR-181, and miR-128b [ 655 ]. Among these microRNAs, miR-223, miR-128b, miR-23a, and let-7g were downregulated in the relapse samples compared with complete response samples, while miR-181 family members, miR-708, and miR-130b were upregulated in the relapse samples [ 655 ]. It should be remained here that miR-130b targets GR [ 674 ], RUNX3 [ 675 ], and p21 [ 676 ], and miR-223 is upregulated by GCs [ 646 ] and targets IGFR [ 701 ] and E2F1 [ 702 ]. E2F1 has a dual role in cell-cycle control, as it affects several cell processes. It can either act as a tumor-suppressor or oncogene depending on the cellular context [ 824 ]. Thus, the upregulation of miR-130b together with downregulation of miR-223 may contributes to GC resistance.

miR-708 was the most upregulated microRNA in the relapse samples, whereas miR-223 was significantly downregulated, suggesting that these two microRNAs may have important role in pediatric ALL relapse [ 655 ]. Moreover, upregulation of miR-708 was found to be associated with the in vivo GC therapy response and with disease risk stratification in childhood ALL [ 655 ]. Standard and middle risk stratification groups had a higher miR-708 expression at diagnosis than the high risk group. Interestingly, miR-708 was low in high relapse patients at diagnosis, while specimens of relapsed samples showed abundance of miR-708, suggesting for an upregulation of miR-708 during disease progression.

FoxO3, that is critical for hematopoietic stem cell self-renewal and mediates the initial apoptotic response [ 825 – 827 ], contains a conserved miR-708 response element in its 3′-UTR [ 655 ]. FoxO3 can act as either an oncogene or a tumor suppressor in leukemia [ 828 , 829 ]. FoxO3 transcriptional activity was found to prevent B-CLL and CML proliferation [ 825 , 828 ]. FoxO3a is also targeted by other microRNAs, including miR-27a (see Section 2.2.6).

Moreover, miR-27a directly regulates the drug-resistant factor P-glycoprotein, and overexpression of miR-27a increased sensitivity of leukemia cells to doxorubicin [ 658 ]. miR-27a is relevant to treatment outcome in vivo and may be involved in relapse of both lymphocytic leukemia and myeloid leukemia [ 658 ]. Low expression of miR-27a might promote ALL relapse [ 655 , 658 ]. On the contrary, miR-27a exerts oncogenic effects by regulating ZBTB10 [ 446 , 830 ] and Fbw7 [ 253 , 438 ].

miR-128b, which was higher in relapse ALL and at diagnosis compared to complete response [ 655 ], has been reported to confer drug resistance in many cancers including ALL [ 672 , 673 ]. Both miR-27a and miR-128b might target BMI1 [ 655 ], a transcription factor of the polycomb-group gene necessary for hematopoietic stem cell (HSC) and leukemia stem-cell self-renewal [ 831 , 832 ]. Deletion of BMI1 inhibits self-renewal of tumor stem cells and prevents leukemia recurrence [ 833 ].

A role for miR-128 and miR-221 in regulating GC sensitivity in cells from MLL-AF4 ALL patients has been proposed [ 672 ]. miR-128b and miR-221 are downregulated in MLL-arranged ALL relative to other types of ALL [ 672 ]. The MLL gene is located at 11q23, a site frequently involved in chromosomal translocations in aggressive human lymphoid and myeloid leukemias. As a result of chromosomal translocations, a portion of MLL becomes fused to one among more than 40 different partner proteins. MLL-AF4 ALL, which results from the translocation between MLL and AF4, is associated with GC resistance and has a poor prognosis [ 834 , 835 ]. Re-expression of mR-128 and miR-221 in cultured MLL-AF4 ALL cells sensitized them to GCs [ 672 ]. miR-128 targets MLL, AF4, and the MLL-AF4 pusion protein resulting in lower expression of HOXA9, whereas miR-221 downregulates CDKN1B (cyclin-dependent kinase inhibitor 1B, p27 Kip1 ), another gene transcriptionally activated by MLL-AF4 as well as the wild-type MLL protein [ 672 ]. The targeting of different proteins may explain the cooperative effect of miR-128b and miR-221 on GC sensitization [ 672 ]. It should be noted that miR-221 in other settings, for example, CLL, has anti-apoptotic effects and functions as an oncogene.

4.4. Potential Use of miRNA Regulators in Therapy of Cancer Cells

In light of the multiple effects of various microRNAs on cell survival and apoptosis, modulating microRNA expression in tumor cells is an attractive approach for sensitizing the tumor cells to chemotherapeutic drugs. Inhibition of specific microRNAs is performed by using antisense sequences (termed antagomiRs) targeting the microRNA guide stand that blocks the interaction with the microRNA recognition elements within the 3′-UTR of the target mRNA genes [ 836 ]. To increase their binding affinity and stability in biological fluids, the antagomiRs are often modified with 2′-O-methyl-, phosphorothioate, or locked nucleic acid substitutions. To overexpress microRNAs, chemically synthesized microRNAs (called microRNA mimics) are used.

One potential use of microRNAs is to repress the expression of MLL-AF4 fusion protein in ALL that is responsible for GC resistance. This fusion protein can be repressed through overexpression of miR-143 [ 837 ], or miR-128 together with miR-221 [ 672 ]. The latter combination was shown to sensitize the MLL-AF4-carrying ALL cells to GCs [ 672 ].

Another promising approach is to target miR-155, an oncogenic microRNA often correlated with poor prognosis. A proof-of-principle was demonstrated by Babar et al. [ 838 ]. They showed that overexpression of miR-155 in lymphoid tissues resulted in disseminatedlymphomacharacterized by a clonal, transplantable pre-B-cell population of neoplastic lymphocytes. Withdrawal of miR-155 in mice with established disease resulted in rapid regression of lymphadenopathy. Systemic delivery of antisense peptide nucleic acids encapsulated in unique polymer nanoparticles inhibited miR-155 and slowed the growth of these pre-B-cell tumors in vivo [ 838 ].

5. Summary

Glucocorticoid-induced apoptosis appears to be a complex process involving several signaling pathways ( Figure 6 ). These include (1) transactivation of pro-apoptotic genes (importantly Bim); (2) alterations in microRNA expression (upregulation of miR-15~16 that targets the pro-apoptotic Bcl-2; miR-223 that targets IGFR; miR-150 that targets Akt and Notch, while suppressing miR-17~92 that prevents Bim and PTEN translation); (3) direct action of GR on the mitochondria (including mitochondrial GR translocation and production of reactive oxygen species within the mitochondria); (4) activation of the protein kinases GSK3 and p38; (5) activation of the FoxO3a transcription factor that upregulates Bim; (6) inhibition of the Notch1, PI3/Akt/mTOR, and ERK1/2 survival pathways. Interruption of any of the pro-apoptotic processes may lead to drug resistance. Altered microRNA expression in malignant cells may modulate many of these processes thereby imposing apoptotic resistance (Figures 1 – 6 ).

GC-resistant lymphoid cells might be divided into two major subgroups according to the underlying mechanism of resistance. The first group consists of cancer cells whose drug resistance can be overcome by exposing the cells to GCs in combination with drugs that target protein kinases such as Akt, mTOR, Src, ALK, and/or BCR, or drugs antagonizing Bcl-2, Bcl-X L , Mcl-1, c-Myc, or Notch. These lymphoid malignancies show in general a more favorable response to combined GC therapy and in many cases may be explained by their growth dependency on these signaling molecules. The second group of GC-resistant cells exhibits an intrinsic defect in the GC-mediated apoptotic process and can thus not be turned sensitive to this drug. It is important to distinguish between these two subgroups prior to therapy initiation in order to choose the right drug combination. A diagnostic test needs to be developed that can distinguish between the different resistance backgrounds.

Recently, Burnsides et al. [ 839 ] have developed an ex vivo stimulation assay that determines the ability of leukocytes to upregulate anti-inflammatory genes such as GILZ and FKBP51 following exposure to dexamethasone. It is reasonable that a similar test may be developed to gene profiling lymphoid malignancies prior to and following GC treatment, where upregulation of the pro-apoptotic Bim gene would be a favorable predictor. Also, Bim induction may be measured after combining GC with a protein kinase inhibitor. Simultaneous expression profiling of microRNAs, Notch1, and Bcl-2 family proteins together with the activated protein kinase status in the malignant cell would provide valuable information for choosing the proper drug combination. A predictor for a good GC response would be to determine the ability of GCs to downregulate miR-17~92 and upregulate miR-15~16, miR-150, and miR-223.

A tentative therapeutic approach would be to modulate the microRNA status of the cell using microRNA mimics or antagomiRs as described in Section 4.4. What we have learned from the studies described in this paper is that it seems that in general it would be favorable to augment the expression of miR-29, miR-27, miR-15a~16, miR-34a, miR-150, and let-7, while suppressing miR-155, miR-181, miR-182, miR-21, and miR-221/222 as well as miR-17~92. Obviously, an initial microRNA profiling should be performed, and the cancer-type classification should be considered. Some microRNAs may have cell-type specific effects. While down-regulation of miR-181 may suppress the growth of T-ALL and MM, augmented miR-181 expression prevents the growth of unmutated IgVH CLL cases. Also, miR-26a has a dual effect. Its overexpression prevents growth of c-Myc-positive Burkitt lymphoma, while it must be downregulated in Notch-positive T-ALL to achieve growth inhibition. miR-451 and miR-709 could prevent growth of Notch-positive T-ALL. A reduction in miR-142, and maybe also of miR-708, which is highly expressed in relapsed childhood T-ALL, is anticipated to improve T-ALL therapy. For classical HL, miR-135a may cause apoptosis.

In conclusion, in certain types of lymphoid malignancies, GC resistance may be overcome by relieving the inhibitory effects of protein kinases and Bcl-2 family members. Both the activity of protein kinases and the expression of Bcl-2 members are affected by the microRNA network. Modulation of microRNA expression might increase GC drug responsiveness and thus improve the therapy of lymphoid malignancies.

Abbreviations

Anaplastic large cell lymphoma

Burkitt's lymphoma

Chronic B-lymphocytic leukemia

Diffuse large B-cell lymphoma

Follicular lymphoma

Glucocorticoid

Glucocorticoid receptor

γ -secretase inhibitor

Hodgkin's lymphoma

Multiple myeloma

Non-Hodgkin's lymphoma

Nuclear receptor subfamily 3, group C, member 1

Nucleophosmin-anaplastic lymphoma kinase

T-cell acute lymphoblastic leukemia.

1 Pui CH Gajjar AJ Kane JR Qaddoumi IA Pappo AS Challenging issues in pediatric oncology Nature Reviews Clinical Oncology 2011 8 540 549 2-s2.0-79959536398 10.1038/nrclinonc.2011.95 PMC3234106 21709698

2 Inaba H Pui CH Glucocorticoid use in acute lymphoblastic leukaemia The Lancet Oncology 2010 11 11 1096 1106 2-s2.0-78049529488 20947430 10.1016/S1470-2045(10)70114-5 PMC3309707

3 Armitage JO The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management American Journal of Hematology 2012 87 511 519 22508369 10.1002/ajh.23144

4 Jiang N Koh GS Suang Lim JY BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia Experimental Hematology 2011 39 3 321.e3 329.e3 2-s2.0-79951944939 21130142 10.1016/j.exphem.2010.11.009

5 den Uyl D Bultink IEM Lems WF Advances in glucocorticoid-induced osteoporosis Current Rheumatology Reports 2011 13 3 233 240 2-s2.0-79957526871 21365209 10.1007/s11926-011-0173-y PMC3092927

6 Dixon WG Bansback N Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know Annals of the Rheumatic Diseases 2012 71 11 1761 1764 22851467 10.1136/annrheumdis-2012-202021

7 Beaudry JL Riddell MC Effects of glucocorticoids and exercise on pancreatic β -cell function and diabetes development Diabetes/Metabolism Research and Reviews 2012 28 7 560 573 22556149 10.1002/dmrr.2310

8 Jörns A Sennholz C Naujok O Lenzen S Beta cell mass regulation in the rat pancreas through glucocorticoids and thyroid hormones Pancreas 2010 39 8 1167 1172 2-s2.0-78049238101 20683219 10.1097/MPA.0b013e3181dfce4f

9 Weinstein RS Glucocorticoid-induced osteoporosis and osteonecrosis Endocrinology and Metabolism Clinics of North America 2012 41 3 595 611 22877431 10.1016/j.ecl.2012.04.004 PMC3417039

10 Lansang MC Hustak LK Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them Cleveland Clinic Journal of Medicine 2011 78 11 748 756 22049542 10.3949/ccjm.78a.10180

11 Reich E Tamary A Sionov RV Melloul D Involvement of thioredoxin-interacting protein (TXNIP) in glucocorticoid-mediated beta cell death Diabetologia 2012 55 1048 1057 22246375 10.1007/s00125-011-2422-z

12 Wang LX Wang YP Chen Z Exendin-4 protects murine pancreatic β -cells from dexamethasone-induced apoptosis through PKA and PI-3K signaling Diabetes Research and Clinical Practice 2010 90 3 297 304 2-s2.0-78649489519 20889222 10.1016/j.diabres.2010.09.004

13 Ranta F Avram D Berchtold S Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4 Diabetes 2006 55 5 1380 1390 2-s2.0-33745319608 16644695 10.2337/db05-1220

14 Moutsatsou P Kassi E Papavassiliou AG Glucocorticoid receptor signaling in bone cells Trends in Molecular Medicine 2012 18 348 359 22578718 10.1016/j.molmed.2012.04.005

15 Yun SI Yoon HY Jeong SY Chung YS Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3 β Journal of Bone and Mineral Metabolism 2009 27 2 140 148 2-s2.0-60849090734 19066717 10.1007/s00774-008-0019-5

16 Li H Qian W Weng X Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells PLoS ONE 2012 7 e37030 10.1371/journal.pone.0037030 PMC3375272 22719835

17 Wong EYH Herbert J Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus Neuroscience 2006 137 1 83 92 2-s2.0-29744434761 16289354 10.1016/j.neuroscience.2005.08.073 PMC2651634

18 Mayer JL Klumpers L Maslam S de Kloet ER Joëls M Lucassen PJ Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis Journal of Neuroendocrinology 2006 18 8 629 631 2-s2.0-33745728406 16867184 10.1111/j.1365-2826.2006.01455.x

19 Hallek M Fischer K Fingerle-Rowson G Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial The Lancet 2010 376 9747 1164 1174 2-s2.0-77957664665 10.1016/S0140-6736(10)61381-5 20888994

20 Robak T Dmoszynska A Solal-Céligny P Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia Journal of Clinical Oncology 2010 28 10 1756 1765 2-s2.0-77950478885 20194844 10.1200/JCO.2009.26.4556

21 Pettitt AR Jackson R Carruthers S Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial Journal of Clinical Oncology 2012 30 1647 1655 22493413 10.1200/JCO.2011.35.9695

22 Skoetz N Bauer K Elter T Alemtuzumab for patients with chronic lymphocytic leukaemia Cochrane Database of Systematic Reviews 2012 2 CD008078 10.1002/14651858.CD008078.pub2 PMC6486055 22336834

23 Cortelezzi A Sciume M Reda G Lenalidomide in the treatment of chronic lymphocytic leukemia Advances in Hematology 2012 2012 393864 10.1155/2012/393864 PMC3407617 22851972

24 Gentile M Recchia AG Vigna E Lenalidomide in the treatment of chronic lymphocytic leukemia Expert Opinion on Investigational Drugs 2011 20 2 273 286 2-s2.0-79951861397 21214505 10.1517/13543784.2011.546343

25 Younes A Bartlett NL Leonard JP Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas The New England Journal of Medicine 2010 363 19 1812 1821 2-s2.0-78049515807 21047225 10.1056/NEJMoa1002965

26 Micallef IN Maurer MJ Wiseman GA Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma Blood 2011 118 4053 4061 21673350 10.1182/blood-2011-02-336990 PMC3204728

27 Cives M Milano A Dammacco F Silvestris F Lenalidomide in multiple myeloma: current experimental and clinical data European Journal of Haematology 2012 88 279 291 22085323 10.1111/j.1600-0609.2011.01735.x

28 Scott LJ Lyseng-Williamson KA Spotlight on lenalidomide in relapsed or refractory multiple myeloma BioDrugs 2011 25 333 337 21942918 10.2165/11207120-000000000-00000

29 Bachmann PS Piazza RG Janes ME Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition Blood 2010 116 16 3013 3022 2-s2.0-77958196417 20647567 10.1182/blood-2010-05-284968

30 Sionov RV Spokoini R Kfir-Erenfeld S Cohen O Yefenof E Chapter 6 mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis Advances in Cancer Research 2008 101 127 248 2-s2.0-56849101027 19055945 10.1016/S0065-230X(08)00406-5

31 Kfir-Erenfeld S Sionov RV Spokoini R Cohen O Yefenof E Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations Leukemia and Lymphoma 2010 51 11 1968 2005 2-s2.0-78649269460 20849387 10.3109/10428194.2010.506570

32 Reed JC Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood 2008 111 7 3322 3330 2-s2.0-43549112759 18362212 10.1182/blood-2007-09-078162 PMC2275002

33 Oltersdorf T Elmore SW Shoemaker AR An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 7042 677 681 2-s2.0-20444486559 15902208 10.1038/nature03579

34 Del Gaizo Moore V Schlis KD Sallan SE Armstrong SA Letai A BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Blood 2008 111 4 2300 2309 2-s2.0-41349123507 18056841 10.1182/blood-2007-06-098012 PMC2234061

35 Deng J Carlson N Takeyama K Dal Cin P Shipp M Letai A BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents Cancer Cell 2007 12 2 171 185 2-s2.0-34547603628 17692808 10.1016/j.ccr.2007.07.001

36 Kelly PN Grabow S Delbridge AR Adams JM Strasser A Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice Cell Death and Differentiation 2013 20 57 63 22814621 10.1038/cdd.2012.92 PMC3524630

37 Spender LC Inman GJ Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics Molecular Cancer Research 2012 10 347 359 22241218 10.1158/1541-7786.MCR-11-0394 PMC3378513

38 Moore VDG Brown JR Certo M Love TM Novina CD Letai A Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 Journal of Clinical Investigation 2007 117 1 112 121 2-s2.0-33845994359 17200714 10.1172/JCI28281 PMC1716201

39 Kang MH Kang HK Szymanska B Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Blood 2007 110 6 2057 2066 2-s2.0-34548814971 17536015 10.1182/blood-2007-03-080325

40 Szymanska B Wilczynska-Kalak U Kang MH Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts PLoS ONE 2012 7 e33894 10.1371/journal.pone.0033894 PMC3315513 22479469

41 Kline MP Rajkumar SV Timm MM ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells Leukemia 2007 21 7 1549 1560 2-s2.0-34250770481 17460700 10.1038/sj.leu.2404719

42 Chauhan D Velankar M Brahmandam M A novel Bcl-2/Bcl-X L /Bcl-w inhibitor ABT-737 as therapy in multiple myeloma Oncogene 2007 26 16 2374 2380 2-s2.0-34147142477 17016430 10.1038/sj.onc.1210028

43 Gandhi L Camidge DR de Oliveira MR Phase I study of navitoclax (ABT-263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors Journal of Clinical Oncology 2011 29 7 909 916 2-s2.0-79952291173 21282543 10.1200/JCO.2010.31.6208 PMC4668282

44 Roberts AW Seymour JF Brown J Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease Journal of Clinical Oncology 2012 30 488 496 22184378 10.1200/JCO.2011.34.7898 PMC4979082

45 Tse C Shoemaker AR Adickes J ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Research 2008 68 9 3421 3428 2-s2.0-44849112219 18451170 10.1158/0008-5472.CAN-07-5836

46 Wilson WH O’Connor OA Czuczman MS Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity The Lancet Oncology 2010 11 12 1149 1159 2-s2.0-78649630259 21094089 10.1016/S1470-2045(10)70261-8 PMC3025495

47 Ackler S Xiao Y Mitten MJ ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Molecular Cancer Therapeutics 2008 7 10 3265 3274 2-s2.0-55749084366 18852130 10.1158/1535-7163.MCT-08-0268

48 Yecies D Carlson NE Deng J Letai A Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1 Blood 2010 115 16 3304 3313 2-s2.0-77951442337 20197552 10.1182/blood-2009-07-233304 PMC2858493

49 Coloff JL Macintyre AN Nichols AG Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition Cancer Research 2011 71 15 5204 5213 2-s2.0-79960944880 21670080 10.1158/0008-5472.CAN-10-4531 PMC3148426

50 Meynet O Beneteau M Jacquin MA Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis Leukemia 2012 26 1145 1147 22076465 10.1038/leu.2011.327

51 O’Brien SM Claxton DF Crump M Phase I study of obatoclax mesylate (GX15-070), a small molecule pan Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia Blood 2009 113 2 299 305 2-s2.0-58849164097 18931344 10.1182/blood-2008-02-137943 PMC4968372

52 Schimmer AD O’Brien S Kantarjian H A phase i study of the pan bcl-2FamilyInhibitor obatoclax mesylate in patients with advanced hematologic malignancies Clinical Cancer Research 2008 14 24 8295 8301 2-s2.0-58149340656 19088047 10.1158/1078-0432.CCR-08-0999

53 Joudeh J Claxton D Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms Expert Opinion on Investigational Drugs 2012 21 363 373 22324354 10.1517/13543784.2012.652302

54 Nguyen M Marcellus RC Roulston A Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proceedings of the National Academy of Sciences of the United States of America 2007 104 49 19512 19517 2-s2.0-37649023004 18040043 10.1073/pnas.0709443104 PMC2148320

55 Pérez-Galán P Roué G Villamor N Campo E Colomer D The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Blood 2007 109 10 4441 4449 2-s2.0-34248362003 17227835 10.1182/blood-2006-07-034173

56 Chen S Dai Y Pei XY CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies Cancer Research 2012 72 4225 4237 22693249 10.1158/0008-5472.CAN-12-1118 PMC3421040

57 Rahmani M Aust MM Attkisson E Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process Blood 2012 119 6089 6098 22446485 10.1182/blood-2011-09-378141 PMC3383017

58 Heidari N Hicks MA Harada H GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy Cell Death and Disease 2010 1 9, article e76 2-s2.0-79958276489 10.1038/cddis.2010.53 PMC3032343 21364679

59 Bonapace L Bornhauser BC Schmitz M Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance Journal of Clinical Investigation 2010 120 4 1310 1323 2-s2.0-77951171023 20200450 10.1172/JCI39987 PMC2846044

60 Kang R Zeh HJ Lotze MT Tang D The Beclin 1 network regulates autophagy and apoptosis Cell Death and Differentiation 2011 18 4 571 580 2-s2.0-79952628267 21311563 10.1038/cdd.2010.191 PMC3131912

61 Declercq W Vanden Berghe T Vandenabeele P RIP kinases at the crossroads of cell death and survival Cell 2009 138 2 229 232 2-s2.0-67650638892 19632174 10.1016/j.cell.2009.07.006

62 Fakler M Loeder S Vogler M Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance Blood 2009 113 8 1710 1722 2-s2.0-61849152327 19036706 10.1182/blood-2007-09-114314

63 Frenzel LP Patz M Pallasch CP Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis British Journal of Haematology 2011 152 2 191 200 2-s2.0-78650388973 21091905 10.1111/j.1365-2141.2010.08426.x

64 Loeder S Drensek A Jeremias I Debatin KM Fulda S Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis International Journal of Cancer 2010 126 9 2216 2228 2-s2.0-77949889993 19676052 10.1002/ijc.24816

65 Hundsdoerfer P Dietrich I Schmelz K Eckert C Henze G XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL Pediatric Blood and Cancer 2010 55 2 260 266 2-s2.0-77955123282 20582956 10.1002/pbc.22541

66 Deftos ML He YW Ojala EW Bevan MJ Correlating notch signaling with thymocyte maturation Immunity 1998 9 6 777 786 2-s2.0-0032442040 9881968 10.1016/s1074-7613(00)80643-3 PMC2789684

67 Spokoini R Kfir-Erenfeld S Yefenof E Sionov RV Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis Molecular Endocrinology 2010 24 6 1136 1150 2-s2.0-77954823170 20371704 10.1210/me.2009-0466 PMC5417474

68 Sade H Krishna S Sarin A The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells The Journal of Biological Chemistry 2004 279 4 2937 2944 2-s2.0-1642576036 14583609 10.1074/jbc.M309924200

69 Radtke F Wilson A Stark G Deficient T cell fate specification in mice with an induced inactivation of Notch1 Immunity 1999 10 5 547 558 2-s2.0-0033136717 10367900 10.1016/s1074-7613(00)80054-0

70 Radtke F Fasnacht N MacDonald HR Notch signaling in the immune system Immunity 2010 32 1 14 27 2-s2.0-74549176827 20152168 10.1016/j.immuni.2010.01.004

71 Yin L Velazquez OC Liu ZJ Notch signaling: emerging molecular targets for cancer therapy Biochemical Pharmacology 2010 80 5 690 701 2-s2.0-77954215506 20361945 10.1016/j.bcp.2010.03.026

72 Ersvaer E Hatfield KJ Reikvam H Bruserud O Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies Bone Marrow Research 2011 2011 15 pages 570796 10.1155/2011/570796 PMC3200006 22046566

73 Pear WS Aster JC Scott ML Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles Journal of Experimental Medicine 1996 183 5 2283 2291 2-s2.0-0029942842 8642337 10.1084/jem.183.5.2283 PMC2192581

74 Bellavia D Campese AF Alesse E Constitutive activation of NF- κ B and T-cell leukemia/lymphoma in Notch3 transgenic mice EMBO Journal 2000 19 13 3337 3348 2-s2.0-0034600850 10880446 10.1093/emboj/19.13.3337 PMC313949

75 Pear WS Aster JC T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling Current Opinion in Hematology 2004 11 6 426 433 2-s2.0-8544262178 15548998 10.1097/01.moh.0000143965.90813.70

76 Ferrando AA The role of NOTCH1 signaling in T-ALL Hematology/the Education Program of the American Society of Hematology 2009 353 361 2-s2.0-77949432758 10.1182/asheducation-2009.1.353 PMC2847371 20008221

77 Tzoneva G Ferrando AA Recent advances on NOTCH signaling in T-ALL Current Topics in Microbiology and Immunology 2012 360 163 182 22673746 10.1007/82_2012_232

78 Pancewicz J Nicot C Current views on the role of Notch signaling and the pathogenesis of human leukemia BMC Cancer 2011 11, article 502 10.1186/1471-2407-11-502 PMC3262490 22128846

79 Paganin M Ferrando A Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia Blood Reviews 2011 25 2 83 90 2-s2.0-79951516547 20965628 10.1016/j.blre.2010.09.004 PMC3033461

80 Ellisen LW Bird J West DC TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms Cell 1991 66 4 649 661 2-s2.0-0025856717 1831692 10.1016/0092-8674(91)90111-b

81 Weng AP Ferrando AA Lee W Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia Science 2004 306 5694 269 271 2-s2.0-5044225888 15472075 10.1126/science.1102160

82 Wang Z Inuzuka H Zhong J Tumor suppressor functions of FBW7 in cancer development and progression FEBS Letters 2012 586 1409 1418 22673505 10.1016/j.febslet.2012.03.017 PMC3372850

83 Palomero T Ferrando A Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia Clinical Lymphoma & Myeloma 2009 9, supplement 3 S205 210 2-s2.0-74049145806 19778842 10.3816/CLM.2009.s.013 PMC2814179

84 Cullion K Draheim KM Hermance N Targeting the Notch1 and mTOR pathways in a mouse T-ALL model Blood 2009 113 24 6172 6181 2-s2.0-67650389196 19246562 10.1182/blood-2008-02-136762 PMC2699237

85 Manfè V Biskup E Rosbjerg A miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma PLoS ONE 2012 7 e29541 10.1371/journal.pone.0029541 PMC3250447 22235305

86 Kamstrup MR Ralfkiaer E Skovgaard GL Gniadecki R Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders British Journal of Dermatology 2008 158 4 747 753 2-s2.0-40949095601 18241263 10.1111/j.1365-2133.2007.08427.x

87 Kogoshi H Sato T Koyama T Nara N Tohda S Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells Oncology Reports 2007 18 1 77 80 2-s2.0-34548018349 17549349

88 Real PJ Tosello V Palomero T γ -secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia Nature Medicine 2009 15 1 50 58 2-s2.0-58149336788 10.1038/nm.1900 PMC2692090 19098907

89 Palomero T Dominguez M Ferrando AA The role of the PTEN/AKT pathway in NOTCH1-induced leukemia Cell Cycle 2008 7 8 965 970 2-s2.0-43549123531 18414037 10.4161/cc.7.8.5753 PMC2600414

90 Palomero T Sulis ML Cortina M Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia Nature Medicine 2007 13 10 1203 1210 2-s2.0-34948908663 10.1038/nm1636 PMC2600418 17873882

91 Wei P Walls M Qiu M Evaluation of selective γ -secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design Molecular Cancer Therapeutics 2010 9 6 1618 1628 2-s2.0-77953368267 20530712 10.1158/1535-7163.MCT-10-0034

92 Samon JB Castillo-Martin M Hadler M Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia Molecular Cancer Therapeutics 2012 11 1565 1575 22504949 10.1158/1535-7163.MCT-11-0938 PMC3392513

93 Moellering RE Cornejo M Davis TN Direct inhibition of the NOTCH transcription factor complex Nature 2009 462 182 188 19907488 10.1038/nature08543 PMC2951323

94 Gutierrez A Look AT NOTCH and PI3K-AKT pathways intertwined Cancer Cell 2007 12 5 411 413 2-s2.0-35748972639 17996644 10.1016/j.ccr.2007.10.027

95 Mungamuri SK Yang X Thor AD Somasundaram K Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53 Cancer Research 2006 66 9 4715 4724 2-s2.0-33646415906 16651424 10.1158/0008-5472.CAN-05-3830

96 Chan SM Weng AP Tibshirani R Aster JC Utz PJ Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia Blood 2007 110 1 278 286 2-s2.0-34347369749 17363738 10.1182/blood-2006-08-039883 PMC1896117

97 Sionov RV The kinome and glucocorticoid-induced apoptosis Chinese Journal of Cancer 2008 27 11 1121 1129 2-s2.0-77954966435 19000440

98 Garza AS Miller AL Johnson BH Thompson EB Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions Leukemia Research 2009 33 5 717 727 2-s2.0-61449100449 19012965 10.1016/j.leukres.2008.10.006 PMC6075689

99 Thompson EB Stepping stones in the path of glucocorticoid-driven apoptosis of lymphoid cells Acta Biochimica et Biophysica Sinica 2008 40 7 595 600 2-s2.0-47549102796 18604450 10.1111/j.1745-7270.2008.00433.x

100 Ruggero D Montanaro L Ma L The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nature Medicine 2004 10 5 484 486 2-s2.0-2442648845 10.1038/nm1042 15098029

101 Wendel HG De Stanchina E Fridman JS Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 2004 428 6980 332 337 2-s2.0-1642586272 15029198 10.1038/nature02369

102 Vega F Medeiros LJ Leventaki V Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma Cancer Research 2006 66 13 6589 6597 2-s2.0-33746118057 16818631 10.1158/0008-5472.CAN-05-3018 PMC4839264

103 Peponi E Drakos E Reyes G Leventaki V Rassidakis GZ Medeiros LJ Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma American Journal of Pathology 2006 169 6 2171 2180 2-s2.0-34248647440 17148679 10.2353/ajpath.2006.051078 PMC1762462

104 Gutierrez A Sanda T Grebliunaite R High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia Blood 2009 114 3 647 650 2-s2.0-70149087158 19458356 10.1182/blood-2009-02-206722 PMC2713461

105 Silva A Yunes JA Cardoso BA PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Journal of Clinical Investigation 2008 118 11 3762 3774 2-s2.0-55849138418 18830414 10.1172/JCI34616 PMC2556239

106 Guo D Teng Q Ji C NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia Leukemia and Lymphoma 2011 52 7 1200 1210 2-s2.0-79959611236 21463127 10.3109/10428194.2011.564696

107 Zhao WL Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways Leukemia 2010 24 1 13 21 2-s2.0-74249106880 19865108 10.1038/leu.2009.223

108 Miller AL Garza AS Johnson BH Thompson EB Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells Cancer Cell International 2007 7, article 3 2-s2.0-34247209568 10.1186/1475-2867-7-3 PMC1852544 17391526

109 Beesley AH Firth MJ Ford J Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism British Journal of Cancer 2009 100 12 1926 1936 2-s2.0-67349261310 19436302 10.1038/sj.bjc.6605072 PMC2714233

110 Batista A Barata JT Raderschall E Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors Experimental Hematology 2011 39 4 457.e3 472.e3 2-s2.0-79952708745 21277936 10.1016/j.exphem.2011.01.005

111 Zhang C Ryu YK Chen TZ Hall CP Webster DR Kang MH Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis Leukemia Research 2012 36 342 349 22137317 10.1016/j.leukres.2011.10.022 PMC3264762

112 Fuka G Kantner HP Grausenburger R Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts Leukemia 2012 26 927 933 22094587 10.1038/leu.2011.322

113 Gu L Zhou C Liu H Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis Journal of Experimental and Clinical Cancer Research 2010 29 1, article 150 2-s2.0-78349294588 10.1186/1756-9966-29-150 PMC2998469 21083937

114 Gu L Gao J Li Q Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis Leukemia 2008 22 11 2091 2096 2-s2.0-56349118798 18685609 10.1038/leu.2008.204

115 López-Royuela N Balsas P Galán-Malo P Anel A Marzo I Naval J Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells Biochimica et Biophysica Acta 2010 1803 2 311 322 2-s2.0-77649272745 19914305 10.1016/j.bbamcr.2009.11.004

116 Yan H Frost P Shi Y Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis Cancer Research 2006 66 4 2305 2313 2-s2.0-33644516582 16489035 10.1158/0008-5472.CAN-05-2447

117 Strömberg T Dimberg A Hammarberg A Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood 2004 103 8 3138 3147 2-s2.0-17444440115 15070696 10.1182/blood-2003-05-1543

118 Schult C Dahlhaus M Glass A The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells Anticancer Research 2012 32 463 474 22287733

119 Kim A Park S Lee JE The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells Leukemia Research 2012 36 912 920 22560334 10.1016/j.leukres.2012.02.010

120 Kfir S Sionov RV Zafrir E Zilberman Y Yefenof E Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: role of Nur77 and Bcl-2 Cell Cycle 2007 6 24 3086 3096 2-s2.0-38149111023 18073527 10.4161/cc.6.24.5023

121 Robak P Robak T A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia Current Medicinal Chemistry 2012 19 31 5294 5318 22830347 10.2174/092986712803833371

122 Trudel S Li ZH Wei E CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma Blood 2005 105 7 2941 2948 2-s2.0-15944378835 15598814 10.1182/blood-2004-10-3913

123 Ohanian M Cortes J Kantarjian H Jabbour E Tyrosine kinase inhibitors in acute and chronic leukemias Expert Opinion on Pharmacotherapy 2012 13 927 938 22519766 10.1517/14656566.2012.672974

124 Carlo GP Cristina M Pogliani EM Crizotinib in anaplastic large-cell lymphoma The New England Journal of Medicine 2011 364 8 775 776 2-s2.0-79951976403 21345110 10.1056/NEJMc1013224

125 Burger JA Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia Current Hematologic Malignancy Reports 2012 7 26 33 22105489 10.1007/s11899-011-0104-z

126 Davis RE Ngo VN Lenz G Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010 463 7277 88 92 2-s2.0-73849145729 20054396 10.1038/nature08638 PMC2845535

127 Honigberg LA Smith AM Sirisawad M The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13075 13080 2-s2.0-77955625479 20615965 10.1073/pnas.1004594107 PMC2919935

128 Winer ES Ingham RR Castillo JJ PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies Expert Opinion on Investigational Drugs 2012 21 355 361 22300471 10.1517/13543784.2012.656199

129 Woyach JA Johnson AJ Byrd JC The B-cell receptor signaling pathway as a therapeutic target in CLL Blood 2012 120 1175 1184 22715122 10.1182/blood-2012-02-362624 PMC3418714

130 Ponader S Chen SS Buggy JJ The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo Blood 2012 119 1182 1189 22180443 10.1182/blood-2011-10-386417 PMC4916557

131 Herman SEM Gordon AL Hertlein E Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 2011 117 23 6287 6296 2-s2.0-79959404661 21422473 10.1182/blood-2011-01-328484 PMC3122947

132 Tai YT Chang BY Kong SY Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma Blood 2012 120 1877 1887 22689860 10.1182/blood-2011-12-396853 PMC3433091

133 Friedberg JW Sharman J Sweetenham J Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010 115 13 2578 2585 2-s2.0-77951002653 19965662 10.1182/blood-2009-08-236471 PMC2852362

134 Young RM Hardy IR Clarke RL Mouse models of non-hodgkin lymphoma reveal Syk as an important therapeutic target Blood 2009 113 11 2508 2516 2-s2.0-63849309885 18981293 10.1182/blood-2008-05-158618 PMC2947310

135 Wang W Corrigan-Cummins M Hudson J MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response Haematologica 2012 97 586 594 22102710 10.3324/haematol.2011.048132 PMC3347661

136 Lannutti BJ Meadows SA Herman SEM CAL-101, a p110 δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 2011 117 2 591 594 2-s2.0-78751553221 20959606 10.1182/blood-2010-03-275305 PMC3694505

137 Ikeda H Hideshima T Fulciniti M PI3K/p110 δ is a novel therapeutic target in multiple myeloma Blood 2010 116 9 1460 1468 2-s2.0-77956592891 20505158 10.1182/blood-2009-06-222943 PMC2938837

138 Castillo JJ Furman M Winer ES CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies Expert Opinion on Investigational Drugs 2012 21 15 22 22112004 10.1517/13543784.2012.640318

139 Jou ST Carpino N Takahashi Y Essential, nonredundant role for the phosphoinositide 3-kinase p110 δ in signaling by the B-cell receptor complex Molecular and Cellular Biology 2002 22 24 8580 8591 2-s2.0-0037695593 12446777 10.1128/MCB.22.24.8580-8591.2002 PMC139888

140 Ringshausen I Schneller F Bogner C Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C δ Blood 2002 100 10 3741 3748 2-s2.0-0037111661 12393602 10.1182/blood-2002-02-0539

141 Pauls SD Lafarge ST Landego I Zhang T Marshall AJ The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions Frontiers in Immunology 2012 3, article 224 10.3389/fimmu.2012.00224 PMC3414724 22908014

142 Baracho GV Miletic AV Omori SA Cato MH Rickert RC Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation Current Opinion in Immunology 2011 23 2 178 183 2-s2.0-79953112441 21277760 10.1016/j.coi.2011.01.001 PMC3070849

143 Accordi B Espina V Giordan M Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL PLoS ONE 2010 5 10 2-s2.0-78149427796 e13552 10.1371/journal.pone.0013552 PMC2958847 21042412

144 Harr MW Caimi PF McColl KS Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia Cell Death and Differentiation 2010 17 9 1381 1391 2-s2.0-77955713928 20300113 10.1038/cdd.2010.25 PMC3130993

145 Görgün G Calabrese E Hideshima T Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood 2010 115 25 5202 5213 2-s2.0-77954686021 20382844 10.1182/blood-2009-12-259523 PMC2892955

146 Kuznetsov JN Leclerc GJ Leclerc GM Barredo JC AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia Molecular Cancer Therapeutics 2011 10 3 437 447 2-s2.0-79955755022 21262957 10.1158/1535-7163.MCT-10-0777 PMC3053424

147 Santidrián AF González-Gironès DM Iglesias-Serret D AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXAin chronic lymphocytic leukemia cells Blood 2010 116 16 3023 3032 2-s2.0-77958198168 20664053 10.1182/blood-2010-05-283960

148 Campàs C López JM Santidrián AF Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes Blood 2003 101 9 3674 3680 2-s2.0-0012889321 12522004 10.1182/blood-2002-07-2339

149 Stefanelli C Stanic’ I Bonavita F Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-Activated protein kinase Biochemical and Biophysical Research Communications 1998 243 3 821 826 2-s2.0-0032562094 9500985 10.1006/bbrc.1998.8154

150 Schlossmacher G Stevens A White A Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells Journal of Endocrinology 2011 211 17 25 21602312 10.1530/JOE-11-0135

151 Distelhorst CW Recent insights into the mechanism of glucocorticosteroid-induced apoptosis Cell Death and Differentiation 2002 9 1 6 19 2-s2.0-0036143203 11803370 10.1038/sj.cdd.4400969

152 Smith LK Cidlowski JA Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes Progress in Brain Research 2010 182 1 30 2-s2.0-77956622984 20541659 10.1016/S0079-6123(10)82001-1 PMC4770454

153 Schmidt S Rainer J Ploner C Presul E Riml S Kofler R Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance Cell Death and Differentiation 2004 11 1 S45 S55 2-s2.0-4344700576 15243581 10.1038/sj.cdd.4401456

154 Kumar R Thompson EB Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions Molecular Endocrinology 2003 17 1 1 10 2-s2.0-0037245786 12511601 10.1210/me.2002-0258

155 Turner JD Alt SR Cao L Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more Biochemical Pharmacology 2010 80 12 1860 1868 2-s2.0-78049433704 20599772 10.1016/j.bcp.2010.06.037

156 Schaaf MJM Cidlowski JA Molecular mechanisms of glucocorticoid action and resistance Journal of Steroid Biochemistry and Molecular Biology 2002 83 1–5 37 48 2-s2.0-0037643416 12650700 10.1016/s0960-0760(02)00263-7

157 de Lange P Segeren CM Koper JW Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells Cancer Research 2001 61 10 3937 3941 2-s2.0-0035872433 11358809

158 Zhou J Cidlowski JA The human glucocorticoid receptor: one gene, multiple proteins and diverse responses Steroids 2005 70 5–7 407 417 2-s2.0-18144399332 15862824 10.1016/j.steroids.2005.02.006

159 Lauten M Fernandez-Munoz I Gerdes K Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia Pediatric Blood and Cancer 2009 52 4 459 463 2-s2.0-62449320537 19061214 10.1002/pbc.21867

160 Lu NZ Cidlowski JA Glucocorticoid receptor isoforms generate transcription specificity Trends in Cell Biology 2006 16 6 301 307 2-s2.0-33745090483 16697199 10.1016/j.tcb.2006.04.005

161 Duma D Jewell CM Cidlowski JA Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification Journal of Steroid Biochemistry and Molecular Biology 2006 102 1–5 11 21 2-s2.0-33751000477 17070034 10.1016/j.jsbmb.2006.09.009

162 Vandevyver S Dejager L Libert C On the trail of the glucocorticoid receptor: into the nucleus and back Traffic 2012 13 364 374 21951602 10.1111/j.1600-0854.2011.01288.x

163 Fitzsimons CP Ahmed S Wittevrongel CFW The microtubule-associated protein doublecortin-like regulates the transport of the glucocorticoid receptor in neuronal progenitor cells Molecular Endocrinology 2008 22 2 248 262 2-s2.0-38749091280 17975023 10.1210/me.2007-0233 PMC5419639

164 Daghestani HN Zhu G Johnston PA Shinde SN Brodsky JL Day BW Characterization of inhibitors of glucocorticoid receptor nuclear translocation: a model of cytoplasmic dynein-mediated cargo transport ASSAY and Drug Development Technologies 2012 10 46 60 21919741 10.1089/adt.2010.0367 PMC3277738

165 Nicolaides NC Galata Z Kino T Chrousos GP Charmandari E The human glucocorticoid receptor: molecular basis of biologic function Steroids 2010 75 1 1 12 2-s2.0-71849112377 19818358 10.1016/j.steroids.2009.09.002 PMC2813911

166 Cao L Leija SC Kumsta R Transcriptional control of the human glucocorticoid receptor: identification and analysis of alternative promoter regions Human Genetics 2011 129 5 533 543 2-s2.0-79955563785 21234764 10.1007/s00439-011-0949-1

167 Pedersen KB Vedeckis WV Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines Biochemistry 2003 42 37 10978 10990 2-s2.0-0141431041 12974633 10.1021/bi034651u

168 Geng CD Schwartz JR Vedeckis WV A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters Molecular Endocrinology 2008 22 12 2624 2642 2-s2.0-56749169163 18945813 10.1210/me.2008-0157 PMC2626199

169 Geng CD Vedeckis WV A new, lineage specific, autoup-regulation mechanism for human glucocorticoid receptor gene expression in 697 pre-b-acute lymphoblastic leukemia cells Molecular Endocrinology 2011 25 1 44 57 2-s2.0-78650861866 21084380 10.1210/me.2010-0249 PMC3033051

170 Tissing WJE Meijerink JPP Brinkhof B Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL Blood 2006 108 3 1045 1049 2-s2.0-33746617271 16574952 10.1182/blood-2006-01-0261

171 Greenstein S Ghias K Krett NL Rosen ST Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies Clinical Cancer Research 2002 8 6 1681 1694 2-s2.0-0036278515 12060604

172 Moalli PA Rosen ST Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies Leukemia and Lymphoma 1994 15 5-6 363 374 2-s2.0-0028067889 7873993 10.3109/10428199409049738

173 Sánchez-Vega B Gandhi V Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1) British Journal of Haematology 2009 144 6 856 864 2-s2.0-60749089432 19133980 10.1111/j.1365-2141.2008.07549.x PMC4303606

174 Sharma S Liechtenstein A Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors Blood 2008 112 4 1338 1345 2-s2.0-51649094129 18515658 10.1182/blood-2007-11-124156 PMC2515111

175 Geley S Hartmann BL Hala M Strasser-Wozak EMC Kapelari K Kofler R Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression Cancer Research 1996 56 21 5033 5038 2-s2.0-0029855029 8895760

176 Ramdas J Liu W Harmon JM Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells Cancer Research 1999 59 6 1378 1385 2-s2.0-0033559204 10096574

177 Schwartz JR Sarvaiya PJ Vedeckis WV Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia Molecular and Cellular Endocrinology 2010 320 1-2 76 86 2-s2.0-77949653920 20170710 10.1016/j.mce.2010.02.014 PMC2844487

178 Gruber G Carlet M Türtscher E Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis Leukemia 2009 23 4 820 823 2-s2.0-64849102392 19151768 10.1038/leu.2008.360

179 Zilberman Y Zafrir E Ovadia H Yefenof E Guy R Sionov RV The glucocorticoid receptor mediates the thymic epithelial cell-induced apoptosis of CD4 + 8 + thymic lymphoma cells Cellular Immunology 2004 227 1 12 23 2-s2.0-1642305885 15051511 10.1016/j.cellimm.2004.01.005

180 Moalli PA Pillay S Weiner D Leikin R Rosen ST A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA Blood 1992 79 1 213 222 2-s2.0-0026502886 1728309

181 Gomi M Moriwaki K Katagiri S Kurata Y Thompson EB Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA Cancer Research 1990 50 6 1873 1878 2-s2.0-0025307589 2106390

182 Bachmann PS Gorman R MacKenzie KL Lutze-Mann L Lock RB Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor Blood 2005 105 6 2519 2526 2-s2.0-15244341393 15572593 10.1182/blood-2004-05-2023

183 Bachmann PS Gorman R Papa RA Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia Cancer Research 2007 67 9 4482 4490 2-s2.0-34249290768 17483364 10.1158/0008-5472.CAN-06-4244

184 Haarman EG Kaspers GJL Pieters R Rottier MMA Veerman AJP Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia Leukemia 2004 18 3 530 537 2-s2.0-1542503874 14724649 10.1038/sj.leu.2403225

185 Beesley AH Weller RE Senanayake S Welch M Kees UR Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines Leukemia Research 2009 33 2 321 325 2-s2.0-56949105269 18789525 10.1016/j.leukres.2008.08.007

186 Labuda M Gahier A Gagné V Moghrabi A Sinnett D Krajinovic M Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL) Leukemia Research 2010 34 4 492 497 2-s2.0-76749097560 19758697 10.1016/j.leukres.2009.08.007

187 Cuzzoni E De Iudicibus S Bartoli F Ventura A Decorti G Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone British Journal of Clinical Pharmacology 2012 73 651 655 22008062 10.1111/j.1365-2125.2011.04130.x PMC3376441

188 Burnstein KL Jewell CM Cidlowski JA Human glucocorticoid receptor cDNA contains sequences sufficient for receptor down-regulation The Journal of Biological Chemistry 1990 265 13 7284 7291 2-s2.0-0025308211 1692020

189 Burnstein KL Jewell CM Sar M Cidlowski JA Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms Molecular Endocrinology 1994 8 12 1764 1773 2-s2.0-0028607388 7708063 10.1210/mend.8.12.7708063

190 Davies L Karthikeyan N Lynch JT Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function Molecular Endocrinology 2008 22 6 1331 1344 2-s2.0-44649085082 18337589 10.1210/me.2007-0360 PMC5419542

191 Faus H Haendler B Post-translational modifications ofsteroid receptors Biomedicine and Pharmacotherapy 2006 60 9 520 528 2-s2.0-33750316364 16949786 10.1016/j.biopha.2006.07.082

192 Wallace AD Cidlowski JA Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids The Journal of Biological Chemistry 2001 276 46 42714 42721 2-s2.0-0035900780 11555652 10.1074/jbc.M106033200

193 Itoh M Adachi M Yasui H Takekawa M Tanaka H Imai K Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation Molecular Endocrinology 2002 16 10 2382 2392 2-s2.0-0036794281 12351702 10.1210/me.2002-0144

194 Chen W Dang T Blind RD Glucocorticoid receptor phosphorylation differentially affects target gene expression Molecular Endocrinology 2008 22 8 1754 1766 2-s2.0-48249157970 18483179 10.1210/me.2007-0219 PMC2725771

195 Miller AL Webb MS Copik AJ p38 mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211 Molecular Endocrinology 2005 19 6 1569 1583 2-s2.0-22344458207 15817653 10.1210/me.2004-0528

196 Hsu S Qi M DeFranco DB Cell cycle regulation of glucocorticoid receptor function EMBO Journal 1992 11 9 3457 3468 2-s2.0-0026658220 1505524 10.1002/j.1460-2075.1992.tb05425.x PMC556881

197 Bodwell JE Webster JC Jewell CM Cidlowski JA Hu JM Munck A Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence Journal of Steroid Biochemistry and Molecular Biology 1998 65 1–6 91 99 2-s2.0-0032053218 9699861 10.1016/s0960-0760(97)00185-4

198 Li MD Ruan HB Singh JP O-GlcNAc transferase is involved in glucocorticoid receptor-mediated transrepression The Journal of Biological Chemistry 2012 287 12904 12912 22371499 10.1074/jbc.M111.303792 PMC3339970

199 Webb MS Miller AL Johnson BH Gene networks in glucocorticoid-evoked apoptosis of leukemic cells Journal of Steroid Biochemistry and Molecular Biology 2003 85 2–5 183 193 2-s2.0-0042978652 12943703 10.1016/s0960-0760(03)00194-8

200 Medh RD Webb MS Miller AL Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis Genomics 2003 81 6 543 555 2-s2.0-0038362418 12782123 10.1016/s0888-7543(03)00045-4 PMC2777808

201 Schmidt S Rainer J Riml S Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia Blood 2006 107 5 2061 2069 2-s2.0-33644542448 16293608 10.1182/blood-2005-07-2853

202 Thompson EB Johnson BH Regulation of a distinctive set of genes in glucocorticoid-evoked apoptosis in CEM human lymphoid cells Recent Progress in Hormone Research 2003 58 175 197 2-s2.0-0041807673 12795419 10.1210/rp.58.1.175

203 Rainer J Lelong J Bindreither D Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia Molecular Endocrinology 2012 26 178 193 22074950 10.1210/me.2011-1213 PMC5417158

204 Chen DW Saha V Liu JZ Schwartz JM Krstic-Demonacos M Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia Oncogene . In press 10.1038/onc.2012.321 22869147

205 Bouillet P Metcalf D Huang DCS Pro-apoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity Science 1999 286 5445 1735 1738 2-s2.0-0033607506 10576740 10.1126/science.286.5445.1735

206 Molitoris JK McColl KS Distelhorst CW Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17 ∼ 92 contributes to the induction of Bim and initiation of apoptosis Molecular Endocrinology 2011 25 409 420 21239610 10.1210/me.2010-0402 PMC3045743

207 Abrams MT Robertson NM Yoon K Wickstrom E Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA The Journal of Biological Chemistry 2004 279 53 55809 55817 2-s2.0-11244305855 15509554 10.1074/jbc.M411767200

208 Wang Z Malone MH He H McColl KS Distelhorst CW Microarray analysis uncovers the induction of the pro-apoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis The Journal of Biological Chemistry 2003 278 26 23861 23867 2-s2.0-0037592259 12676946 10.1074/jbc.M301843200

209 Sionov RV Kfir S Zafrir E Cohen O Zilberman Y Yefenof E Glucocorticoid-induced apoptosis revisited: a novel role for glucocorticoid receptor translocation to the mitochondria Cell Cycle 2006 5 10 1017 1026 2-s2.0-33646868555 16687934 10.4161/cc.5.10.2738

210 O’Reilly LA Cullen L Visvader J The pro-apoptotic BH3-only protein Bim is expressed in hematopoietic, epithelial, neuronal, and germ cells American Journal of Pathology 2000 157 2 449 461 2-s2.0-0033883377 10934149 10.1016/S0002-9440(10)64557-9 PMC1850143

211 Zhao YN Guo X Ma ZG Gu L Ge J Li Q Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells Medical Oncology 2011 28 4 1609 1617 2-s2.0-77955211910 20697841 10.1007/s12032-010-9641-x

212 Bhojwani D Kang H Menezes RX Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: a Children’s Oncology Group Study on Behalf of the Dutch Childhood Oncology Group and the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia Journal of Clinical Oncology 2008 26 27 4376 4384 2-s2.0-52449106497 18802149 10.1200/JCO.2007.14.4519 PMC2736991

213 Tagawa H Karnan S Suzuki R Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the pro-apoptotic gene BIM Oncogene 2005 24 8 1348 1358 2-s2.0-14844285335 15608680 10.1038/sj.onc.1208300

214 Mestre-Escorihuela C Rubio-Moscardo F Richter JA Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas Blood 2007 109 1 271 280 2-s2.0-33846010700 16960149 10.1182/blood-2006-06-026500

215 Happo L Strasser A Cory S BH3-only proteins in apoptosis at a glance Journal of Cell Science 2012 125 1081 1087 22492984 10.1242/jcs.090514 PMC3324577

216 Chipuk JE Moldoveanu T Llambi F Parsons MJ Green DR The BCL-2 family reunion Molecular Cell 2010 37 3 299 310 2-s2.0-75949105922 20159550 10.1016/j.molcel.2010.01.025 PMC3222298

217 Willis SN Fletcher JI Kaufmann T Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak Science 2007 315 5813 856 859 2-s2.0-33846964621 17289999 10.1126/science.1133289

218 Gillings AS Balmanno K Wiggins CM Johnson M Cook SJ Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics FEBS Journal 2009 276 21 6050 6062 2-s2.0-70350004886 19788418 10.1111/j.1742-4658.2009.07329.x

219 Melarangi T Zhuang J Lin K Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak Cell Death and Disease 2012 3 e372 10.1038/cddis.2012.102 PMC3434667 22898870

220 Erlacher M Michalak EM Kelly PN BH3-only proteins Puma and Bim are rate-limiting for γ -radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo Blood 2005 106 13 4131 4138 2-s2.0-28844472952 16118324 10.1182/blood-2005-04-1595 PMC1895232

221 Labi V Erlacher M Kiessling S Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates γ irradiation—induced thymic lymphoma development Journal of Experimental Medicine 2008 205 3 641 655 2-s2.0-41149127750 18299399 10.1084/jem.20071658 PMC2275386

222 Rathmell JC Lindsten T Zong WX Cinalli RM Thompson CB Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis Nature Immunology 2002 3 10 932 939 2-s2.0-0036794390 12244308 10.1038/ni834

223 Wang Z Rong YP Malone MH Davis MC Zhong F Distelhorst CW Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis Oncogene 2006 25 13 1903 1913 2-s2.0-33645284675 16301999 10.1038/sj.onc.1209218

224 Ploner C Rainer J Lobenwein S Geley S Kofler R Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells Apoptosis 2009 14 6 821 828 2-s2.0-67349150662 19421859 10.1007/s10495-009-0355-5

225 Mansha M Wasim M Kofler A Ploner C Expression and glucocorticoid-regulation of, “Bam”, a novel BH3-only transcript in acute lymphoblastic leukemia Molecular Biology Reports 2012 39 6007 6013 22237863 10.1007/s11033-011-1414-x

226 Lu J Quearry B Harada H p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells FEBS Letters 2006 580 14 3539 3544 2-s2.0-33746391136 16730715 10.1016/j.febslet.2006.05.031

227 Dijkers PF Medema RH Lammers JWJ Koenderman L Coffer PJ Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1 Current Biology 2000 10 19 1201 1204 2-s2.0-0034609737 11050388 10.1016/s0960-9822(00)00728-4

228 Gilley J Coffer PJ Ham J FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons Journal of Cell Biology 2003 162 4 613 622 2-s2.0-0042477712 12913110 10.1083/jcb.200303026 PMC2173804

229 Essafi A Fernández de Mattos S Hassen YAM Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells Oncogene 2005 24 14 2317 2329 2-s2.0-17444405985 15688014 10.1038/sj.onc.1208421

230 Wildey GM Howe PH Runx1 is a co-activator with FOXO3 to mediate transforming growth factor β (TGF β )-induced Bim transcription in hepatic cells The Journal of Biological Chemistry 2009 284 30 20227 20239 2-s2.0-67749127709 19494111 10.1074/jbc.M109.027201 PMC2740449

231 Lützner N Kalbacher H Krones-Herzig A Rosl F FOXO3 is a glucocorticoid receptor target and regulates lkb1 and its own expression based on cellular amp levels via a positive autoregulatory loop PLoS ONE 2012 7 e42166 10.1371/journal.pone.0042166 PMC3407083 22848740

232 Tzivion G Dobson M Ramakrishnan G FoxO transcription factors; Regulation by AKT and 14-3-3 proteins Biochimica et Biophysica Acta 2011 1813 11 1938 1945 2-s2.0-79960173362 21708191 10.1016/j.bbamcr.2011.06.002

233 Zhang X Tang N Hadden TJ Rishi AK Akt, FoxO and regulation of apoptosis Biochimica et Biophysica Acta 2011 1813 11 1938 1945 2-s2.0-79953645824 21440011 10.1016/j.bbamcr.2011.03.010

234 Ho KK McGuire VA Koo CY Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin The Journal of Biological Chemistry 2012 287 1545 1555 22128155 10.1074/jbc.M111.284224 PMC3256863

235 Cai B Xia Z p38 MAP kinase mediates arsenite-induced apoptosis through FOXO3a activation and induction of Bim transcription Apoptosis 2008 13 6 803 810 2-s2.0-44149119739 18465250 10.1007/s10495-008-0218-5 PMC2442769

236 Yang JY Zong CS Xia W ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation Nature Cell Biology 2008 10 2 138 148 2-s2.0-38849139580 18204439 10.1038/ncb1676 PMC2376808

237 Ley R Balmanno K Hadfield K Weston C Cook SJ Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim The Journal of Biological Chemistry 2003 278 21 18811 18816 2-s2.0-0038482050 12646560 10.1074/jbc.M301010200

238 Dehan E Bassermann F Guardavaccaro D β TrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis Molecular Cell 2009 33 1 109 116 2-s2.0-58149312710 19150432 10.1016/j.molcel.2008.12.020 PMC2655121

239 Ewings KE Hadfield-Moorhouse K Wiggins CM ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL EMBO Journal 2007 26 12 2856 2867 2-s2.0-34250892541 17525735 10.1038/sj.emboj.7601723 PMC1894764

240 Lei K Davis RJ JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2432 2437 2-s2.0-0037418238 12591950 10.1073/pnas.0438011100 PMC151358

241 Putcha GV Le S Frank S JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis Neuron 2003 38 6 899 914 2-s2.0-0037860975 12818176 10.1016/s0896-6273(03)00355-6

242 Engelbrecht Y De Wet H Horsch K Langeveldt CR Hough FS Hulley PA Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines Endocrinology 2003 144 2 412 422 2-s2.0-0037320305 12538600 10.1210/en.2002-220769 PMC2820733

243 Rambal AA Panaguiton ZLG Kramer L Grant S Harada H MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM Leukemia 2009 23 10 1744 1754 2-s2.0-70350105769 19404317 10.1038/leu.2009.80 PMC2761998

244 Zhou F Thompson EB Role of c-jun induction in the glucocorticoid-evoked apoptotic pathway in human leukemic lymphoblasts Molecular Endocrinology 1996 10 3 306 316 2-s2.0-0029881514 8833659 10.1210/mend.10.3.8833659

245 Heidari N Miller AV Hicks MA Marking CB Harada H Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells Cell Death and Disease 2012 3 e349 10.1038/cddis.2012.89 PMC3406588 22825467

246 Ventura A Young AG Winslow MM Targeted deletion reveals essential and overlapping functions of the miR-17 ∼ 92 family of miRNA clusters Cell 2008 132 5 875 886 2-s2.0-39749143354 18329372 10.1016/j.cell.2008.02.019 PMC2323338

247 Xiao C Srinivasan L Calado DP Lymphoproliferative disease and autoimmunity in mice with increased miR-17 ∼ 92 expression in lymphocytes Nature Immunology 2008 9 4 405 414 2-s2.0-39749163245 18327259 10.1038/ni1575 PMC2533767

248 Mu P Han YC Betel D Genetic dissection of the miR-17 ∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas Genes & Development 2009 23 2806 2811 20008931 10.1101/gad.1872909 PMC2800095

249 Olive V Jiang I He L miR-17 ∼ 92, a cluster of miRNAs in the midst of the cancer network International Journal of Biochemistry and Cell Biology 2010 42 8 1348 1354 2-s2.0-77954382780 20227518 10.1016/j.biocel.2010.03.004 PMC3681296

250 van Haaften G Agami R Tumorigenicity of the miR-17 ∼ 92 cluster distilled Genes and Development 2010 24 1 1 4 2-s2.0-73549124785 20047995 10.1101/gad.1887110 PMC2802185

251 Mi S Li Z Chen P Aberrant overexpression and function of the miR-17 ∼ 92 cluster in MLL-rearranged acute leukemia Proceedings of the National Academy of Sciences of the United States of America 2010 107 8 3710 3715 2-s2.0-77649241350 20133587 10.1073/pnas.0914900107 PMC2840429

252 Lee SK Calin GA Non-coding RNAs and cancer: new paradigms in oncology Discovery Medicine 2011 11 58 245 254 2-s2.0-79960127278 21447283

253 Mavrakis KJ Van Der Meulen J Wolfe AL A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia Nature Genetics 2011 43 8 p. 815 2-s2.0-79960901824 10.1038/ng.858 PMC4121855 21642990

254 Wu WKK Lee CW Cho CH MicroRNA dysregulation in gastric cancer: a new player enters the game Oncogene 2010 29 43 5761 5771 2-s2.0-78049346482 20802530 10.1038/onc.2010.352

255 O’Donnell KA Wentzel EA Zeller KI Dang CV Mendell JT c-Myc-regulated microRNAs modulate E2F1 expression Nature 2005 435 7043 839 843 2-s2.0-20444479428 15944709 10.1038/nature03677

256 Li Y Tan W Neo TWL Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma Cancer Science 2009 100 7 1234 1242 2-s2.0-67449102314 19486339 10.1111/j.1349-7006.2009.01164.x

257 Haftmann C Stittrich AB Sgouroudis E Lymphocyte signaling: regulation of FoxO transcription factors by microRNAs Annals of the New York Academy of Sciences 2012 1247 46 55 22236474 10.1111/j.1749-6632.2011.06264.x

258 Guttilla IK White BA Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells The Journal of Biological Chemistry 2009 284 35 23204 23216 2-s2.0-69949119988 19574223 10.1074/jbc.M109.031427 PMC2749094

259 Segura MF Hanniford D Menendez S Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor Proceedings of the National Academy of Sciences of the United States of America 2009 106 6 1814 1819 2-s2.0-60549112361 19188590 10.1073/pnas.0808263106 PMC2634798

260 Stittrich AB Haftmann C Sgouroudis E The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes Nature Immunology 2010 11 11 1057 1062 2-s2.0-77958149675 20935646 10.1038/ni.1945

261 Yang A Ma J Wu M Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies Leukemia & Lymphoma 2012 53 12 2465 2473 22582938 10.3109/10428194.2012.693178

262 Elia L Contu R Quintavalle M Reciprocal regulation of microrna-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions Circulation 2009 120 23 2377 2385 2-s2.0-73449086958 19933931 10.1161/CIRCULATIONAHA.109.879429 PMC2825656

263 Yamamoto M Kondo E Takeuchi M miR-155, a modulator of FOXO3a protein expression, is underexpressed and cannot be upregulated by stimulation of HOZOT, a line of multifunctional Treg PLoS ONE 2011 6 2 2-s2.0-79751488378 e16841 10.1371/journal.pone.0016841 PMC3033424 21304824

264 Kong W He L Coppola M MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer The Journal of Biological Chemistry 2010 285 23 17869 17879 2-s2.0-77952944048 20371610 10.1074/jbc.M110.101055 PMC2878550

265 O’Connell RM Rao DS Chaudhuri AA Baltimore D Physiological and pathological roles for microRNAs in the immune system Nature Reviews Immunology 2010 10 2 111 122 2-s2.0-75649139134 10.1038/nri2708 20098459

266 Thai TH Calado DP Casola S Regulation of the germinal center response by MicroRNA-155 Science 2007 316 5824 604 608 2-s2.0-34247594818 17463289 10.1126/science.1141229

267 Dai R Zhang Y Khan D Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus PLoS ONE 2010 5 12 p. e14302 2-s2.0-79960143279 10.1371/journal.pone.0014302 PMC3000827 21170274

268 Wang K Li PF Foxo3a regulates apoptosis by negatively targeting miR-21 The Journal of Biological Chemistry 2010 285 22 16958 16966 2-s2.0-77952760958 20371612 10.1074/jbc.M109.093005 PMC2878079

269 Meng F Henson R Wehbe-Janek H Ghoshal K Jacob ST Patel T MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer Gastroenterology 2007 133 2 647 658 2-s2.0-34547524771 17681183 10.1053/j.gastro.2007.05.022 PMC4285346

270 Iliopoulos D Jaeger SA Hirsch HA Bulyk ML Struhl K STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer Molecular Cell 2010 39 4 493 506 2-s2.0-77955992756 20797623 10.1016/j.molcel.2010.07.023 PMC2929389

271 Ma J Xie Y Shi Y Qin W Zhao B Jin Y Glucocorticoid-induced apoptosis requires FOXO3A activity Biochemical and Biophysical Research Communications 2008 377 3 894 898 2-s2.0-56049109272 18957280 10.1016/j.bbrc.2008.10.097

272 Sionov RV Cohen O Kfir S Zilberman Y Yefenof E Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis Journal of Experimental Medicine 2006 203 1 189 201 2-s2.0-31344468014 16390935 10.1084/jem.20050433 PMC2118093

273 Talabér G Boldizsár F Bartis D Mitochondrial translocation of the glucocorticoid receptor in double-positive thymocytes correlates with their sensitivity to glucocorticoid-induced apoptosis International Immunology 2009 21 11 1269 1276 2-s2.0-71049190866 19737783 10.1093/intimm/dxp093

274 Du J Wang Y Hunter R Dynamic regulation of mitochondrial function by glucocorticoids Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3543 3548 2-s2.0-62549154977 19202080 10.1073/pnas.0812671106 PMC2637276

275 Tome ME Lee K Jaramillo MC Briehl MM Mitochondria are the primary source of the H 2 O 2 signal for glucocorticoid-induced apoptosis of lymphoma cells Experimental and Therapeutic Medicine 2012 4 237 242 22844350 10.3892/etm.2012.595 PMC3404723

276 Tome ME Jaramillo MC Briehl MM Hydrogen peroxide signaling is required for glucocorticoid-induced apoptosis in lymphoma cells Free Radical Biology and Medicine 2011 51 2048 2059 21964507 10.1016/j.freeradbiomed.2011.09.002 PMC3208737

277 Psarra AMG Hermann S Panayotou G Spyrou G Interaction of mitochondrial thioredoxin with glucocorticoid receptor and NF- κ B modulates glucocorticoid receptor and NF- κ B signalling in HEK-293 cells Biochemical Journal 2009 422 3 521 531 2-s2.0-70249089081 19570036 10.1042/BJ20090107

278 Psarra AMG Sekeris CE Glucocorticoids induce mitochondrial gene transcription in HepG2 cells. Role of the mitochondrial glucocorticoid receptor Biochimica et Biophysica Acta 2011 1813 10 1814 1821 2-s2.0-79958256305 21664385 10.1016/j.bbamcr.2011.05.014

279 Eberhart K Rainer J Bindreither D Glucocorticoid-induced alterations in mitochondrial membrane properties and respiration in childhood acute lymphoblastic leukemia Biochimica et Biophysica Acta 2011 1807 6 719 725 2-s2.0-79955615949 21237131 10.1016/j.bbabio.2010.12.010

280 Fujita C Ichikawa F Teratani T Direct effects of corticosterone on ATP production by mitochondria from immortalized hypothalamic GT1-7 neurons Journal of Steroid Biochemistry and Molecular Biology 2009 117 1–3 50 55 2-s2.0-70249134532 19631743 10.1016/j.jsbmb.2009.07.002

281 Beck IME Berghe WV Vermeulen L Yamamoto KR Haegeman G De Bosscher K Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases Endocrine Reviews 2009 30 7 830 882 2-s2.0-73249115366 19890091 10.1210/er.2009-0013 PMC2818158

282 Nuutinen U Ropponen A Suoranta S Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3 Leukemia Research 2009 33 12 1714 1717 2-s2.0-70349167016 19559478 10.1016/j.leukres.2009.06.004

283 Nuutinen U Postila V Mättö M Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line Experimental Cell Research 2006 312 3 322 330 2-s2.0-29144497967 16309671 10.1016/j.yexcr.2005.10.023

284 Rubio-Patiño C Palmeri CM Perez-Perarnau A Glycogen synthase kinase-3beta is involved in ligand-dependent activation of transcription and cellular localization of the glucocorticoid receptor Molecular Endocrinology 2012 26 1508 1520 22771494 10.1210/me.2011-1366 PMC5416974

285 Wang FS Ko JY Weng LH Yeh DW Ke HJ Wu SL Inhibition of glycogen synthase kinase-3 β attenuates glucocorticoid-induced bone loss Life Sciences 2009 85 19-20 685 692 2-s2.0-70350279569 19782693 10.1016/j.lfs.2009.09.009

286 Bornhauser BC Bonapace L Lindholm D Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway Blood 2007 110 6 2084 2091 2-s2.0-34548850030 17537996 10.1182/blood-2006-12-060970

287 Wei G Twomey D Lamb J Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance Cancer Cell 2006 10 4 331 342 2-s2.0-33749443714 17010674 10.1016/j.ccr.2006.09.006

288 Morishita N Tsukahara H Chayama K Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia Pediatric Blood & Cancer 2012 59 83 89 22183914 10.1002/pbc.24034

289 Hay N Sonenberg N Upstream and downstream of mTOR Genes and Development 2004 18 16 1926 1945 2-s2.0-4043171462 15314020 10.1101/gad.1212704

290 Lee K Nam KT Cho SH Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia Journal of Experimental Medicine 2012 209 713 728 22473959 10.1084/jem.20111470 PMC3328370

291 Martelli AM Evangelisti C Chiarini F McCubrey JA The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients Oncotarget 2010 1 2 89 103 2-s2.0-77957819681 20671809 10.18632/oncotarget.114 PMC2911128

292 Carnero A The PKB/AKT pathway in cancer Current Pharmaceutical Design 2010 16 1 34 44 2-s2.0-77949452524 20214616 10.2174/138161210789941865

293 Hafsi S Pezzino FM Candido S Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance International Journal of Oncology 2012 40 639 644 22200790 10.3892/ijo.2011.1312

294 Guertin DA Sabatini DM Defining the role of mTOR in cancer Cancer Cell 2007 12 1 9 22 2-s2.0-34347220473 17613433 10.1016/j.ccr.2007.05.008

295 Sarbassov DD Guertin DA Ali SM Sabatini DM Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005 307 5712 1098 1101 2-s2.0-13844312400 15718470 10.1126/science.1106148

296 Wang Z Malone MH Thomenius MJ Zhong F Xu F Distelhorst CW Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals The Journal of Biological Chemistry 2003 278 29 27053 27058 2-s2.0-0038373385 12736248 10.1074/jbc.M303723200

297 Shinjyo T Kuribara R Inukai T Downregulation of Bim, a pro-apoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors Molecular and Cellular Biology 2001 21 3 854 864 2-s2.0-0035135349 11154272 10.1128/MCB.21.3.854-864.2001 PMC86676

298 Argyriou P Economopoulou P Papageorgiou S The role of mTOR inhibitors for the treatment of B-Cell lymphomas Advances in Hematology 2012 2012 13 pages 435342 10.1155/2012/435342 PMC3124126 21822434

299 Salmena L Carracedo A Pandolfi PP Tenets of PTEN tumor suppression Cell 2008 133 3 403 414 2-s2.0-43049128529 18455982 10.1016/j.cell.2008.04.013

300 Jotta PY Ganazza MA Silva A Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia Leukemia 2010 24 1 239 242 2-s2.0-74249086850 19829307 10.1038/leu.2009.209

301 Fata JE Debnath S Jenkins EC Jr Fournier MV Nongenomic mechanisms of PTEN regulation International Journal of Cell Biology 2012 2012 10 pages 379685 10.1155/2012/379685 PMC3320059 22536248

302 García JM Silva J Peña C Promoter methylation of the PTEN gene is a common molecular change in breast cancer Genes Chromosomes and Cancer 2004 41 2 117 124 2-s2.0-4143138570 15287024 10.1002/gcc.20062

303 Kang YH Hye SL Woo HK Promoter methylation and silencing of PTEN in gastric carcinoma Laboratory Investigation 2002 82 3 285 291 2-s2.0-0036127525 11896207 10.1038/labinvest.3780422

304 Brauer PM Tyner AL RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK Cell Cycle 2009 8 17 2728 2732 2-s2.0-69749083045 19652529 10.4161/cc.8.17.9389 PMC3005195

305 Torres J Pulido R The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation The Journal of Biological Chemistry 2001 276 2 993 998 2-s2.0-0035847102 11035045 10.1074/jbc.M009134200

306 Maccario H Perera NM Davidson L Downes CP Leslie NR PTEN is destabilized by phosphorylation on Thr366 Biochemical Journal 2007 405 3 439 444 2-s2.0-34547490078 17444818 10.1042/BJ20061837 PMC2267318

307 Wang X Trotman LC Koppie T NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN Cell 2007 128 1 129 139 2-s2.0-33845991111 17218260 10.1016/j.cell.2006.11.039 PMC1828909

308 Guo H Qiao G Ying H E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity Cell Reports 2012 1 472 482 22763434 10.1016/j.celrep.2012.04.008 PMC3387815

309 Van Themsche C Leblanc V Parent S Asselin E X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization The Journal of Biological Chemistry 2009 284 31 20462 20466 2-s2.0-68949121012 19473982 10.1074/jbc.C109.009522 PMC2742810

310 Redondo-Muñoz J Escobar-Díaz E Del Cerro MH Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation Clinical Cancer Research 2010 16 17 4382 4391 2-s2.0-77956234118 20534739 10.1158/1078-0432.CCR-10-0072

311 Maddika S Kavela S Rani N WWP2 is an E3 ubiquitin ligase for PTEN Nature Cell Biology 2011 13 6 728 733 2-s2.0-79957926724 21532586 10.1038/ncb2240 PMC3926303

312 Ahmed SF Deb S Paul I The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation The Journal of Biological Chemistry 2012 287 15996 16006 22427670 10.1074/jbc.M111.321083 PMC3346122

313 Ni Z Tang J Cai Z A new pathway of glucocorticoid action for asthma treatment through the regulation of PTEN expression Respiratory Research 2011 12 p. 47 2-s2.0-79953848794 10.1186/1465-9921-12-47 PMC3096598 21489309

314 Poliseno L Salmena L Riccardi L Identification of the miR-106b ∼ 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation Science Signaling 2010 3 ra29 10.1126/scisignal.2000594 PMC2982149 20388916

315 Huse JT Brennan C Hambardzumyan D The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes and Development 2009 23 11 1327 1337 2-s2.0-66149173789 19487573 10.1101/gad.1777409 PMC2701585

316 Wang C Bian Z Wei D Zhang JG miR-29b regulates migration of human breast cancer cells Molecular and Cellular Biochemistry 2011 352 1-2 197 207 2-s2.0-79959250957 21359530 10.1007/s11010-011-0755-z

317 Jindra PT Bagley J Godwin JG Iacomini J Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten Journal of Immunology 2010 185 2 990 997 2-s2.0-77955508072 10.4049/jimmunol.1000793 PMC3004219 20548023

318 Yang H Kong W He L MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN Cancer Research 2008 68 5 p. 1609 2-s2.0-40449112145 10.1158/0008-5472.CAN-07-2488 18199536

319 Kato M Putta S Wang M TGF- β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN Nature Cell Biology 2009 11 7 881 889 2-s2.0-67650085171 19543271 10.1038/ncb1897 PMC2744130

320 Incoronato M Garofalo M Urso L miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the anti-apoptotic protein PED Cancer Research 2010 70 9 3638 3646 2-s2.0-77951716642 20388802 10.1158/0008-5472.CAN-09-3341

321 Garofalo M Di Leva G Romano G miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation Cancer Cell 2009 16 6 498 509 2-s2.0-70949104622 19962668 10.1016/j.ccr.2009.10.014 PMC2796583

322 Brunelle JK Letai A Control of mitochondrial apoptosis by the Bcl-2 family Journal of Cell Science 2009 122 4 437 441 2-s2.0-64849113485 19193868 10.1242/jcs.031682 PMC2714431

323 Krishna S Low ICC Pervaiz S Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2 Biochemical Journal 2011 435 3 545 551 2-s2.0-79954459921 21486225 10.1042/BJ20101996

324 Feng H Xiang H Mao YW Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes Oncogene 2004 23 44 7310 7321 2-s2.0-6044277953 15326476 10.1038/sj.onc.1208041

325 Vairo G Soos TJ Upton TM Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation Molecular and Cellular Biology 2000 20 13 4745 4753 2-s2.0-0034082459 10848600 10.1128/mcb.20.13.4745-4753.2000 PMC85901

326 Katayama N Mahmud N Nishi K Bcl-2 in cell-cycle regulation of hematopoietic cells by transforming growth factor- β 1 Leukemia and Lymphoma 2000 39 5-6 601 605 2-s2.0-0034487956 11342343 10.3109/10428190009113390

327 Janumyan Y Cui Q Yan L Sansam CG Valentin M Yang E G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by mirk, revealing a novel role of BAX and BAK in quiescence regulation The Journal of Biological Chemistry 2008 283 49 34108 34120 2-s2.0-57749107725 18818203 10.1074/jbc.M806294200 PMC2590681

328 Greider C Chattopadhyay A Parkhurst C Yang E BCL-xL and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases Oncogene 2002 21 51 7765 7775 2-s2.0-0037038682 12420213 10.1038/sj.onc.1205928

329 Wang HG Rapp UR Reed JC Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 1996 87 4 629 638 2-s2.0-0345498292 8929532 10.1016/s0092-8674(00)81383-5

330 Reed JC Double identity for proteins of the Bcl-2 family Nature 1997 387 6635 773 776 2-s2.0-0030979773 9194558 10.1038/42867

331 Batsi C Markopoulou S Kontargiris E Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27Kip1-dependent G1/S cell cycle arrest in conjunction with NF- κ B activation Biochemical Pharmacology 2009 78 1 33 44 2-s2.0-67349208974 19447221 10.1016/j.bcp.2009.03.017 PMC2782607

332 Sionov RV Kfir-Erenfeld S Spokoini R Yefenof E A role for bcl-2 in notch1-dependent transcription in thymic lymphoma cells Advances in Hematology 2012 2012 5 pages 435241 10.1155/2012/435241 PMC3272787 22319533

333 Wang Z Azmi AS Ahmad A TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of notch-1 signaling pathway Cancer Research 2009 69 7 2757 2765 2-s2.0-66149090396 19318573 10.1158/0008-5472.CAN-08-3060 PMC3798007

334 Cheng N van de Wetering CI Knudson CM p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma PLoS ONE 2008 3 4 2-s2.0-44849092993 e1911 10.1371/journal.pone.0001911 PMC2270898 18382684

335 Tucker CA Kapanen AI Chikh G Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- κ B, p53, bax, and p27 levels Molecular Cancer Therapeutics 2008 7 4 749 758 2-s2.0-42249098698 18375822 10.1158/1535-7163.MCT-07-0302

336 Janumyan YM Sansam CG Chattopadhyay A Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry EMBO Journal 2003 22 20 5459 5470 2-s2.0-0142073728 14532118 10.1093/emboj/cdg533 PMC213787

337 Hartmann BL Geley S Löffler M Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis Oncogene 1999 18 3 713 719 2-s2.0-0033590601 9989821 10.1038/sj.onc.1202339

338 Rogalińska M Kiliańska ZM Targeting Bcl-2 in CLL Current Medicinal Chemistry 2012 19 30 5109 5115 22856663 10.2174/092986712803530566

339 Tzifi F Economopoulou C Gourgiotis D Ardavanis A Papageorgiou S Scorilas A The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias Advances in Hematology 2012 2012 15 pages 524308 10.1155/2012/524308 PMC3173728 21941553

340 Ploner C Rainer J Niederegger H The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia Leukemia 2008 22 2 370 377 2-s2.0-39149095948 18046449 10.1038/sj.leu.2405039 PMC4950962

341 Menendez P Vargas A Bueno C Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation Leukemia 2004 18 3 491 498 2-s2.0-1542713470 14724650 10.1038/sj.leu.2403231

342 Tsujimoto Y Finger LR Yunis J Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation Science 1984 226 4678 1097 1099 2-s2.0-0021679848 6093263 10.1126/science.6093263

343 Tsujimoto Y Cossman J Jaffe E Croce CM Involvement of the bcl-2 gene in human follicular lymphoma Science 1985 228 4706 1440 1443 2-s2.0-0021821903 3874430 10.1126/science.3874430

344 Nambiar M Raghavan SC Mechanism of fragility at BCL2 gene minor breakpoint cluster region during t(14,18) chromosomal translocation Journal of Biological Chemistry 2012 287 8688 8701 22275374 10.1074/jbc.M111.307363 PMC3308786

345 Calin GA Dumitru CD Shimizu M Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proceedings of the National Academy of Sciences of the United States of America 2002 99 24 15524 15529 2-s2.0-18744396337 12434020 10.1073/pnas.242606799 PMC137750

346 Cimmino A Calin GA Fabbri M miR-15 and miR-16 induce apoptosis by targeting BCL2 Proceedings of the National Academy of Sciences of the United States of America 2005 102 39 13944 13949 2-s2.0-25444520537 16166262 10.1073/pnas.0506654102 PMC1236577

347 Hermeking H p53 enters the microRNA world Cancer Cell 2007 12 5 414 418 2-s2.0-35748961986 17996645 10.1016/j.ccr.2007.10.028

348 Li L Yuan L Luo J Gao J Guo J Xie X MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1 Clinical and Experimental Medicine . In press 10.1007/s10238-012-0186-5 22623155

349 Willimott S Wagner SD miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells The Journal of Biological Chemistry 2012 287 2608 2617 22139839 10.1074/jbc.M111.285718 PMC3268420

350 Gong J Zhang JP Li B MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R Oncogene . In press 10.1038/onc.2012.318 22824797

351 Zhao A Zeng Q Xie X MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression Journal of Genetics and Genomics 2012 39 29 35 22293115 10.1016/j.jgg.2011.12.003

352 Liu LH Li H Li JP miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3 Biochemical and Biophysical Research Communications 2011 416 31 38 22093834 10.1016/j.bbrc.2011.10.117

353 Zhou M Liu Z Zhao Y MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression The Journal of Biological Chemistry 2010 285 28 21496 21507 2-s2.0-77954378366 20460378 10.1074/jbc.M109.083337 PMC2898411

354 Zhang H Luo XQ Feng DD Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia Molecular Cancer 2011 10, article 108 10.1186/1476-4598-10-108 PMC3189170 21880154

355 Surdziel E Cabanski M Dallmann I Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways Blood 2011 117 16 4338 4348 2-s2.0-79955959210 21368288 10.1182/blood-2010-06-289058

356 Xia HF He TZ Liu CM MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf Cellular Physiology and Biochemistry 2009 23 4–6 347 358 2-s2.0-66749182257 19471102 10.1159/000218181

357 Bousquet M Harris MH Zhou B Lodish HF MicroRNA miR-125b causes leukemia Proceedings of the National Academy of Sciences of the United States of America 2010 107 50 21558 21563 2-s2.0-78650736233 21118985 10.1073/pnas.1016611107 PMC3003065

358 Zhu DX Zhu W Fang C miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes Carcinogenesis 2012 33 1294 1301 22610076 10.1093/carcin/bgs179

359 Li H Hui L Xu W miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2 Acta Biochimica et Biophysica Sinica 2012 44 269 277 22285729 10.1093/abbs/gmr128

360 Ouyang YB Lu Y Yue S Giffard RG miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes Mitochondrion 2012 12 213 219 21958558 10.1016/j.mito.2011.09.001 PMC3250561

361 Shimizu S Takehara T Hikita H The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma Journal of Hepatology 2010 52 5 698 704 2-s2.0-77951620660 20347499 10.1016/j.jhep.2009.12.024

362 Nakano H Miyazawa T Kinoshita K Yamada Y Yoshida T Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-XLin colorectal cancer cells International Journal of Cancer 2010 127 5 1072 1080 2-s2.0-77955492383 20039318 10.1002/ijc.25143

363 Guan H Zhang P Liu C Characterization and functional analysis of the human microRNA let-7a2 promoter in lung cancer A549 cell lines Molecular Biology Reports 2011 38 8 5327 5334 2-s2.0-79952065626 21365266 10.1007/s11033-011-0683-8

364 Holleman A Cheok MH Den Boer ML Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment The New England Journal of Medicine 2004 351 6 533 542 2-s2.0-3543054544 15295046 10.1056/NEJMoa033513

365 Stam RW Den Boer ML Schneider P Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia Blood 2010 115 5 1018 1025 2-s2.0-77649213702 19965632 10.1182/blood-2009-02-205963

366 Thomas LW Lam C Edwards SW Mcl-1; the molecular regulation of protein function FEBS Letters 2010 584 14 2981 2989 2-s2.0-77954175674 20540941 10.1016/j.febslet.2010.05.061

367 Taniai M Grambihler A Higuchi H Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells Cancer Research 2004 64 10 3517 3524 2-s2.0-2442663096 15150106 10.1158/0008-5472.CAN-03-2770

368 Opferman JT Green DR DUB-le trouble for cell survival Cancer Cell 2010 17 2 117 119 2-s2.0-76249089627 20159606 10.1016/j.ccr.2010.01.011

369 Ding Q He X Hsu JM Degradation of Mcl-1 by β -TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization Molecular and Cellular Biology 2007 27 11 4006 4017 2-s2.0-34347350211 17387146 10.1128/MCB.00620-06 PMC1900029

370 Maurer U Charvet C Wagman AS Dejardin E Green DR Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1 Molecular Cell 2006 21 6 749 760 2-s2.0-33644855216 16543145 10.1016/j.molcel.2006.02.009

371 Zhong Q Gao W Du F Wang X Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis Cell 2005 121 7 1085 1095 2-s2.0-21244472965 15989957 10.1016/j.cell.2005.06.009

372 Inuzuka H Fukushima H Shaik S Wei W Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction Oncotarget 2010 1 7 685 690 2-s2.0-79958010386 21317463 10.18632/oncotarget.202 PMC3248122

373 Schwickart M Huang X Lill JR Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival Nature 2010 463 7277 103 107 2-s2.0-73849083434 20023629 10.1038/nature08646

374 Agrawal P Chen YT Schilling B Gibson BW Hughes RE Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR) Journal of Biological Chemistry 2012 287 21164 21175 22544753 10.1074/jbc.M111.328021 PMC3375539

375 Czabotar PE Lee EF Van Delft MF Structural insights into the degradation of Mcl-1 induced by BH3 domains Proceedings of the National Academy of Sciences of the United States of America 2007 104 15 6217 6222 2-s2.0-34547098188 17389404 10.1073/pnas.0701297104 PMC1851040

376 Gomez-Bougie P Menoret E Juin P Dousset C Pellat-Deceunynck C Amiot M Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction Biochemical and Biophysical Research Communications 2011 413 460 464 21907705 10.1016/j.bbrc.2011.08.118

377 Mills JR Hippo Y Robert F mTORC1 promotes survival through translational control of Mcl-1 Proceedings of the National Academy of Sciences of the United States of America 2008 105 31 10853 10858 2-s2.0-49449108291 18664580 10.1073/pnas.0804821105 PMC2504845

378 Inoki K Ouyang H Zhu T TSC2 integrates wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth Cell 2006 126 5 955 968 2-s2.0-33748153690 16959574 10.1016/j.cell.2006.06.055

379 Willis SN Chen L Dewson G Pro-apoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins Genes and Development 2005 19 11 1294 1305 2-s2.0-22244464818 15901672 10.1101/gad.1304105 PMC1142553

380 Desjobert C Renalier MH Bergalet J MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression Blood 2011 117 24 6627 6637 2-s2.0-79959213619 21471522 10.1182/blood-2010-09-301994

381 Zhang YK Wang H Leng Y Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1 Biochemical and Biophysical Research Communications 2011 414 233 239 21951844 10.1016/j.bbrc.2011.09.063

382 Mott JL Kobayashi S Bronk SF Gores GJ mir-29 regulates Mcl-1 protein expression and apoptosis Oncogene 2007 26 42 6133 6140 2-s2.0-34548687035 17404574 10.1038/sj.onc.1210436 PMC2432524

383 Garzon R Heaphy CEA Havelange V MicroRNA 29b functions in acute myeloid leukemia Blood 2009 114 26 5331 5341 2-s2.0-73949118737 19850741 10.1182/blood-2009-03-211938 PMC2796138

384 Wang HJ Ruan HJ He XJ MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion European Journal of Cancer 2010 46 12 2295 2303 2-s2.0-77955717754 20712078 10.1016/j.ejca.2010.05.012

385 Visone R Rassenti LZ Veronese A Karyotype-specific microRNA signature in chronic lymphocytic leukemia Blood 2009 114 18 3872 3879 2-s2.0-70449713652 19717645 10.1182/blood-2009-06-229211 PMC2773482

386 Crawford M Batte K Yu L MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer Biochemical and Biophysical Research Communications 2009 388 3 483 489 2-s2.0-69549101926 19654003 10.1016/j.bbrc.2009.07.143 PMC2824514

387 Chen J Zhang X Lentz C miR-193b Regulates Mcl-1 in melanoma American Journal of Pathology 2011 179 2162 2168 21893020 10.1016/j.ajpath.2011.07.010 PMC3204027

388 Saito Y Suzuki H Tsugawa H Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells Oncogene 2009 28 30 2738 2744 2-s2.0-68149126345 19503096 10.1038/onc.2009.140

389 Spijkers-Hagelstein JA Schneider P Hulleman E Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia Leukemia 2012 26 1255 1265 22282267 10.1038/leu.2011.388

390 Minagawa N Kruglov EA Dranoff JA Robert ME Gores GJ Nathanson MH The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca 2+ signals The Journal of Biological Chemistry 2005 280 39 33637 33644 2-s2.0-25844497007 16027162 10.1074/jbc.M503210200

391 Bassik MC Scorrano L Oakes SA Pozzan T Korsmeyer SJ Phosphorylation of BCL-2 regulates ER Ca 2+ homeostasis and apoptosis EMBO Journal 2004 23 5 1207 1216 2-s2.0-1842472069 15010700 10.1038/sj.emboj.7600104 PMC380968

392 Thomenius MJ Distelhorst CW Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance Journal of Cell Science 2003 116 22 4493 4499 2-s2.0-0344897663 14576343 10.1242/jcs.00829

393 Giorgi C Baldassari F Bononi A Mitochondrial Ca 2+ and apoptosis Cell Calcium 2012 52 36 43 22480931 10.1016/j.ceca.2012.02.008 PMC3396846

394 Rong YP Aromolaran AS Bultynck G Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals Molecular Cell 2008 31 2 255 265 2-s2.0-47349089719 18657507 10.1016/j.molcel.2008.06.014 PMC3660092

395 Li C Wang X Vais H Thompson CB Foskett JK White C Apoptosis regulation by Bcl-xL modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating Proceedings of the National Academy of Sciences of the United States of America 2007 104 30 12565 12570 2-s2.0-34547617018 17636122 10.1073/pnas.0702489104 PMC1941509

396 Eckenrode EF Yang J Velmurugan GV Kevin Foskett J White C Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca 2+ signaling The Journal of Biological Chemistry 2010 285 18 13678 13684 2-s2.0-77951562760 20189983 10.1074/jbc.M109.096040 PMC2859530

397 Li C Fox CJ Master SR Bindokas VP Chodosh LA Thompson CB Bcl-XL affects Ca 2+ homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors Proceedings of the National Academy of Sciences of the United States of America 2002 99 15 9830 9835 2-s2.0-0037162528 12118121 10.1073/pnas.152571899 PMC125032

398 Jaramillo MC Frye JB Crapo JD Briehl MM Tome ME Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells Cancer Research 2009 69 13 5450 5457 2-s2.0-67650481198 19549914 10.1158/0008-5472.CAN-08-4031 PMC2757156

399 Tome ME Baker AF Powis G Payne CM Briehl MM Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth Cancer Research 2001 61 6 2766 2773 2-s2.0-0035866773 11289160

400 Tome ME Lutz NW Briehl MM Overexpression of catalase or Bcl-2 alters glucose and energy metabolism concomitant with dexamethasone resistance Biochimica et Biophysica Acta 2004 1693 1 57 72 2-s2.0-3242754314 15276325 10.1016/j.bbamcr.2004.05.004

401 Low IC Kang J Pervaiz S Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells Antioxidants & Redox Signaling 2011 15 2975 2987 21574773 10.1089/ars.2010.3851

402 Aster JC Blacklow SC Pear WS Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies Journal of Pathology 2011 223 2 262 273 2-s2.0-78649991073 20967796 10.1002/path.2789 PMC2996483

403 Malyukova A Dohda T Von Der Lehr N The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling Cancer Research 2007 67 5611 5616 17575125 10.1158/0008-5472.CAN-06-4381

404 Öberg C Li J Pauley A Wolf E Gurney M Lendahl U The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog The Journal of Biological Chemistry 2001 276 38 35847 35853 2-s2.0-0035929669 11461910 10.1074/jbc.M103992200

405 Ferrando A NOTCH mutations as prognostic markers in T-ALL Leukemia 2010 24 12 2003 2004 2-s2.0-78650333573 21157484 10.1038/leu.2010.237

406 Lai EC Protein degradation: four E3s for the Notch pathway Current Biology 2002 12 2 R74 R78 2-s2.0-0037154292 11818085 10.1016/s0960-9822(01)00679-0

407 Bray SJ Notch signalling: a simple pathway becomes complex Nature Reviews Molecular Cell Biology 2006 7 9 678 689 2-s2.0-33747623018 16921404 10.1038/nrm2009

408 Nie J McGill MA Dermer M Dho SE Wolting CD McGlade CJ LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation EMBO Journal 2002 21 1-2 93 102 2-s2.0-0037080811 11782429 10.1093/emboj/21.1.93 PMC125803

409 Itoh M Kim CH Palardy G Mind bomb is a ubiquitin ligase that is essential for efficient activation of notch signaling by delta Developmental Cell 2003 4 1 67 82 2-s2.0-0037238008 12530964 10.1016/s1534-5807(02)00409-4

410 Pavlopoulos E Pitsouli C Klueg KM Muskavitch MAT Moschonas NK Delidakis C Neuralized encodes a peripheral membrane protein involved in delta signaling and endocytosis Developmental Cell 2001 1 6 807 816 2-s2.0-0035653308 11740942 10.1016/s1534-5807(01)00093-4

411 Qiu L Joazeiro C Fang N Recognition and ubiquitination of Notch by Itch, a Hect-type E3 ubiquitin ligase The Journal of Biological Chemistry 2000 275 46 35734 35737 2-s2.0-0034680909 10940313 10.1074/jbc.M007300200

412 Nwabo Kamdje AH Krampera M Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood 2011 118 6506 6514 21979940 10.1182/blood-2011-08-376061

413 Kamdje AHN Mosna F Bifari F Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells Blood 2011 118 2 380 389 2-s2.0-79960476475 21602525 10.1182/blood-2010-12-326694

414 Nefedova Y Sullivan DM Bolick SC Dalton WS Gabrilovich DI Inhibition of notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy Blood 2008 111 4 2220 2229 2-s2.0-41349095228 18039953 10.1182/blood-2007-07-102632

415 Tetzlaff MT Yu W Li M Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein Proceedings of the National Academy of Sciences of the United States of America 2004 101 10 3338 3345 2-s2.0-1542409037 14766969 10.1073/pnas.0307875101 PMC373463

416 Koepp DM Schaefer LK Ye X Phosphorylation-dependent ubiquitination of cyctin E by the SCFFbw7 ubiquitin ligase Science 2001 294 5540 173 177 2-s2.0-0035812709 11533444 10.1126/science.1065203

417 Baron M Endocytic routes to Notch activation Seminars in Cell & Developmental Biology 2012 23 437 442 22285298 10.1016/j.semcdb.2012.01.008

418 Jang J Choi YI Choi J Notch1 confers thymocytes a resistance to GC-induced apoptosis through Deltex1 by blocking the recruitment of p300 to the SRG3 promoter Cell Death and Differentiation 2006 13 9 1495 1505 2-s2.0-33747041405 16341126 10.1038/sj.cdd.4401827

419 Talora C Campese AF Bellavia D Notch signaling and diseases: n evolutionary journey from a simple beginning to complex outcomes Biochimica et Biophysica Acta 2008 1782 9 489 497 2-s2.0-49349097988 18625307 10.1016/j.bbadis.2008.06.008

420 Palomero T Ferrando A Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapyinT-cell acute lymphoblastic leukemias and lymphomas Clinical Cancer Research 2008 14 17 5314 5317 2-s2.0-53049085101 18765521 10.1158/1078-0432.CCR-07-4864 PMC2577004

421 Chadwick N Zeef L Portillo V Notch protection against apoptosis in T-ALL cells mediated by GIMAP5 Blood Cells, Molecules, and Diseases 2010 45 3 201 209 2-s2.0-77956871809 10.1016/j.bcmd.2010.07.006 20817506

422 Chadwick N Zeef L Portillo V Identification of novel Notch target genes in T cell leukaemia Molecular Cancer 2009 8, article 35 2-s2.0-67749110455 10.1186/1476-4598-8-35 PMC2698846 19508709

423 Nitta T Nasreen M Seike T IAN family critically regulates survival and development of T lymphocytes PLoS Biology 2006 4 4 p. e103 2-s2.0-33846172748 10.1371/journal.pbio.0040103 PMC1393758 16509771

424 Zenz T Roessner A Thomas A hlan5: the human ortholog to the rat lan4/lddm1/lyp is a new member of the Ian family that is overexpressed in B-cell lymphoid malignancies Genes and Immunity 2004 5 2 109 116 2-s2.0-3242809708 14724691 10.1038/sj.gene.6364044

425 Keita M Leblanc C Andrews D Ramanathan S GIMAP5 regulates mitochondrial integrity from a distinct subcellular compartment Biochemical and Biophysical Research Communications 2007 361 2 481 486 2-s2.0-34547538302 17655828 10.1016/j.bbrc.2007.07.048

426 Filén S Lahesmaa R GIMAP proteins in T-lymphocytes Journal of Signal Transduction 2010 2010 10 pages 268589 10.1155/2010/268589 PMC3100574 21637352

427 Hyun MS Minter LM Ok HC Notch1 augments NF- κ B activity by facilitating its nuclear retention EMBO Journal 2006 25 1 129 138 2-s2.0-30444450802 16319921 10.1038/sj.emboj.7600902 PMC1356346

428 Palomero T Wei KL Odom DT NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth Proceedings of the National Academy of Sciences of the United States of America 2006 103 48 18261 18266 2-s2.0-33845306813 17114293 10.1073/pnas.0606108103 PMC1838740

429 Sharma VM Calvo JA Draheim KM Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc Molecular and Cellular Biology 2006 26 21 8022 8031 2-s2.0-33750317437 16954387 10.1128/MCB.01091-06 PMC1636748

430 Weng AP Millholland JM Yashiro-Ohtani Y c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma Genes and Development 2006 20 15 2096 2109 2-s2.0-33947109380 16847353 10.1101/gad.1450406 PMC1536060

431 Cialfi S Palermo R Manca S Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression Leukemia . In press 10.1038/leu.2012.192 22846929

432 Mo JS Ann EJ Yoon JH Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls notch1 signaling by downregulation of protein stability through Fbw7 ubiquitin ligase Journal of Cell Science 2011 124 1 100 112 2-s2.0-78651104178 21147854 10.1242/jcs.073924

433 Kox C Zimmermann M Stanulla M The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function Leukemia 2010 24 12 2005 2013 2-s2.0-78650305754 20944675 10.1038/leu.2010.203 PMC3035973

434 Zuurbier L Homminga I Calvert V NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols Leukemia 2010 24 12 2014 2022 2-s2.0-78650307928 20861909 10.1038/leu.2010.204

435 Asnafi V Buzyn A Le Noir S NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study Blood 2009 113 17 3918 3924 2-s2.0-65449135968 19109228 10.1182/blood-2008-10-184069

436 Clappier E Collette S Grardel N NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951 Leukemia 2010 24 12 2023 2031 2-s2.0-78650311120 20861920 10.1038/leu.2010.205

437 Tang Y Wang Y Chen L Weintraub N Pan Y Cross talk between the notch signaling and noncoding RNA on the fate of stem cells Progress in Molecular Biology and Translational Science 2012 111 175 193 22917231 10.1016/B978-0-12-398459-3.00008-3

438 Lerner M Lundgren J Akhoondi S MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression Cell Cycle 2011 10 13 2172 2183 2-s2.0-79959923295 21597324 10.4161/cc.10.13.16248

439 Wang Q Li DC Li ZF Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen Oncogene 2011 30 3875 3886 2-s2.0-79953243224 21460851 10.1038/onc.2011.103

440 Li X Sanda T Thomas Look A Novina CD von Boehmer H Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL Journal of Experimental Medicine 2011 208 4 663 675 2-s2.0-79955756373 21464222 10.1084/jem.20102384 PMC3135352

441 Ghisi M Corradin A Basso K Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150 Blood 2011 117 26 7053 7062 2-s2.0-79959842615 21551231 10.1182/blood-2010-12-326629

442 Kefas B Comeau L Floyd DH The neuronal microRNA miR-326 acts in a feedback loop with Notch and has therapeutic potential against brain tumors Journal of Neuroscience 2009 29 48 15161 15168 2-s2.0-72849108572 19955368 10.1523/JNEUROSCI.4966-09.2009 PMC2823067

443 Lewis BP Shih IH Jones-Rhoades MW Bartel DP Burge CB Prediction of mammalian microRNA targets Cell 2003 115 7 787 798 2-s2.0-0346094457 14697198 10.1016/s0092-8674(03)01018-3

444 de Antonellis P Medaglia C Cusanelli E MiR-34a targeting of Notch ligand delta-like 1 impairs CD15 + /CD133 + tumor-propagating cells and supports neural differentiation in medulloblastoma PLoS ONE 2011 6 e24584 10.1371/journal.pone.0024584 PMC3171461 21931765

445 Manfè V Holst LM Rosbjerg A Kamstrup MR Kaczkowski B Gniadecki R Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition Leukemia Research 2010 34 9 e235 e236 2-s2.0-77955233086 20416947 10.1016/j.leukres.2010.03.035

446 Mertens-Talcott SU Chintharlapalli S Li X Safe S The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells Cancer Research 2007 67 22 11001 11011 2-s2.0-36349001297 18006846 10.1158/0008-5472.CAN-07-2416

447 Dang CV MYC on the path to cancer Cell 2012 149 22 35 22464321 10.1016/j.cell.2012.03.003 PMC3345192

448 Medh RD Wang A Zhou F Thompson EB Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells Oncogene 2001 20 34 4629 4639 2-s2.0-0035797489 11498786 10.1038/sj.onc.1204680 PMC2761604

449 Felsher DW Bishop JM Reversible tumorigenesis by MYC in hematopoietic lineages Molecular Cell 1999 4 2 199 207 2-s2.0-0033180211 10488335 10.1016/s1097-2765(00)80367-6

450 Bonnet M Loosveld M Montpellier B Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia Blood 2011 117 24 6650 6659 2-s2.0-79959248268 21527520 10.1182/blood-2011-02-336842

451 Battey J Moulding C Taub R The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt-lymphoma Cell 1983 34 3 779 787 2-s2.0-0020603359 6414718 10.1016/0092-8674(83)90534-2

452 Dominguez-Sola D Dalla-Favera R Burkitt lymphoma: much more than MYC Cancer Cell 2012 22 141 142 22897844 10.1016/j.ccr.2012.07.018

453 Molyneux EM Rochford R Griffin B Burkitt's lymphoma The Lancet 2012 379 1234 1244 10.1016/S0140-6736(11)61177-X 22333947

454 Yamamoto K Matsuoka H Yakushijin K A novel five-way translocation, t(3,9,13,8,14)(q27,p13,q32,q24,q32), with concurrent MYC and BCL6 rearrangements in a primary bone marrow B-cell lymphoma Cancer Genetics 2011 204 501 506 22018272 10.1016/j.cancergen.2011.08.017

455 Tomita N BCL2 and MYC dual-hit lymphoma/leukemia Journal of Clinical and Experimental Hematopathology 2011 51 7 12 21628855 10.3960/jslrt.51.7

456 Snuderl M Kolman OK Chen YB B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma American Journal of Surgical Pathology 2010 34 3 327 340 2-s2.0-77649230092 20118770 10.1097/PAS.0b013e3181cd3aeb PMC3152212

457 Slack GW Gascoyne RD MYC and aggressive B-cell lymphomas Advances in Anatomic Pathology 2011 18 3 219 228 2-s2.0-79955096411 21490439 10.1097/PAP.0b013e3182169948

458 Shiratori S Kondo T Fujisawa S C-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions Leukemia and Lymphoma 2011 52 4 716 718 2-s2.0-79953222616 21314486 10.3109/10428194.2010.551158

459 Slovak ML Ho JP Pettenati MJ Localization of amplified MYC gene sequences to double minute chromosomes in acute myelogenous leukemia Genes Chromosomes and Cancer 1994 9 1 62 67 2-s2.0-0028078646 7507702 10.1002/gcc.2870090111

460 Medh RD Saeed MF Johnson BH Thompson EB Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression Cancer Research 1998 58 16 3684 3693 2-s2.0-0032529237 9721879

461 Thompson EB Thulasi R Saeed MF Johnson BH Glucocorticoid antagonist RU 486 reverses agonist-induced apoptosis and c-myc repression in human leukemic CEM-C7 cells Annals of the New York Academy of Sciences 1995 761 261 275 2-s2.0-0029166344 7625725 10.1111/j.1749-6632.1995.tb31383.x

462 Ausserlechner MJ Obexer P Böck G Geley S Kofler R Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells Cell Death and Differentiation 2004 11 2 165 174 2-s2.0-0742289478 14576768 10.1038/sj.cdd.4401328

463 Blackwood EM Eisenman RN Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science 1991 251 4998 1211 1217 2-s2.0-0025763419 2006410 10.1126/science.2006410

464 Zeller KI Zhao X Lee CWH Global mapping of c-Myc binding sites and target gene networks in human B cells Proceedings of the National Academy of Sciences of the United States of America 2006 103 47 17834 17839 2-s2.0-33845187907 17093053 10.1073/pnas.0604129103 PMC1635161

465 Sander S Bullinger L Wirth T Repressing the repressor—a new mode of MYC action in lymphomagenesis Cell Cycle 2009 8 4 556 559 2-s2.0-61449238163 19197161 10.4161/cc.8.4.7599

466 Kleine-Kohlbrecher D Adhikary S Eilers M Mechanisms of transcriptional repression by Myc Current Topics in Microbiology and Immunology 2006 302 51 62 2-s2.0-33144477930 16620025 10.1007/3-540-32952-8_3

467 Sylvestre Y De Guire V Querido E An E2F/miR-20a autoregulatory feedback loop The Journal of Biological Chemistry 2007 282 4 2135 2143 2-s2.0-34047267329 17135249 10.1074/jbc.M608939200

468 Yu Z Wang C Wang M A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation Journal of Cell Biology 2008 182 3 509 517 2-s2.0-49749086530 18695042 10.1083/jcb.200801079 PMC2500136

469 He L Thomson JM Hemann MT A microRNA polycistron as a potential human oncogene Nature 2005 435 7043 828 833 2-s2.0-20444467290 15944707 10.1038/nature03552 PMC4599349

470 Polager S Ginsberg D E2F—at the crossroads of life and death Trends in Cell Biology 2008 18 11 528 535 2-s2.0-54049120956 18805009 10.1016/j.tcb.2008.08.003

471 Ofir M Hacohen D Ginsberg D miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E Molecular Cancer Research 2011 9 4 440 447 2-s2.0-79954459249 21454377 10.1158/1541-7786.MCR-10-0344

472 Bashari D Hacohen D Ginsberg D JNK activation is regulated by E2F and promotes E2F1-induced apoptosis Cellular Signalling 2011 23 1 65 70 2-s2.0-77957767952 20800677 10.1016/j.cellsig.2010.08.004

473 Chang TC Yu D Lee YS Widespread microRNA repression by Myc contributes to tumorigenesis Nature Genetics 2008 40 1 43 50 2-s2.0-37549008310 18066065 10.1038/ng.2007.30 PMC2628762

474 Zhu H Wu H Liu X Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells Autophagy 2009 5 6 816 823 2-s2.0-69449097865 19535919 10.4161/auto.9064 PMC3669137

475 Zou Z Wu L Ding H MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy The Journal of Biological Chemistry 2012 287 4148 4156 22157765 10.1074/jbc.M111.307405 PMC3281695

476 Johnson SM Grosshans H Shingara J RAS is regulated by the let-7 microRNA family Cell 2005 120 5 635 647 2-s2.0-20044395613 15766527 10.1016/j.cell.2005.01.014

477 Yong SL Dutta A The tumor suppressor microRNA let-7 represses the HMGA2 oncogene Genes and Development 2007 21 9 1025 1030 2-s2.0-34247565615 17437991 10.1101/gad.1540407 PMC1855228

478 Mayr C Hemann MT Bartel DP Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation Science 2007 315 5818 1576 1579 2-s2.0-33947431322 17322030 10.1126/science.1137999 PMC2556962

479 Johnson CD Esquela-Kerscher A Stefani G The let-7 microRNA represses cell proliferation pathways in human cells Cancer Research 2007 67 16 7713 7722 2-s2.0-34548012848 17699775 10.1158/0008-5472.CAN-07-1083

480 Gao P Tchernyshyov I Chang TC C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism Nature 2009 458 7239 762 765 2-s2.0-64749116346 19219026 10.1038/nature07823 PMC2729443

481 Lu J He ML Wang L MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2 Cancer Research 2011 71 1 225 233 2-s2.0-78651411120 21199804 10.1158/0008-5472.CAN-10-1850

482 Ji J Shi J Budhu A MicroRNA expression, survival, and response to interferon in liver cancer The New England Journal of Medicine 2009 361 15 1437 1447 2-s2.0-70349871321 19812400 10.1056/NEJMoa0901282 PMC2786938

483 Sander S Bullinger L Klapproth K MYC stimulates EZH2 expression by repression of its negative regulator miR-26a Blood 2008 112 10 4202 4212 2-s2.0-61349112251 18713946 10.1182/blood-2008-03-147645

484 Chang TC Wentzel EA Kent OA Transactivation of miR-34a by p53 broadlyinfluences gene expression andpromotesapoptosis Molecular Cell 2007 26 5 745 752 2-s2.0-34249817549 17540599 10.1016/j.molcel.2007.05.010 PMC1939978

485 He L He X Lim LP A microRNA component of the p53 tumour suppressor network Nature 2007 447 7148 1130 1134 2-s2.0-34250851115 17554337 10.1038/nature05939 PMC4590999

486 Raver-Shapira N Marciano E Meiri E Transcriptional activation of miR-34a contributes to p53-mediated apoptosis Molecular Cell 2007 26 5 731 743 2-s2.0-34249822779 17540598 10.1016/j.molcel.2007.05.017

487 Chang TC Zeitels LR Hwang HW Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3384 3389 2-s2.0-62549160957 19211792 10.1073/pnas.0808300106 PMC2651245

488 Piskounova E Polytarchou C Thornton JE Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms Cell 2011 147 1066 1079 22118463 10.1016/j.cell.2011.10.039 PMC3227872

489 Viswanathan SR Daley GQ Gregory RI Selective blockade of microRNA processing by Lin28 Science 2008 320 5872 97 100 2-s2.0-40849108663 18292307 10.1126/science.1154040 PMC3368499

490 Viswanathan SR Powers JT Einhorn W Lin28 promotes transformation and is associated with advanced human malignancies Nature Genetics 2009 41 7 843 848 2-s2.0-67649881121 19483683 10.1038/ng.392 PMC2757943

491 Yu J Vodyanik MA Smuga-Otto K Induced pluripotent stem cell lines derived from human somatic cells Science 2007 318 5858 1917 1920 2-s2.0-36749043230 18029452 10.1126/science.1151526

492 Dangi-Garimella S Yun J Eves EM Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7 EMBO Journal 2009 28 4 347 358 2-s2.0-60549104367 19153603 10.1038/emboj.2008.294 PMC2646152

493 Wu WKK Coffelt SB Cho CH The autophagic paradox in cancer therapy Oncogene 2011 31 939 953 2-s2.0-79960328846 21765470 10.1038/onc.2011.295

494 Levine B Sinha S Kroemer G Bcl-2 family members: dual regulators of apoptosis and autophagy Autophagy 2008 4 5 600 606 2-s2.0-48249092267 10.4161/auto.6260 PMC2749577 18497563

495 Maiuri MC Le Toumelin G Criollo A Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1 EMBO Journal 2007 26 10 2527 2539 2-s2.0-34248998801 17446862 10.1038/sj.emboj.7601689 PMC1868901

496 Pattingre S Tassa A Qu X Bcl-2 anti-apoptotic proteins inhibit Beclin 1-dependent autophagy Cell 2005 122 6 927 939 2-s2.0-25144457455 16179260 10.1016/j.cell.2005.07.002

497 Wirawan E Vande Walle L Kersse K Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of pro-apoptotic factors from mitochondria Cell Death and Disease 2010 1 1, article e18 2-s2.0-78649636176 10.1038/cddis.2009.16 PMC3032505 21364619

498 Wang J Beclin 1 bridges autophagy, apoptosis and differentiation Autophagy 2008 4 7 947 948 2-s2.0-53549132786 18769161 10.4161/auto.6787

499 Qu X Yu J Bhagat G Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene Journal of Clinical Investigation 2003 112 12 1809 1820 2-s2.0-9144240441 14638851 10.1172/JCI20039 PMC297002

500 Huang JJ Zhu YJ Lin TY Jiang WQ Huang HQ Li ZM Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP Human Pathology 2011 42 10 1459 1466 2-s2.0-79952984701 21450329 10.1016/j.humpath.2010.12.014

501 Laane E Tamm KP Buentke E Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy Cell Death and Differentiation 2009 16 7 p. 1071 2-s2.0-67549149082 10.1038/cdd.2009.46 19390558

502 Swerdlow S McColl K Rong Y Lam M Gupta A Distelhorst CW Apoptosis inhibition by Bcl-2 gives way to autophagy in glucocorticoid-treated lymphocytes Autophagy 2008 4 5 612 620 2-s2.0-48249088861 18362516 10.4161/auto.5920 PMC3625121

503 Molitoris JK McColl KS Swerdlow S Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes The Journal of Biological Chemistry 2011 286 30181 30189 21733849 10.1074/jbc.M111.245423 PMC3191057

504 Deyoung MP Horak P Sofer A Sgroi D Ellisen LW Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling Genes and Development 2008 22 2 239 251 2-s2.0-38349056675 18198340 10.1101/gad.1617608 PMC2192757

505 Galluzzi L Kroemer G Necroptosis: a specialized pathway of programmed Necrosis Cell 2008 135 7 1161 1163 2-s2.0-57649167477 19109884 10.1016/j.cell.2008.12.004

506 Ye H Liu X Lv M MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia Nucleic Acids Research 2012 40 5201 5214 22362744 10.1093/nar/gks175 PMC3384304

507 Otsuki T Clark HM Wellmann A Jaffe ES Raffeld M Involvement of CDKN2 (p16(INK4A)/MTS1) and p15(INK4B)/MTS2 in human leukemias and lymphomas Cancer Research 1995 55 7 1436 1440 2-s2.0-0028987262 7882348

508 Okuda T Shurtleff SA Valentine MB Frequent deletion of p16(INK4a)/MTS1 and p15(INK4b)/MTS2 in pediatric acute lymphoblastic leukemia Blood 1995 85 9 2321 2330 2-s2.0-0028988044 7727766

509 Kees UR Burton PR Lü C Baker DL Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome Blood 1997 89 11 4161 4166 2-s2.0-0030941813 9166859

510 Fizzotti M Cimino G Pisegna S Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features Blood 1995 85 10 2685 2690 2-s2.0-0029029358 7742527

511 Obexer P Hagenbuchner J Rupp M p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2 The Journal of Biological Chemistry 2009 284 45 30933 30940 2-s2.0-71449097361 19737931 10.1074/jbc.M109.051441 PMC2781493

512 Jardin F Jais JP Molina TJ Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study Blood 2010 116 7 1092 1104 2-s2.0-77956553931 20435884 10.1182/blood-2009-10-247122

513 Savage KJ Johnson NA Ben-Neriah S MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood 2009 114 17 3533 3537 2-s2.0-70449589073 19704118 10.1182/blood-2009-05-220095

514 Bissels U Bosio A Wagner W MicroRNAs are shaping the hematopoietic landscape Haematologica 2012 97 160 167 22058204 10.3324/haematol.2011.051730 PMC3269472

515 Garzon R Sandhu SK Croce CM Micro-RNA expression and function in lymphomas Advances in Hematology 2011 2011 2-s2.0-79959200772 347137 10.1155/2011/347137 PMC3063410 21461378

516 Babashah S Soleimani M The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis European Journal of Cancer 2011 47 8 1127 1137 2-s2.0-79955543736 21402473 10.1016/j.ejca.2011.02.008

517 Kasinski AL Slack FJ Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nature Reviews Cancer 2011 11 849 864 22113163 10.1038/nrc3166 PMC4314215

518 Ryan BM Robles AI Harris CC Genetic variation in microRNA networks: the implications for cancer research Nature Reviews Cancer 2010 10 6 389 402 2-s2.0-77952918274 20495573 10.1038/nrc2867 PMC2950312

519 Calin GA Croce CM MicroRNA signatures in human cancers Nature Reviews Cancer 2006 6 11 857 866 2-s2.0-33750370444 17060945 10.1038/nrc1997

520 Schotte D Chau JCK Sylvester G Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia Leukemia 2009 23 2 313 322 2-s2.0-60149100762 18923441 10.1038/leu.2008.286

521 Lu M Zhang Q Deng M An analysis of human microRNA and disease associations PLoS ONE 2008 3 10 2-s2.0-54849408182 e3420 10.1371/journal.pone.0003420 PMC2559869 18923704

522 Iorio MV Croce CM MicroRNAs in cancer: small molecules with a huge impact Journal of Clinical Oncology 2009 27 34 5848 5856 2-s2.0-73349125465 19884536 10.1200/JCO.2009.24.0317 PMC2793003

523 Lu J Getz G Miska EA MicroRNA expression profiles classify human cancers Nature 2005 435 7043 834 838 2-s2.0-20444460289 15944708 10.1038/nature03702

524 Filipowicz W Bhattacharyya SN Sonenberg N Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics 2008 9 2 102 114 2-s2.0-38349169664 10.1038/nrg2290 18197166

525 Di Leva G Briskin D Croce CM MicroRNA in cancer: new hopes for antineoplastic chemotherapy Upsala Journal of Medical Sciences 2012 117 202 216 22348396 10.3109/03009734.2012.660551 PMC3339552

526 Ruby JG Jan CH Bartel DP Intronic microRNA precursors that bypass Drosha processing Nature 2007 448 7149 83 86 2-s2.0-34447097693 17589500 10.1038/nature05983 PMC2475599

527 Berezikov E Chung WJ Willis J Cuppen E Lai EC Mammalian mirtron genes Molecular Cell 2007 28 2 328 336 2-s2.0-35348933779 17964270 10.1016/j.molcel.2007.09.028 PMC2763384

528 Wu L Belasco JG Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs Molecular Cell 2008 29 1 1 7 2-s2.0-38148999355 18206964 10.1016/j.molcel.2007.12.010

529 Buchan JR Parker R The two faces of miRNA Science 2007 318 5858 1877 1878 2-s2.0-37549033548 18096794 10.1126/science.1152623

530 Orkin SH Zon LI Hematopoiesis: an evolving paradigm for stem cell biology Cell 2008 132 4 631 644 2-s2.0-39349096526 18295580 10.1016/j.cell.2008.01.025 PMC2628169

531 Lodish HF Zhou B Liu G Chen CZ Micromanagement of the immune system by microRNAs Nature Reviews Immunology 2008 8 2 120 130 2-s2.0-38549095711 10.1038/nri2252 18204468

532 Lindsay MA microRNAs and the immune response Trends in Immunology 2008 29 7 343 351 2-s2.0-45549103746 18515182 10.1016/j.it.2008.04.004

533 Malumbres R Sarosiek KA Cubedo E Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas Blood 2009 113 16 3754 3764 2-s2.0-65549112644 19047678 10.1182/blood-2008-10-184077 PMC2670792

534 Muljo SA Mark Ansel K Kanellopoulou C Livingston DM Rao A Rajewsky K Aberrant T cell differentiation in the absence of Dicer Journal of Experimental Medicine 2005 202 2 261 269 2-s2.0-22944433872 16009718 10.1084/jem.20050678 PMC2212998

535 Cobb BS Hertweck A Smith J A role for Dicer in immune regulation Journal of Experimental Medicine 2006 203 11 2519 2527 2-s2.0-33750499991 17060477 10.1084/jem.20061692 PMC2118134

536 Liston A Lu LF O’Carroll D Tarakhovsky A Rudensky AY Dicer-dependent microRNA pathway safeguards regulatory T cell function Journal of Experimental Medicine 2008 205 9 1993 2004 2-s2.0-51049110261 18725526 10.1084/jem.20081062 PMC2526195

537 Koralov SB Muljo SA Galler GR Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage Cell 2008 132 5 860 874 2-s2.0-39749101294 18329371 10.1016/j.cell.2008.02.020

538 Cifuentes D Xue H Taylor DW A novel miRNA processing pathway independent of dicer requires argonaute2 catalytic activity Science 2010 328 5986 1694 1698 2-s2.0-77953897182 20448148 10.1126/science.1190809 PMC3093307

539 Neilson JR Zheng GXY Burge CB Sharp PA Dynamic regulation of miRNA expression in ordered stages of cellular development Genes and Development 2007 21 5 578 589 2-s2.0-33947104955 17344418 10.1101/gad.1522907 PMC1820899

540 Wiegers GJ Knoflach M Bock G CD4 + CD8 + TCR low thymocytes express low levels of glucocorticoid receptors while being sensitive to glucocorticoid-induced apoptosis European Journal of Immunology 2001 31 2293 2301 11477541 10.1002/1521-4141(200108)31:8<2293::aid-immu2293>3.0.co;2-i

541 Rosenheimer-Goudsmid N Haupt Y Yefenof E Zilberman Y Guy R p53 and thymic ‘death by neglect’: thymic epithelial cell-induced apoptosis of CD4 + 8 + thymocytes is p53-independent Cell Death and Differentiation 2000 7 3 241 249 2-s2.0-0034125553 10745269 10.1038/sj.cdd.4400657

542 Ashwell JD Lu FWM Vacchio MS Glucocorticoids in T cell development and function Annual Review of Immunology 2000 18 309 345 2-s2.0-0034049874 10.1146/annurev.immunol.18.1.309 10837061

543 Cobb BS Nesterova TB Thompson E T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer Journal of Experimental Medicine 2005 201 9 1367 1373 2-s2.0-20844432885 15867090 10.1084/jem.20050572 PMC2213187

544 Ceribelli A Satoh M Chan EK MicroRNAs and autoimmunity Current Opinion in Immunology 2012 24 6 686 691 22902047 10.1016/j.coi.2012.07.011 PMC3508200

545 Rusca N Monticelli S MiR-146a in immunity and disease Molecular Biology International 2011 2011 7 pages 437301 10.4061/2011/437301 PMC3200075 22091404

546 Li QJ Chau J Ebert PJR miR-181a is an intrinsic modulator of T cell sensitivity and selection Cell 2007 129 1 147 161 2-s2.0-33947721625 17382377 10.1016/j.cell.2007.03.008

547 Xiao C Calado DP Galler G MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb Cell 2007 131 1 146 159 2-s2.0-34547941361 17923094 10.1016/j.cell.2007.07.021

548 Ebert PJ Jiang S Xie J Li QJ Davis MM An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a Nature Immunology 2009 10 11 1162 1169 2-s2.0-70350435670 19801983 10.1038/ni.1797 PMC3762483

549 Fragoso R Mao T Wang S Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1 PLOS Genetics 2012 8 e1002855 10.1371/journal.pgen.1002855 PMC3415433 22916024

550 Chen CZ Li L Lodish HF Bartel DP MicroRNAs modulate hematopoietic lineage differentiation Science 2004 303 5654 83 86 2-s2.0-0346727524 14657504 10.1126/science.1091903

551 Cichocki F Felices M McCullar V Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling Journal of Immunology 2011 187 6171 6175 10.4049/jimmunol.1100835 PMC3237765 22084432

552 Li X Zhang J Gao L MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit Cell Death & Differentiation 2012 19 378 386 21979467 10.1038/cdd.2011.127 PMC3278736

553 Zhou B Wang S Mayr C Bartel DP Lodish HF miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely Proceedings of the National Academy of Sciences of the United States of America 2007 104 17 7080 7085 2-s2.0-56649100636 17438277 10.1073/pnas.0702409104 PMC1855395

554 Lu J Guo S Ebert BL MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors Developmental Cell 2008 14 6 843 853 2-s2.0-44449108570 18539114 10.1016/j.devcel.2008.03.012 PMC2688789

555 Bezman NA Chakraborty T Bender T Lanier LL miR-150 regulates the development of NK and iNKT cells Journal of Experimental Medicine 2011 208 2717 2731 22124110 10.1084/jem.20111386 PMC3244033

556 Zheng Q Zhou L Mi QS MicroRNA miR-150 is involved in Valpha14 invariant NKT cell development and function Journal of Immunology 2012 188 2118 2126 10.4049/jimmunol.1103342 PMC7375412 22287707

557 Zanette DL Rivadavia F Molfetta GA miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia Brazilian Journal of Medical and Biological Research 2007 40 11 1435 1440 2-s2.0-37349032529 17934639 10.1590/s0100-879x2007001100003

558 Zhao H Wang D Du W Gu D Yang R MicroRNA and leukemia: tiny molecule, great function Critical Reviews in Oncology/Hematology 2010 74 3 149 155 2-s2.0-77953358265 19520590 10.1016/j.critrevonc.2009.05.001

559 Wang Y Li Z He C MicroRNAs expression signatures are associated with lineage and survival in acute leukemias Blood Cells, Molecules, and Diseases 2010 44 3 191 197 2-s2.0-76849084080 10.1016/j.bcmd.2009.12.010 PMC2829339 20110180

560 Agirre X Vilas-Zornoza A Jiménez-Velasco A Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia Cancer Research 2009 69 10 4443 4453 2-s2.0-66249148694 19435910 10.1158/0008-5472.CAN-08-4025

561 Mi S Lu J Sun M MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia Proceedings of the National Academy of Sciences of the United States of America 2007 104 50 19971 19976 2-s2.0-38049123402 18056805 10.1073/pnas.0709313104 PMC2148407

562 Babashah S Sadeghizadeh M Tavirani MR Farivar S Soleimani M Aberrant microRNA expression and its implications in the pathogenesis of leukemias Cellular Oncology 2012 35 5 317 334 22956261 10.1007/s13402-012-0095-3 PMC12995094

563 Calin GA Ferracin M Cimmino A A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia The New England Journal of Medicine 2005 353 17 1793 1801 2-s2.0-27244434788 16251535 10.1056/NEJMoa050995

564 Di Lisio L Sanchez-Beato M Gomez-Lopez G MicroRNA signatures in B-cell lymphomas Blood Cancer Journal 2012 2 e57 10.1038/bcj.2012.1 PMC3288280 22829247

565 Li S Moffett HF Lu J Microrna expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells PLoS ONE 2011 6 3 2-s2.0-79952392451 e16956 10.1371/journal.pone.0016956 PMC3050979 21408091

566 Fulci V Chiaretti S Goldoni M Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia Blood 2007 109 11 4944 4951 2-s2.0-34249661649 17327404 10.1182/blood-2006-12-062398

567 Mraz M Pospisilova S Malinova K Slapak I Mayer J MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes Leukemia and Lymphoma 2009 50 3 506 509 2-s2.0-67650905183 19347736 10.1080/10428190902763517

568 Marton S Garcia MR Robello C Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis Leukemia 2008 22 2 330 338 2-s2.0-39149134593 17989717 10.1038/sj.leu.2405022

569 Pekarsky Y Santanam U Cimmino A Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181 Cancer Research 2006 66 24 11590 11593 2-s2.0-33846190181 17178851 10.1158/0008-5472.CAN-06-3613

570 Zenz T Mohr J Eldering E miR-34a as part of the resistance network in chronic lymphocytic leukemia Blood 2009 113 16 3801 3808 2-s2.0-65549110908 18941118 10.1182/blood-2008-08-172254

571 Tili E Michaille JJ Luo Z The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state Blood 2012 120 13 2631 2638 22723551 10.1182/blood-2012-03-415737 PMC3460685

572 Barbarotto E Schmittgen TD Calin GA MicroRNAs and cancer: profile, profile, profile International Journal of Cancer 2008 122 5 969 977 2-s2.0-38749083425 18098138 10.1002/ijc.23343

573 Akao Y Nakagawa Y Kitade Y Kinoshita T Naoe T Downregulation of microRNAs-143 and -145 in B-cell malignancies Cancer Science 2007 98 12 1914 1920 2-s2.0-35548995316 17892514 10.1111/j.1349-7006.2007.00618.x PMC11158757

574 Pichiorri F Suh SS Ladetto M MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 12885 12890 2-s2.0-51349093465 18728182 10.1073/pnas.0806202105 PMC2529070

575 Roccaro AM Sacco A Thompson B MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma Blood 2009 113 26 6669 6680 2-s2.0-69249225706 19401561 10.1182/blood-2009-01-198408 PMC2710922

576 Pichiorri F De Luca L Aqeilan RI MicroRNAs: new players in multiple myeloma Frontiers in Genetics 2011 2, article 22 10.3389/fgene.2011.00022 PMC3268577 22303318

577 Unno K Zhou Y Zimmerman T Platanias LC Wickrema A Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma Leukemia and Lymphoma 2009 50 11 1865 1871 2-s2.0-71049129806 19883314 10.3109/10428190903221010 PMC2774220

578 Gutiérrez NC Sarasquete ME Misiewicz-Krzeminska I Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling Leukemia 2010 24 3 629 637 2-s2.0-77949423427 20054351 10.1038/leu.2009.274

579 Lionetti M Biasiolo M Agnelli L Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma Blood 2009 114 25 e20 e26 2-s2.0-73949101367 19846888 10.1182/blood-2009-08-237495

580 Lawrie CH Soneji S Marafioti T MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma International Journal of Cancer 2007 121 5 1156 1161 2-s2.0-34547135697 17487835 10.1002/ijc.22800

581 Lawrie CH Chi J Taylor S Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma Journal of Cellular and Molecular Medicine 2009 13 7 1248 1260 2-s2.0-68149114040 19413891 10.1111/j.1582-4934.2008.00628.x PMC4496139

582 Roehle A Hoefig KP Repsilber D MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas British Journal of Haematology 2008 142 5 732 744 2-s2.0-48749084382 18537969 10.1111/j.1365-2141.2008.07237.x

583 Zhao JJ Lin J Lwin T MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma Blood 2010 115 13 2630 2639 2-s2.0-77951003346 20086245 10.1182/blood-2009-09-243147 PMC2852365

584 Kluiver J Poppema S de Jong D BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas Journal of Pathology 2005 207 2 243 249 2-s2.0-26044481464 16041695 10.1002/path.1825

585 Li C Kim SW Rai D Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma Blood 2009 113 26 6681 6690 2-s2.0-68249144342 19278952 10.1182/blood-2009-01-202028 PMC3401058

586 Benner MF Ballabio E van Kester MS Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides Experimental Dermatology 2012 21 632 634 22776000 10.1111/j.1600-0625.2012.01548.x

587 Merkel O Hamacher F Laimer D Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma Proceedings of the National Academy of Sciences of the United States of America 2010 107 37 16228 16233 2-s2.0-77957984238 20805506 10.1073/pnas.1009719107 PMC2941277

588 Matsuyama H Suzuki HI Nishimori H miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma Blood 2011 118 6881 6892 22042699 10.1182/blood-2011-05-354654

589 Gibcus JH Tan LP Harms G Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile Neoplasia 2009 11 2 167 176 2-s2.0-61349196873 19177201 10.1593/neo.08980 PMC2631141

590 Navarro A Gaya A Martinez A MicroRNA expression profiling in classic Hodgkin lymphoma Blood 2008 111 5 2825 2832 2-s2.0-41949122480 18089852 10.1182/blood-2007-06-096784

591 Di Lisio L Gómez-López G Sánchez-Beato M Mantle cell lymphoma: transcriptional regulation by microRNAs Leukemia 2010 24 7 1335 1342 2-s2.0-77954656203 20485376 10.1038/leu.2010.91

592 Rossi RL Rossetti G Wenandy L Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4 + T cells by the microRNA miR-125b Nature Immunology 2011 12 796 803 2-s2.0-79959486788 21706005 10.1038/ni.2057

593 Klein U Casola S Cattoretti G Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination Nature Immunology 2006 7 7 773 782 2-s2.0-33745182931 16767092 10.1038/ni1357

594 Angelin-Duclos C Cattoretti G Lin KI Calame K Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo Journal of Immunology 2000 165 10 5462 5471 2-s2.0-0034669911 10.4049/jimmunol.165.10.5462 11067898

595 Chaudhuri AA So AY Mehta A Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A Proceedings of the National Academy of Sciences United States of America 2012 109 4233 4238 10.1073/pnas.1200677109 PMC3306721 22366319

596 Klusmann JH Li Z Böhmer K miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia Genes and Development 2010 24 5 478 490 2-s2.0-77649143631 20194440 10.1101/gad.1856210 PMC2827843

597 Rodriguez A Vigorito E Clare S Requirement of bic/microRNA-155 for normal immune function Science 2007 316 5824 608 611 2-s2.0-34247584465 17463290 10.1126/science.1139253 PMC2610435

598 O’Connell RM Rao DS Chaudhuri AA Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder Journal of Experimental Medicine 2008 205 3 585 594 2-s2.0-41149130219 18299402 10.1084/jem.20072108 PMC2275382

599 Vigorito E Perks KL Abreu-Goodger C microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells Immunity 2007 27 6 847 859 2-s2.0-37049002638 18055230 10.1016/j.immuni.2007.10.009 PMC4135426

600 Ruggiero T Trabucchi M De Santa F LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages FASEB Journal 2009 23 9 2898 2908 2-s2.0-70349323601 19423639 10.1096/fj.09-131342

601 Kohlhaas S Garden OA Scudamore C Turner M Okkenhaug K Vigorito E Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells1 Journal of Immunology 2009 182 5 2578 2582 2-s2.0-64849100152 10.4049/jimmunol.0803162 19234151

602 Costinean S Zanesi N Pekarsky Y Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E μ -miR155 transgenic mice Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 7024 7029 2-s2.0-33646471662 16641092 10.1073/pnas.0602266103 PMC1459012

603 Tili E Michaille JJ Wernicke D Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer Proceedings of the National Academy of Sciences of the United States of America 2011 108 12 4908 4913 2-s2.0-79953197948 21383199 10.1073/pnas.1101795108 PMC3064319

604 Wu T Wieland A Araki K Temporal expression of microRNA cluster miR-17 ∼ 92 regulates effector and memory CD8 + T-cell differentiation Proceedings of the National Academy of Sciences of the United States of America 2012 109 9965 9970 22665768 10.1073/pnas.1207327109 PMC3382487

605 Fulci V Colombo T Chiaretti S Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of microRNA and mRNA expression profiles Genes Chromosomes and Cancer 2009 48 12 1069 1082 2-s2.0-70350233444 19760605 10.1002/gcc.20709

606 Ralfkiaer U Hagedorn PH Bangsgaard N Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL) Blood 2011 118 5891 5900 21865341 10.1182/blood-2011-06-358382 PMC3342856

607 Cocco C Airoldi I Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia Cytokine and Growth Factor Reviews 2011 22 3 149 156 2-s2.0-79960208669 21764355 10.1016/j.cytogfr.2011.05.003

608 Zhang J Jima DD Jacobs C Patterns of microRNA expression characterize stages of human B-cell differentiation Blood 2009 113 19 4586 4594 2-s2.0-66549101276 19202128 10.1182/blood-2008-09-178186 PMC2680365

609 Jima DD Zhang J Jacobs C Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs Blood 2010 116 23 e118 e127 2-s2.0-78649743127 20733160 10.1182/blood-2010-05-285403 PMC3012600

610 Culpin RE Proctor SJ Angus B Crosier S Anderson JJ Mainou-Fowler T A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines International Journal of Oncology 2010 37 2 367 376 2-s2.0-77954146007 20596664 10.3892/ijo_00000685

611 Zhoua Y Chena L Barlogiea B High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 Proceedings of the National Academy of Sciences of the United States of America 2010 107 17 7904 7909 2-s2.0-77952340609 20385818 10.1073/pnas.0908441107 PMC2867889

612 Corthals SL Jongen-Lavrencic M de Knegt Y Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma Leukemia Research 2010 34 5 677 681 2-s2.0-77950099097 20031211 10.1016/j.leukres.2009.10.026

613 Iqbal J Shen Y Liu Y Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis Blood 2012 119 4939 4948 22490335 10.1182/blood-2011-07-370122 PMC3367895

614 Schiffman JD Lorimer PD Rodic V Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression British Journal of Haematology 2011 155 477 486 21981616 10.1111/j.1365-2141.2011.08883.x PMC3204171

615 Leich E Zamo A Horn H MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype Blood 2011 118 5550 5558 21960592 10.1182/blood-2011-06-361972 PMC3217356

616 Mavrakis KJ Wolfe AL Oricchio E Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia Nature Cell Biology 2010 12 4 372 379 2-s2.0-77950518606 20190740 10.1038/ncb2037 PMC2989719

617 Olive V Bennett MJ Walker JC miR-19 is a key oncogenic component of miR-17 ∼ 92 Genes and Development 2009 23 24 2839 2849 2-s2.0-72849120988 20008935 10.1101/gad.1861409 PMC2800084

618 Ota A Tagawa H Karnan S Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma Cancer Research 2004 64 9 3087 3095 2-s2.0-2342449399 15126345 10.1158/0008-5472.can-03-3773

619 Mourelatos Z Dostie J Paushkin S miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs Genes and Development 2002 16 6 720 728 2-s2.0-0037087780 11914277 10.1101/gad.974702 PMC155365

620 Nagel S Venturini L Przybylski GK Activation of miR-17 ∼ 92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia Leukemia and Lymphoma 2009 50 1 101 108 2-s2.0-59249099105 19148830 10.1080/10428190802626632

621 Dorsam ST Ferrell CM Dorsam GP The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells Blood 2004 103 5 1676 1684 2-s2.0-10744230627 14604967 10.1182/blood-2003-07-2202

622 Ferrando AA Armstrong SA Neuberg DS Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation Blood 2003 102 1 262 268 2-s2.0-0038240453 12637319 10.1182/blood-2002-10-3221

623 Schotte D Lange-Turenhout EAM Stumpel DJPM Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia Haematologica 2010 95 10 1675 1682 2-s2.0-77957821737 20494936 10.3324/haematol.2010.023481 PMC2948092

624 Wong GW Knowles GC Mak TW Ferrando AA Zuniga-Pflucker JC HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRbeta-selected mouse thymocytes Blood 2012 120 1439 1448 22649105 10.1182/blood-2011-12-395319 PMC3423782

625 Koch U Radtke F Notch in T-ALL: new players in a complex disease Trends in Immunology 2011 32 9 434 442 2-s2.0-79960325063 21775206 10.1016/j.it.2011.06.005

626 Li X Gounari F Protopopov A Khazaie K Von Boehmer H Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1 Journal of Experimental Medicine 2008 205 12 2851 2861 2-s2.0-58149308526 18981238 10.1084/jem.20081561 PMC2585834

627 Sharma VM Draheim KM Kelliher MA The Notch1/c-Myc pathway in T cell leukemia Cell Cycle 2007 6 8 927 930 2-s2.0-34247476739 17404512 10.4161/cc.6.8.4134

628 Tian Y Nan Y Han L MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma International Journal of Oncology 2012 40 1105 1112 22179124 10.3892/ijo.2011.1306 PMC3584578

629 Salvatori B Iosue I Djodji Damas N Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2 Genes & Cancer 2011 2 585 592 21901171 10.1177/1947601911416357 PMC3161419

630 Volinia S Calin GA Liu CG A microRNA expression signature of human solid tumors defines cancer gene targets Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2257 2261 2-s2.0-33144490646 16461460 10.1073/pnas.0510565103 PMC1413718

631 Dahiya N Sherman-Baust CA Wang TL MicroRNA expression and identification of putative miRNA targets in ovarian cancer PLoS ONE 2008 3 6 2-s2.0-49149086082 e2436 10.1371/journal.pone.0002436 PMC2410296 18560586

632 He H Jazdzewski K Li W The role of microRNA genes in papillary thyroid carcinoma Proceedings of the National Academy of Sciences of the United States of America 2005 102 52 19075 19080 2-s2.0-30044436911 16365291 10.1073/pnas.0509603102 PMC1323209

633 Wang X Tang S Le SY Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth PLoS ONE 2008 3 7 2-s2.0-49749107841 e2557 10.1371/journal.pone.0002557 PMC2438475 18596939

634 Starczynowski DT Kuchenbauer F Wegrzyn J MicroRNA-146a disrupts hematopoietic differentiation and survival Experimental Hematology 2011 39 2 167.e4 178.e4 2-s2.0-78751523598 20933052 10.1016/j.exphem.2010.09.011

635 Boldin MP Taganov KD Rao DS miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice Journal of Experimental Medicine 2011 208 6 1189 1201 2-s2.0-79958257077 21555486 10.1084/jem.20101823 PMC3173243

636 Zhao JL Rao DS Boldin MP Taganov KD O’Connell RM Baltimore D NF- κ B dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies Proceedings of the National Academy of Sciences of the United States of America 2011 108 22 9184 9189 2-s2.0-79959362128 21576471 10.1073/pnas.1105398108 PMC3107319

637 Taganov KD Boldin MP Chang KJ Baltimore D NF- κ B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses Proceedings of the National Academy of Sciences of the United States of America 2006 103 33 12481 12486 2-s2.0-33747608638 16885212 10.1073/pnas.0605298103 PMC1567904

638 Paik JH Jang JY Jeon YK MicroRNA-146a downregulates NF κ B activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma Clinical Cancer Research 2011 17 14 4761 4771 2-s2.0-79960434259 21610143 10.1158/1078-0432.CCR-11-0494

639 Landgraf P Rusu M Sheridan R A mammalian microRNA expression atlas based on small RNA library sequencing Cell 2007 129 7 1401 1414 2-s2.0-34250877841 17604727 10.1016/j.cell.2007.04.040 PMC2681231

640 Nie K Gomez M Landgraf P MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed—sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas American Journal of Pathology 2008 173 1 242 252 2-s2.0-46749136860 18583325 10.2353/ajpath.2008.080009 PMC2438301

641 Guo LM Pu Y Han Z MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF- κ B1 FEBS Journal 2009 276 19 5537 5546 2-s2.0-70349263692 19702828 10.1111/j.1742-4658.2009.07237.x

642 Ruiz-Ballesteros E Mollejo M Mateo M Algara P Martínez P Piris MA MicroRNA losses in the frequently deleted region of 7q in SMZL Leukemia 2007 21 12 2547 2549 2-s2.0-36348963610 17625607 10.1038/sj.leu.2404853

643 Calin GA Pekarsky Y Croce CM The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia Best Practice and Research in Clinical Haematology 2007 20 3 425 437 2-s2.0-34547854381 17707831 10.1016/j.beha.2007.02.003

644 Klein U Lia M Crespo M The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia Cancer Cell 2010 17 1 28 40 2-s2.0-73649116987 20060366 10.1016/j.ccr.2009.11.019

645 Salerno E Scaglione BJ Coffman FD Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity Molecular Cancer Therapeutics 2009 8 9 2684 2692 2-s2.0-70349495864 19723889 10.1158/1535-7163.MCT-09-0127

646 Rainer J Ploner C Jesacher S Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia Leukemia 2009 23 4 746 752 2-s2.0-64849103952 19148136 10.1038/leu.2008.370

647 Inomata M Tagawa H Guo YM Kameoka Y Takahashi N Sawada K MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes Blood 2009 113 2 396 402 2-s2.0-58849148000 18941111 10.1182/blood-2008-07-163907

648 Smith LK Shah RR Cidlowski JA Glucocorticoids modulate microRNA expression and processing during lymphocyte apoptosis The Journal of Biological Chemistry 2010 285 47 36698 36708 2-s2.0-78449239272 20847043 10.1074/jbc.M110.162123 PMC2978599

649 Vreugdenhil E Verissimo CSL Mariman R MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain Endocrinology 2009 150 5 2220 2228 2-s2.0-66449105070 19131573 10.1210/en.2008-1335

650 Calin GA Croce CM Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes Blood 2009 114 23 4761 4770 2-s2.0-74049097902 19745066 10.1182/blood-2009-07-192740 PMC2786287

651 Zhu S Si ML Wu H Mo YY MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1) The Journal of Biological Chemistry 2007 282 19 14328 14336 2-s2.0-34347266556 17363372 10.1074/jbc.M611393200

652 Lionetti M Agnelli L Mosca L Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles Genes Chromosomes and Cancer 2009 48 6 521 531 2-s2.0-65349160295 19306352 10.1002/gcc.20660

653 Yamanaka Y Tagawa H Takahashi N Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia Blood 2009 114 15 3265 3275 2-s2.0-70350457646 19641183 10.1182/blood-2009-06-222794

654 Frankel LB Christoffersen NR Jacobsen A Lindow M Krogh A Lund AH Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells The Journal of Biological Chemistry 2008 283 2 1026 1033 2-s2.0-38149042783 17991735 10.1074/jbc.M707224200

655 Han BW Feng DD Li ZG A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL Human Molecular Genetics 2011 20 4903 4915 21926415 10.1093/hmg/ddr428 PMC3221537

656 Wang Z Wei W Sarkar FH miR-23a, a critical regulator of, “migR”ation and metastasis in colorectal cancer Cancer Discovery 2012 2 489 491 22684455 10.1158/2159-8290.CD-12-0177 PMC3375870

657 Harada M Pokrovskaja-Tamm K Soderhall S Heyman M Grander D Corcoran M Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia Leukemia & Lymphoma 2012 53 2041 2050 22475310 10.3109/10428194.2012.678004

658 Feng DD Zhang H Zhang P Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia Journal of Cellular and Molecular Medicine 2011 15 2164 2175 21070600 10.1111/j.1582-4934.2010.01213.x PMC4394226

659 Pekarsky Y Croce CM Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 2010 1 224 227 20936047 10.18632/oncotarget.129 PMC2951328

660 Park SY Lee JH Ha M Nam JW Kim VN miR-29 miRNAs activate p53 by targeting p85 α and CDC42 Nature Structural and Molecular Biology 2009 16 1 23 29 2-s2.0-58149215802 10.1038/nsmb.1533 19079265

661 Han YC Park CY Bhagat G MicroRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia Journal of Experimental Medicine 2010 207 3 475 489 2-s2.0-77949518018 20212066 10.1084/jem.20090831 PMC2839143

662 Mott JL Kurita S Cazanave SC Bronk SF Werneburg NW Fernandez-Zapico ME Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB Journal of Cellular Biochemistry 2010 110 5 1155 1164 2-s2.0-77954950168 20564213 10.1002/jcb.22630 PMC2922950

663 Fabbri M Bottoni A Shimizu M Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of b-cell chronic lymphocytic leukemia Journal of the American Medical Association 2011 305 1 59 67 2-s2.0-78650861867 21205967 10.1001/jama.2010.1919 PMC3690301

664 Zauli G Voltan R Di Iasio MG miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells Clinical Cancer Research 2011 17 9 2712 2724 2-s2.0-79955506666 21367750 10.1158/1078-0432.CCR-10-3244

665 Hermeking H The miR-34 family in cancer and apoptosis Cell Death and Differentiation 2010 17 2 193 199 2-s2.0-74249123570 19461653 10.1038/cdd.2009.56

666 Yamakuchi M Ferlito M Lowenstein CJ miR-34a repression of SIRT1 regulates apoptosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13421 13426 2-s2.0-51649115553 18755897 10.1073/pnas.0801613105 PMC2533205

667 Hashimi ST Fulcher JA Chang MH Gov L Wang S Lee B MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation Blood 2009 114 2 404 414 2-s2.0-67651098994 19398721 10.1182/blood-2008-09-179150 PMC2927176

668 Ivanovska I Ball AS Diaz RL MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression Molecular and Cellular Biology 2008 28 7 2167 2174 2-s2.0-41149101523 18212054 10.1128/MCB.01977-07 PMC2268421

669 Petrocca F Visone R Onelli MR E2F1-regulated microRNAs impair TGF β -dependent cell-cycle arrest and apoptosis in gastric cancer Cancer Cell 2008 13 3 272 286 2-s2.0-39849095077 18328430 10.1016/j.ccr.2008.02.013

670 Wang C Yao N Lu CL Li D Ma X Mouse microRNA-124 regulates the expression of Hes1 in P19 cells Frontiers in Bioscience 2010 2 127 132 2-s2.0-77954471096 10.2741/e74 20036862

671 Bousquet M Nguyen D Chen C Schields L Lodish H miR-125b transforms myeloid cell lines by repressing multiple mRNA targets Haematologica 2012 97 11 1713 1721 22689670 10.3324/haematol.2011.061515 PMC3487446

672 Kotani A Ha D Hsieh J miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221 Blood 2009 114 19 4169 4178 2-s2.0-77950546589 19749093 10.1182/blood-2008-12-191619 PMC2774553

673 Kotani A Ha D Schotte D Den Boer ML Armstrong SA Lodish HF A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells Cell Cycle 2010 9 6 1037 1042 2-s2.0-77953528169 20237425 10.4161/cc.9.6.11011 PMC3096720

674 Tessel MA Benham AL Krett NL Rosen ST Gunaratne PH Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma Hormones and Cancer 2011 2 3 182 189 2-s2.0-79955654560 21761344 10.1007/s12672-011-0072-8 PMC3725966

675 Lai KW Koh KX Loh M MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer European Journal of Cancer 2010 46 8 1456 1463 2-s2.0-77951666669 20176475 10.1016/j.ejca.2010.01.036

676 Borgdorff V Lleonart ME Bishop CL Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21 Waf1/Cip1 Oncogene 2010 29 15 2262 2271 2-s2.0-77951054607 20101223 10.1038/onc.2009.497

677 Navarro A Diaz T Martinez A Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma Blood 2009 114 14 2945 2951 2-s2.0-70449500709 19666866 10.1182/blood-2009-02-204842

678 Lv M Zhang X Jia H An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways Leukemia 2012 26 769 777 21979877 10.1038/leu.2011.273

679 Huang B Zhao J Lei Z miR-142-3p restricts cAMP production in CD4 + CD25 − T cells and CD4 + CD25 + TREG cells by targeting AC9 mRNA EMBO Reports 2009 10 2 180 185 2-s2.0-59649119933 19098714 10.1038/embor.2008.224 PMC2637310

680 Huang X Yang M Jin J Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs Leukemia & Lymphoma 2012 53 1188 1195 22260163 10.3109/10428194.2011.638069

681 Robertus JL Kluiver J Weggemans C MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma British Journal of Haematology 2010 149 6 896 899 2-s2.0-77952730045 20331457 10.1111/j.1365-2141.2010.08111.x

682 Wang M Tan LP Dijkstra MK miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression Journal of Pathology 2008 215 1 13 20 2-s2.0-42949127525 18348159 10.1002/path.2333

683 Watanabe A Tagawa H Yamashita J The role of microRNA-150 as a tumor suppressor in malignant lymphoma Leukemia 2011 25 1324 1334 2-s2.0-79955090161 21502955 10.1038/leu.2011.81

684 Belkaya S Silge RL Hoover AR Dynamic modulation of thymic microRNAs in response to stress PLoS ONE 2011 6 e27580 10.1371/journal.pone.0027580 PMC3217971 22110677

685 Metzler M Wilda M Busch K Viehmann S Borkhardt A High expression of precursor MicroRNA-155/BIC RNA in children with Burkitt lymphoma Genes Chromosomes and Cancer 2004 39 2 167 169 2-s2.0-0346727383 14695998 10.1002/gcc.10316

686 Kluiver J Haralambieva E De Jong D Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma Genes Chromosomes and Cancer 2006 45 2 147 153 2-s2.0-31944435282 16235244 10.1002/gcc.20273

687 Vargova K Curik N Burda P MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia Blood 2011 117 14 3816 3825 2-s2.0-79953822796 21296997 10.1182/blood-2010-05-285064

688 Costinean S Sandhu SK Pedersen IM Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of E μ -MiR-155 transgenic mice Blood 2009 114 7 1374 1382 2-s2.0-70349331525 19520806 10.1182/blood-2009-05-220814 PMC2727407

689 Gatto G Rossi A Rossi D Kroening S Bonatti S Mallardo M Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF- κ B pathway Nucleic Acids Research 2008 36 20 6608 6619 2-s2.0-56649123539 18940871 10.1093/nar/gkn666 PMC2582607

690 Zheng Y Xiong S Jiang P Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism Free Radical Biology and Medicine 2012 52 1307 1317 22326887 10.1016/j.freeradbiomed.2012.01.031

691 Eis PS Tam W Sun L Accumulation of miR-155 and BIC RNA in human B cell lymphomas Proceedings of the National Academy of Sciences of the United States of America 2005 102 10 3627 3632 2-s2.0-14844354250 15738415 10.1073/pnas.0500613102 PMC552785

692 Li Z Huang H Li Y Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML Blood 2012 119 2314 2324 22251480 10.1182/blood-2011-10-386235 PMC3311258

693 Alencar AJ Malumbres R Kozloski GA MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Clinical Cancer Research 2011 17 12 4125 4135 2-s2.0-79959259030 21525173 10.1158/1078-0432.CCR-11-0224 PMC3117929

694 Wang X Gocek E Liu CG Studzinski GP MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3 Cell Cycle 2009 8 5 736 741 2-s2.0-62449121929 19221487 10.4161/cc.8.5.7870 PMC2804747

695 Le Sage C Nagel R Egan DA Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation EMBO Journal 2007 26 15 3699 3708 2-s2.0-34547791273 17627278 10.1038/sj.emboj.7601790 PMC1949005

696 Galardi S Mercatelli N Giorda E miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 The Journal of Biological Chemistry 2007 282 32 23716 23724 2-s2.0-34548168073 17569667 10.1074/jbc.M701805200

697 Felli N Fontana L Pelosi E MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation Proceedings of the National Academy of Sciences of the United States of America 2005 102 50 18081 18086 2-s2.0-29144440077 16330772 10.1073/pnas.0506216102 PMC1312381

698 Medina R Zaidi SK Liu CG MicroRNAs 221 and 222 bypass quiescence and compromise cell survival Cancer Research 2008 68 8 2773 2780 2-s2.0-42349093068 18413744 10.1158/0008-5472.CAN-07-6754 PMC3613850

699 Miller TE Ghoshal K Ramaswamy B MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 The Journal of Biological Chemistry 2008 283 44 29897 29903 2-s2.0-56449092072 18708351 10.1074/jbc.M804612200 PMC2573063

700 Stamatopoulos B Meuleman N Haibe-Kains B microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification Blood 2009 113 21 5237 5245 2-s2.0-67149147424 19144983 10.1182/blood-2008-11-189407

701 Johnnidis JB Harris MH Wheeler RT Regulation of progenitor cell proliferation and granulocyte function by microRNA-223 Nature 2008 451 7182 1125 1129 2-s2.0-39849096995 18278031 10.1038/nature06607

702 Pulikkan JA Dengler V Peramangalam PS Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia Blood 2010 115 9 1768 1778 2-s2.0-77950354353 20029046 10.1182/blood-2009-08-240101 PMC2832809

703 Fazi F Racanicchi S Zardo G Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein Cancer Cell 2007 12 5 457 466 2-s2.0-35748979703 17996649 10.1016/j.ccr.2007.09.020

704 Jia CY Li HH Zhu XC MiR-223 suppresses cell proliferation by targeting IGF-1R PLoS ONE 2011 6 e27008 10.1371/journal.pone.0027008 PMC3206888 22073238

705 Xu Y Sengupta T Kukreja L Minella AC MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7 The Journal of Biological Chemistry 2010 285 45 34439 34446 2-s2.0-78049392503 20826802 10.1074/jbc.M110.152306 PMC2966058

706 Yuan JY Wang F Yu J Yang GH Liu XL Zhang JW MicroRNA-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells Journal of Cellular and Molecular Medicine 2009 13 11-12 4551 4559 2-s2.0-77951181323 19017354 10.1111/j.1582-4934.2008.00585.x PMC4515070

707 Laine J Künstle G Obata T Sha M Noguchi M The protooncogene TCL1 is an Akt kinase coactivator Molecular Cell 2000 6 2 395 407 2-s2.0-0033636528 10983986 10.1016/s1097-2765(00)00039-3

708 Munker R Calin GA MicroRNA profiling in cancer Clinical Science 2011 121 4 141 158 2-s2.0-79956190689 21526983 10.1042/CS20110005

709 Smonskey MT Block AW Deeb G Monoallelic and biallelic deletions of 13q14. 3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection American Journal of Clinical Pathology 2012 137 641 646 22431542 10.1309/AJCPP31FSSRQTTAQ

710 Sampath D Liu C Vasan K Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia Blood 2012 119 1162 1172 22096249 10.1182/blood-2011-05-351510 PMC3277352

711 Calin GA Liu CG Sevignani C MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11755 11760 2-s2.0-4143142117 15284443 10.1073/pnas.0404432101 PMC511048

712 Bandi N Zbinden S Gugger M miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer Cancer Research 2009 69 13 5553 5559 2-s2.0-67650422613 19549910 10.1158/0008-5472.CAN-08-4277

713 Raveche ES Salerno E Scaglione BJ Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice Blood 2007 109 12 5079 5086 2-s2.0-34250013672 17351108 10.1182/blood-2007-02-071225 PMC1890829

714 Rossi S Shimizu M Barbarotto E MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival Blood 2010 116 6 945 952 2-s2.0-77956556260 20393129 10.1182/blood-2010-01-263889 PMC4916575

715 Longo PG Laurenti L Gobessi S Sica S Leone G Efremov DG The Akt/Mcl-1 pathway plays a prominent role in mediating anti-apoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells Blood 2008 111 2 846 855 2-s2.0-38349107623 17928528 10.1182/blood-2007-05-089037

716 Santanam U Zanesi N Efanov A Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression Proceedings of the National Academy of Sciences of the United States of America 2010 107 27 12210 12215 2-s2.0-77955435090 20566844 10.1073/pnas.1007186107 PMC2901490

717 Fabbri M Garzon R Cimmino A MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proceedings of the National Academy of Sciences of the United States of America 2007 104 40 15805 15810 2-s2.0-35649020283 17890317 10.1073/pnas.0707628104 PMC2000384

718 Frenquelli M Muzio M Scielzo C MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 Blood 2010 115 19 3949 3959 2-s2.0-77953004738 20203269 10.1182/blood-2009-11-254656

719 Fornari F Gramantieri L Ferracin M MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma Oncogene 2008 27 43 5651 5661 2-s2.0-52949127316 18521080 10.1038/onc.2008.178

720 Di Leva G Gasparini P Piovan C MicroRNA cluster 221-222 and estrogen receptor α interactions in breast cancer Journal of the National Cancer Institute 2010 102 10 706 721 2-s2.0-77952921840 20388878 10.1093/jnci/djq102 PMC2873185

721 Hamada N Fujita Y Kojima T MicroRNA expression profiling of NGF-treated PC12 cells revealed a critical role for miR-221 in neuronal differentiation Neurochemistry International 2012 60 743 750 22465943 10.1016/j.neuint.2012.03.010

722 Garofalo M Romano G Di Leva G EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nature Medicine 2012 18 74 82 10.1038/nm.2577 PMC3467100 22157681

723 Gramantieri L Fornari F Ferracin M MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality Clinical Cancer Research 2009 15 16 5073 5081 2-s2.0-69349083676 19671867 10.1158/1078-0432.CCR-09-0092 PMC3900721

724 Navarro A Beà S Fernández V MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas Cancer Research 2009 69 17 7071 7078 2-s2.0-70149118546 19690137 10.1158/0008-5472.CAN-09-1095

725 Rao E Jiang C Ji M The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation Leukemia 2012 26 1064 1072 22116552 10.1038/leu.2011.305

726 Li Y Zhu X Gu J Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis Cancer Science 2010 101 4 948 954 2-s2.0-77957270582 20148895 10.1111/j.1349-7006.2010.01489.x PMC11158335

727 Medina PP Nolde M Slack FJ OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma Nature 2010 467 7311 86 90 2-s2.0-77956339881 20693987 10.1038/nature09284

728 Hatley ME Patrick DM Garcia MR Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21 Cancer Cell 2010 18 3 282 293 2-s2.0-77956501846 20832755 10.1016/j.ccr.2010.08.013 PMC2971666

729 Ma X Kumar M Choudhury SN Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis Proceedings of the National Academy of Sciences of the United States of America 2011 108 25 10144 10149 2-s2.0-79959918202 21646541 10.1073/pnas.1103735108 PMC3121848

730 Sayed D Rane S Lypowy J MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths Molecular Biology of the Cell 2008 19 8 3272 3282 2-s2.0-54249096193 18508928 10.1091/mbc.E08-02-0159 PMC2488276

731 Asangani IA Rasheed SAK Nikolova DA MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer Oncogene 2008 27 15 2128 2136 2-s2.0-41749113108 17968323 10.1038/sj.onc.1210856

732 Valeri N Gasparini P Braconi C MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) Proceedings of the National Academy of Sciences of the United States of America 2010 107 49 21098 21103 2-s2.0-78650500590 21078976 10.1073/pnas.1015541107 PMC3000294

733 Papagiannakopoulos T Shapiro A Kosik KS MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells Cancer Research 2008 68 19 8164 8172 2-s2.0-54249136806 18829576 10.1158/0008-5472.CAN-08-1305

734 Yang HS Jansen AP Nair R A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF- κ B or ODC transactivation Oncogene 2001 20 6 669 676 2-s2.0-0035825611 11314000 10.1038/sj.onc.1204137

735 Göke R Barth P Schmidt A Samans B Lankat-Buttgereit B Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1 American Journal of Physiology 2004 287 6 C1541 C1546 2-s2.0-8644227794 15317660 10.1152/ajpcell.00025.2004

736 Yang HS Knies JL Stark C Colburn NH Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation Oncogene 2003 22 24 3712 3720 2-s2.0-0038209450 12802278 10.1038/sj.onc.1206433

737 Chen Y Knösel T Kristiansen G Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis Journal of Pathology 2003 200 5 640 646 2-s2.0-0042524204 12898601 10.1002/path.1378

738 Gao F Zhang P Zhou C Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma Oncology Reports 2007 17 1 123 128 2-s2.0-38149139712 17143488

739 Zhang H Ozaki I Mizuta T Involvement of programmed cell death 4 in transforming growth factor- β 1-induced apoptosis in human hepatocellular carcinoma Oncogene 2006 25 45 6101 6112 2-s2.0-33749868662 16682950 10.1038/sj.onc.1209634

740 Gottwein E Mukherjee N Sachse C A viral microRNA functions as an orthologue of cellular miR-155 Nature 2007 450 7172 1096 1099 2-s2.0-37249092180 18075594 10.1038/nature05992 PMC2614920

741 Dagan LN Jiang X Bhatt S Cubedo E Rajewsky K Lossos IS miR-155 regulates HGAL expression and increases lymphoma cell motility Blood 2012 119 513 520 22096245 10.1182/blood-2011-08-370536 PMC3257016

742 Rai D Kim SW McKeller MR Dahia PLM Aguiar RCT Targeting of SMAD5 links microRNA-155 to the TGF- β pathway and lymphomagenesis Proceedings of the National Academy of Sciences of the United States of America 2010 107 7 3111 3116 2-s2.0-77649242925 20133617 10.1073/pnas.0910667107 PMC2840369

743 Jiang X Lu X McNamara G HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway Blood 2010 116 24 5217 5227 2-s2.0-78650071942 20844236 10.1182/blood-2010-04-281568 PMC3012539

744 Lu X Kazmierczak K Jiang X Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin FEBS Journal 2011 278 11 1922 1931 2-s2.0-79956194190 21447067 10.1111/j.1742-4658.2011.08109.x PMC3097272

745 Massagué J Seoane J Wotton D Smad transcription factors Genes and Development 2005 19 23 2783 2810 2-s2.0-27644494876 16322555 10.1101/gad.1350705

746 Fonseca R Blood E Rue M Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood 2003 101 11 4569 4575 2-s2.0-0038142356 12576322 10.1182/blood-2002-10-3017

747 Kuehl WM Bergsagel PL Multiple myeloma: evolving genetic events and host interactions Nature Reviews Cancer 2002 2 3 175 187 2-s2.0-0036512435 11990854 10.1038/nrc746

748 Aqeilan RI Calin GA Croce CM MiR-15a and miR-16-1 in cancer: discovery, function and future perspectives Cell Death and Differentiation 2010 17 2 215 220 2-s2.0-74249084440 19498445 10.1038/cdd.2009.69

749 Weiss BM Abadie J Verma P Howard RS Kuehl WM A monoclonal gammopathy precedes multiple myeloma in most patients Blood 2009 113 22 5418 5422 2-s2.0-67049114114 19234139 10.1182/blood-2008-12-195008 PMC2689043

750 Chesi M Robbiani DF Sebag M AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies Cancer Cell 2008 13 2 167 180 2-s2.0-38549131395 18242516 10.1016/j.ccr.2008.01.007 PMC2255064

751 Chesi M Bergsagel PL Many multiple myelomas: making more of the molecular mayhem Hematology/the Education Program of the American Society of Hematology 2011 2011 344 353 10.1182/asheducation-2011.1.344 PMC3903307 22160056

752 Sarasquete ME Gutiérrez NC Misiewicz-Krzeminska I Upregulation of dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients Haematologica 2011 96 3 468 471 2-s2.0-79952356831 21160068 10.3324/haematol.2010.033845 PMC3046281

753 Liu J Carmell MA Rivas FV Argonaute2 is the catalytic engine of mammalian RNAi Science 2004 305 5689 1437 1441 2-s2.0-4444368187 15284456 10.1126/science.1102513

754 Diederichs S Haber DA Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression Cell 2007 131 6 1097 1108 2-s2.0-36849048778 18083100 10.1016/j.cell.2007.10.032

755 Katz BZ Adhesion molecules—the lifelines of multiple myeloma cells Seminars in Cancer Biology 2010 20 3 186 195 2-s2.0-77956619675 20416379 10.1016/j.semcancer.2010.04.003

756 Frassanito MA Cusmai A Iodice G Dammacco F Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis Blood 2001 97 2 483 489 2-s2.0-0035863942 11154226 10.1182/blood.v97.2.483

757 Hideshima T Richardson P Chauhan D The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Research 2001 61 7 3071 3076 2-s2.0-0035300479 11306489

758 Bharti AC Donato N Aggarwal BB Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells Journal of Immunology 2003 171 7 3863 3871 2-s2.0-0141955061 10.4049/jimmunol.171.7.3863 14500688

759 Bharti AC Donato N Singh S Aggarwal BB Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor- κ B and I κ B α kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis Blood 2003 101 3 1053 1062 2-s2.0-0037305821 12393461 10.1182/blood-2002-05-1320

760 Feinman R Koury J Thames M Barlogie B Epstein J Siegel DS Role of NF- κ B in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2 Blood 1999 93 9 3044 3052 2-s2.0-0033121314 10216101

761 Löffler D Brocke-Heidrich K Pfeifer G Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer Blood 2007 110 4 1330 1333 2-s2.0-34548039517 17496199 10.1182/blood-2007-03-081133

762 Wang X Li C Ju S Wang Y Wang H Zhong R Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation Leukemia & Lymphoma 2011 52 1991 1998 21718132 10.3109/10428194.2011.591004

763 Linares LK Kiernan R Triboulet R Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2 Nature Cell Biology 2007 9 3 331 338 2-s2.0-33847388041 17293853 10.1038/ncb1545

764 Chen YH Lavelle D DeSimone J Uddin S Platanias LC Hankewych M Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1) Blood 1999 94 1 251 259 2-s2.0-0033168314 10381520

765 Lavelle D Chen YH Hankewych M Desimone J Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression American Journal of Hematology 2001 68 3 170 178 2-s2.0-0034770423 11754398 10.1002/ajh.1174

766 Lerner M Harada M Lovén J DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1 Experimental Cell Research 2009 315 17 2941 2952 2-s2.0-70349456537 19591824 10.1016/j.yexcr.2009.07.001

767 Xia L Zhang D Du R miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells International Journal of Cancer 2008 123 2 372 379 2-s2.0-44949249814 18449891 10.1002/ijc.23501

768 Calin GA Cimmino A Fabbri M MiR-15a and miR-16-1 cluster functions in human leukemia Proceedings of the National Academy of Sciences of the United States of America 2008 105 13 5166 5171 2-s2.0-42449152333 18362358 10.1073/pnas.0800121105 PMC2278188

769 Ria R Vacca A Russo F A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma Thrombosis and Haemostasis 2004 92 6 1438 1445 2-s2.0-10444265117 15583754 10.1160/TH04-06-0334

770 Vacca A Ria R Ribatti D A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma Haematologica 2003 88 2 176 185 2-s2.0-0038284068 12604407

771 Pearson JD Lee JK Bacani JT Lai R Ingham RJ NPM-ALK: the prototypic member of a family of oncogenic fusion tyrosine kinases Journal of Signal Transduction 2012 2012 14 pages 123253 10.1155/2012/123253 PMC3407651 22852078

772 Campo E Swerdlow SH Harris NL Pileri S Stein H Jaffe ES The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 2011 117 19 5019 5032 2-s2.0-79955961315 21300984 10.1182/blood-2011-01-293050 PMC3109529

773 Carbone A Gloghini A Aiello A Testi A Cabras A B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology Human Pathology 2010 41 5 621 631 2-s2.0-77950550833 20398809 10.1016/j.humpath.2009.10.027

774 Savage KJ Therapies for peripheral T-cell lymphomas Hematology American Society of Hematology Education Program 2011 2011 515 524 22160083 10.1182/asheducation-2011.1.515

775 Raetz EA Perkins SL Carlson MA Schooler KP Carroll WL Virshup DM The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas American Journal of Pathology 2002 161 3 875 883 2-s2.0-0036731862 12213716 10.1016/S0002-9440(10)64248-4 PMC1867246

776 Wang FZ Weber F Croce C Liu CG Liao X Pellett PE Human cytomegalovirus infection alters the expression of cellular MicroRNA species that affect its replication Journal of Virology 2008 82 18 9065 9074 2-s2.0-50949132066 18596100 10.1128/JVI.00961-08 PMC2546905

777 Su H Yang JR Xu T MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity Cancer Research 2009 69 3 1135 1142 2-s2.0-59149098054 19155302 10.1158/0008-5472.CAN-08-2886

778 Friedman JM Liang G Liu CC The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2 Cancer Research 2009 69 6 2623 2629 2-s2.0-65549083102 19258506 10.1158/0008-5472.CAN-08-3114

779 Varambally S Cao Q Mani RS Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Science 2008 322 5908 1695 1699 2-s2.0-58149239686 19008416 10.1126/science.1165395 PMC2684823

780 Montes-Moreno S Martinez N Sanchez-Espiridión B MiRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy Blood 2011 118 4 1034 1040 2-s2.0-79961017480 21633089 10.1182/blood-2010-11-321554

781 Lenz G Wright GW Emre NCT Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13520 13525 2-s2.0-51649111684 18765795 10.1073/pnas.0804295105 PMC2533222

782 Lenz G Wright G Dave SS Stromal gene signatures in large-B-cell lymphomas The New England Journal of Medicine 2008 359 22 2313 2323 2-s2.0-57149089307 19038878 10.1056/NEJMoa0802885 PMC9103713

783 Jais JP Haioun C Molina TJ The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab Leukemia 2008 22 10 1917 1924 2-s2.0-54049093957 18615101 10.1038/leu.2008.188 PMC2675107

784 Banham AH Beasley N Campo E The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p Cancer Research 2001 61 24 8820 8829 2-s2.0-0035893741 11751404

785 Shaffer AL Rosenwald A Staudt LM Lymphoid malignancies: the dark side of B-cell differentiation Nature Reviews Immunology 2002 2 12 920 932 2-s2.0-0036884169 10.1038/nri953 12461565

786 Wlodarska I Veyt E De Paepe P FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations Leukemia 2005 19 8 1299 1305 2-s2.0-23744460273 15944719 10.1038/sj.leu.2403813

787 Streubel B Vinatzer U Lamprecht A Raderer M Chott A T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma Leukemia 2005 19 4 652 658 2-s2.0-16844369469 15703784 10.1038/sj.leu.2403644

788 Banham AH Connors JM Brown PJ Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma Clinical Cancer Research 2005 11 3 1065 1072 2-s2.0-12944273473 15709173

789 Barrans SL Fenton JAL Banham A Owen RG Jack AS Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome Blood 2004 104 9 2933 2935 2-s2.0-7244242358 15238418 10.1182/blood-2004-03-1209

790 Mandelbaum J Bhagat G Tang H BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma Cancer Cell 2010 18 6 568 579 2-s2.0-78650004237 21156281 10.1016/j.ccr.2010.10.030 PMC3030476

791 Calado DP Zhang B Srinivasan L Constitutive canonical NF- κ B activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma Cancer Cell 2010 18 6 580 589 2-s2.0-78650023995 21156282 10.1016/j.ccr.2010.11.024 PMC3018685

792 Martins G Calame K Regulation and functions of Blimp-1 in T and B lymphocytes Annual Review of Immunology 2008 26 133 169 2-s2.0-42649120075 10.1146/annurev.immunol.26.021607.090241 18370921

793 Kuo TC Shaffer AL Haddad J Yong SC Staudt LM Calame K Repression of BCL-6 is required for the formation of human memory B cells in vitro Journal of Experimental Medicine 2007 204 4 819 830 2-s2.0-34247387876 17403935 10.1084/jem.20062104 PMC2118536

794 Tunyaplin C Shaffer AL Angelin-Duclos CD Yu X Staudt LM Calame KL Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation Journal of Immunology 2004 173 2 1158 1165 2-s2.0-3142728530 10.4049/jimmunol.173.2.1158 15240705

795 Pasqualucci L Compagno M Houldsworth J Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma Journal of Experimental Medicine 2006 203 2 311 317 2-s2.0-33344454909 16492805 10.1084/jem.20052204 PMC2118216

796 Küppers R The biology of Hodgkin’s lymphoma Nature Reviews Cancer 2009 9 1 15 27 2-s2.0-57749171165 19078975 10.1038/nrc2542

797 Gozgit JM Bebernitz G Patil P Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2 The Journal of Biological Chemistry 2008 283 47 32334 32343 2-s2.0-57749084579 18775810 10.1074/jbc.M803813200

798 Croce CM Calin GA miRNAs, cancer, and stem cell division Cell 2005 122 1 6 7 2-s2.0-22144461002 16009126 10.1016/j.cell.2005.06.036

799 Linnstaedt SD Gottwein E Skalsky RL Luftig MA Cullen BR Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus Journal of Virology 2010 84 22 11670 11678 2-s2.0-78049489278 20844043 10.1128/JVI.01248-10 PMC2977875

800 de Kloet ER Fitzsimons CP Datson NA Meijer OC Vreugdenhil E Glucocorticoid signaling and stress-related limbic susceptibility pathway: about receptors, transcription machinery and microRNA Brain Research 2009 1293 129 141 2-s2.0-67649517165 19332027 10.1016/j.brainres.2009.03.039

801 Uchida S Nishida A Hara K Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor European Journal of Neuroscience 2008 27 9 2250 2261 2-s2.0-42549159408 18445216 10.1111/j.1460-9568.2008.06218.x

802 Hayashita Y Osada H Tatematsu Y A polycistronic MicroRNA cluster, miR-17 ∼ 92, is overexpressed in human lung cancers and enhances cell proliferation Cancer Research 2005 65 21 9628 9632 2-s2.0-27544495514 16266980 10.1158/0008-5472.CAN-05-2352

803 Matsubara H Takeuchi T Nishikawa E Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17 ∼ 92 Oncogene 2007 26 41 6099 6105 2-s2.0-34447101200 17384677 10.1038/sj.onc.1210425

804 Sommer P Le Rouzic P Gillingham H Glucocorticoid receptor overexpression exerts an anti-survival effect on human small cell lung cancer cells Oncogene 2007 26 50 7111 7121 2-s2.0-35948965282 17496926 10.1038/sj.onc.1210524

805 Ledderose C Mohnle P Limbeck E Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha Critical Care Medicine 2012 40 10 2745 2753 22846781 10.1097/CCM.0b013e31825b8ebc

806 Malzkorn B Wolter M Liesenberg F Identification and functional characterization of microRNAs involved in the malignant progression of gliomas Brain Pathology 2010 20 3 539 550 2-s2.0-77950824571 19775293 10.1111/j.1750-3639.2009.00328.x PMC8094849

807 Ji Z Mei FC Miller AL Thompson EB Cheng X Protein kinase A (PKA) isoform RII β mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells The Journal of Biological Chemistry 2008 283 32 21920 21925 2-s2.0-52049119312 18544528 10.1074/jbc.M803193200 PMC2494930

808 Kim SW Rai D Aguiar RC Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma Clinical Cancer Research 2011 17 6723 6732 21742807 10.1158/1078-0432.CCR-11-0770 PMC4651210

809 Yang M Huang J Pan HZ Jin J Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF- κ B pathways in human multiple myeloma cells International Journal of Molecular Medicine 2008 22 4 489 496 2-s2.0-54049083409 18813856

810 Zhu W Shan X Wang T Shu Y Liu P MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines International Journal of Cancer 2010 127 11 2520 2529 2-s2.0-77955619456 20162574 10.1002/ijc.25260

811 Allen DL Loh AS Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle American Journal of Physiology 2011 300 1 C124 C137 2-s2.0-78651353542 20980549 10.1152/ajpcell.00142.2010 PMC3023185

812 Rodriguez A Griffiths-Jones S Ashurst JL Bradley A Identification of mammalian microRNA host genes and transcription units Genome Research 2004 14 10 1902 1910 2-s2.0-6344281172 15364901 10.1101/gr.2722704 PMC524413

813 Linsley PS Schelter J Burchard J Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression Molecular and Cellular Biology 2007 27 6 2240 2252 2-s2.0-33947224690 17242205 10.1128/MCB.02005-06 PMC1820501

814 Fazi F Rosa A Fatica A A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBP α regulates human granulopoiesis Cell 2005 123 5 819 831 2-s2.0-28344438648 16325577 10.1016/j.cell.2005.09.023

815 Sun W Shen W Yang S Hu F Li H Zhu TH MiR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP- β Cell Research 2010 20 10 1158 1169 2-s2.0-77957572525 20856265 10.1038/cr.2010.134

816 Li J Guo Y Liang X MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4 Journal of Cancer Research and Clinical Oncology 2012 138 763 774 22270966 10.1007/s00432-012-1154-x PMC11824240

817 Sempowski GD Hale LP Sundy JS Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy Journal of Immunology 2000 164 4 2180 2187 2-s2.0-0034651657 10.4049/jimmunol.164.4.2180 10657672

818 Sempowski GD Rhein ME Scearce RM Haynes BF Leukemia inhibitory factor is a mediator of Escherichia coli lipopolysaccharide-induced acute thymic atrophy European Journal of Immunology 2002 32 3066 3070 12385026 10.1002/1521-4141(200211)32:11<3066::AID-IMMU3066>3.0.CO;2-J

819 Gearing DP Gough NM King JA Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF) EMBO Journal 1987 6 13 3995 4002 2-s2.0-2442690993 3127201 10.1002/j.1460-2075.1987.tb02742.x PMC553879

820 Tili E Michaille JJ Cimino A Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF- α stimulation and their possible roles in regulating the response to endotoxin shock Journal of Immunology 2007 179 8 5082 5089 2-s2.0-38049030287 10.4049/jimmunol.179.8.5082 17911593

821 Kawashima H Numakawa T Kumamaru E Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression Neuroscience 2010 165 4 1301 1311 2-s2.0-73749088302 19958814 10.1016/j.neuroscience.2009.11.057

822 Vo N Klein ME Varlamova O A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis Proceedings of the National Academy of Sciences of the United States of America 2005 102 45 16426 16431 2-s2.0-28044439909 16260724 10.1073/pnas.0508448102 PMC1283476

823 Rodrigues AC Li X Radecki L MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines Biopharmaceutics and Drug Disposition 2011 32 6 355 367 2-s2.0-79960654837 21796641 10.1002/bdd.764 PMC3158292

824 Biswas AK Johnson DG Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage Cancer Research 2012 72 13 17 22180494 10.1158/0008-5472.CAN-11-2196 PMC3563329

825 Hui RCY Gomes AR Constantinidou D The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression Molecular and Cellular Biology 2008 28 19 5886 5898 2-s2.0-52649115891 18644865 10.1128/MCB.01265-07 PMC2547013

826 Miyamoto K Araki KY Naka K Foxo3a is essential for maintenance of the hematopoietic stem cell pool Cell Stem Cell 2007 1 1 101 112 2-s2.0-34249882777 18371339 10.1016/j.stem.2007.02.001

827 Tothova Z Kollipara R Huntly BJ FoxOs are critical mediators of hematopoietic stem cell resistance tophysiologic oxidative stress Cell 2007 128 2 325 339 2-s2.0-33846419112 17254970 10.1016/j.cell.2007.01.003

828 Naka K Hoshii T Muraguchi T TGF- β -FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia Nature 2010 463 7281 676 680 2-s2.0-76249087423 20130650 10.1038/nature08734

829 Myatt SS Lam EWF The emerging roles of forkhead box (Fox) proteins in cancer Nature Reviews Cancer 2007 7 11 847 859 2-s2.0-35548930209 17943136 10.1038/nrc2223

830 Chintharlapalli S Papineni S Abdelrahim M Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18 β -olean-1,12-dien-30-oate in colon cancer cells International Journal of Cancer 2009 125 8 1965 1974 2-s2.0-67650142347 19582879 10.1002/ijc.24530 PMC2766353

831 Raaphorst FM Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1 Trends in Immunology 2003 24 10 522 524 2-s2.0-0141670822 14552834 10.1016/s1471-4906(03)00241-2

832 Park IK Qian D Kiel M Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells Nature 2003 423 6937 302 305 2-s2.0-0038349957 12714971 10.1038/nature01587

833 Lessard J Sauvageau G Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells Nature 2003 423 6937 255 260 2-s2.0-0037673984 12714970 10.1038/nature01572

834 Pui CH Chessells JM Camitta B Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements Leukemia 2003 17 4 700 706 2-s2.0-0242500374 12682627 10.1038/sj.leu.2402883

835 Pieters R Schrappe M De Lorenzo P A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial The Lancet 2007 370 9583 240 250 2-s2.0-34447519040 10.1016/S0140-6736(07)61126-X 17658395

836 Meister G Landthaler M Dorsett Y Tuschl T Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing RNA 2004 10 3 544 550 2-s2.0-1242318826 14970398 10.1261/rna.5235104 PMC1370948

837 Dou L Zheng D Li J Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression Oncogene 2011 31 507 517 2-s2.0-79959470064 21706045 10.1038/onc.2011.248

838 Babar IA Cheng CJ Booth CJ Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma Proceedings of the National Academy of Sciences of the United States of America 2012 109 E1695 E1704 22685206 10.1073/pnas.1201516109 PMC3387084

839 Burnsides C Corry J Alexander J Ex vivo stimulation of whole blood as a means to determine glucocorticoid sensitivity Journal of Inflammation Research 2012 5 89 97 22952414 10.2147/JIR.S33569 PMC3430009